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ABSTRACT 
 
Human Cripto-1 (CR-1) is the founding member of the epidermal growth factors (EGF-
CFC) superfamily, composed of structurally related protein members.  
CR-1 is involved in many biological functions. Among the others, it is a key regulator 
of the embryogenesis, promoting the differentiation of embryonic stem cells and the 
organogenesis of brain and heart. Interestingly, CR-1 also promotes tumorigenesis, 
regulating cell proliferation, migration, epithelial-mesenchimal transition, survival and 
angiogenesis. The functional part of CR-1 protein consists of two central Cysteine Rich 
Domains, EGF-like and CFC, that independently interact with several partners. The 
increasing interest on CR-1 as a novel diagnostic and therapeutic target is derived from 
the evidence that it is highly expressed in many human solid tumors, while it is barely 
present or totally absent in normal adult tissues. CR-1 can promote tumorigenesis by 
activation of several pathways; we have focused our attention on the CR-1/ALK4 
interaction which triggers the Smads cascade, leading to the activation of gene 
transcription encoding tumor-related factors (Nodal, Lefty).  
Thus, the aim of this study was the generation and development of smart and highly 
selective biomolecules such as mAbs and their fragments that target the CFC domain of 
CR-1, directly involved in the CR-1/ALK4 as well as in the CR-1/ GRP78 interactions. 
For this purpose, as starting point, a set of monoclonal antibodies was generated by the 
hybridoma technique, using as antigen the synthetic and correctly folded human CFC 
[112-150] domain.   
A screening was performed to identify the mAbs with the highest affinity toward the 
full-length recombinant human CR-1 protein (rhCR-1) and with the highest specificity 
toward the two “hot spots” residues (H120 and W123) of the CFC domain. We thus 
identified two mAbs, named 10D1 and 1B4. 10D1 and 1B4 interacted very strongly 
with CR-1, as they were characterized by KD of 70 pM and 200 pM, respectively. 
A subsequent comparative epitope study, combining a computational and a biochemical 
approach, confirmed that both mAbs recognized the region of the CFC domain 
containing the H120 and W123, suggesting that these molecules may act as potential 
blocking antibodies and/or at least be the starting point to develop potential therapeutic 
tools to be employed on cancer cells over-expressing CR-1. In addition, preliminary in 
vitro assays suggested  that the 1B4 mAb had such properties, as it promoted cell death 
on GEO cancer cell lines.   
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The second phase of this study was focused on the generation of functional antibody 
fragments of the 1B4 mAb. A first proteolytic approach was unsuccessful, leading to a 
partially inactive Fab fragment. We thus next moved to generate an engineered 
recombinant chimeric Fab fragment of the same mAb (1B4 rFab) that only retained a 
partial binding activity (KD 6 nM) toward the target protein. Using this recombinant 
fragment as template, a new innovative dimeric format (1B4 rFab2) was created 
exploiting an elegant conjugation strategy based on the use of the M-TGase enzyme. 
This dimeric 1B4 rFab2 protein displayed to rhCR1 a binding affinity comparable to 
that one of the whole 1B4 antibody. Finally, with the aim of increasing the cell killing 
potential of the 1B4 rFab and to exploit its CR-1 specificity in tumor homing 
approaches, we designed and realized a strategy to generate an ADC (Antibody Drug 
Conjugate), arming the 1B4 rFab with a payload consisting of the cytotoxic agent 
Doxorubicin.  
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I.1 THE EGF-CFC SUPERFAMILY 
 
The epidermal growth factor (EGF)-Cripto-1/Fibroblast Growth factor related 
ligand (FRL-1)/Cryptic (CFC) gene family encodes a group of structurally related 
proteins, found only in vertebrates [1], whose human Cripto-1, also known as 
teratocarcinoma derived growth factor (TDGF-1), is the founding member.  
Human Cripto-1 was initially isolated for the first time from NTERA-2 human 
embryonal carcinoma cells [2] and orthologs of human Cripto-1 were secondly 
identified in mouse (Cripto-1/cfc2 and Cryptic/cfc1), zebrafish (one-eyed 
pinhead/oep), Xenopus (XCR1/FRL-1, XCR2, and XCR3), chicken and monkey 
[3,4]. The EGF-CFC members display several functions depending on the 
organism in which they are expressed, mainly related to embryogenesis.          
Human Cripto-1 acts predominantly both as a regulator of gastrulation during 
embryogenesis and of mammary morphogenesis [1]. 
In mouse, cripto-1 is involved in several processes, including  mesoderm and 
endoderm formation, and cardiomycites development [5]. 
FRL-1 and Oep exert similar functions, such as mesoderm and neuroectoderm 
formation [6,7].  
The core of the EGF-CFC proteins is made up of around 180-200 amino acid 
residues. Mouse and human Cripto proteins have a molecular weight of  24, 28 
and 36 kDa by virtue of differential glycosylation status at N- and O-linked Asn 
and Ser residues [8-13]. With regard to the other members, cryptic protein exists as 
20, 21.8 and 23 kDa isoforms, while oep protein as 18 and 20 kDa forms [11-13]. 
All the members of the EGF-CFC family exhibit a highly shared structure 
consisting of a NH2-terminal signal sequence, a modified epidermal growth factor 
(EGF)-like motif, a conserved cysteine-rich motif (CFC region) and a short 
hydrophobic COOH-terminal region which in some cases contains additional 
consensus sequences for potential glycosylphosphatidylinositol (GPI) cleavage 
and attachment [2,14,15]. An overall sequence identity of 22–32% is found among 
mouse and human Cripto, mouse cryptic, human criptin, Xenopus FRL-1 and 
zebrafish oep. More precisely, the EGF-like domain exhibits a sequence similarity 
of 60-70%, whereas the CFC region shows a similarity of 35-48% [13]. 
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I.2 HUMAN CRIPTO-1 
 
2.1 Structure 
Human Cripto-1 gene (2 kb mRNA) is localized on chromosome 3p21.3 [16] and 
consistists of six exons and five introns, in which exon 4 encodes the EGF-like 
motif, while the exon 5 encodes the CFC motif.  Moreover, a truncated form was 
found to be expressed in some cancers encoded by a 1.7 kb mRNA, that lacks 
exons 1 and 2 [5,16].  
The human Cipto-1 protein is composed of 188 amino acids, showing a structure 
correlated to the other members of the EGF-CFC family. Thus, the structure of 
human Cripto-1 contains:  
 a signal sequence at the N-terminus 
 two Cysteine-Rich Domains (CRDs): the EGF-like and the CFC 
 a hydrophobic region at the C-terminus                                     
 
Figure 1.1: Schematic structure of human CR-1 protein, in which the glycosylation sites are 
reported. 
 
The signal sequence (Met1-Gly30) at the N-terminal region allows the secretion 
of CR-1 from the endoplasmic reticulum (ER) into the Golgi body, where the 
protein is processed and undergoes post-translational modifications, mainly 
glycosylation. 
The core of the protein is mainly represented by the EGF-CFC region, of ~20 kDa 
but glycosylation and further post-translational modifications give a provide an 
increased molecular weight (28-36 kDa). The EGF-CFC domain has been 
demonstrated  to be sufficient to CR-1 to exert its biological functions [8,13].  
A. N-terminal Signal sequence
B. EGF-like domain
C. CFC domain
D. C-terminal hydrophobic region  
Cell membrane
A CB D
1 31 78 107 112 150 169 188
Ser40-O Asn79-N
Thr88-fucose
Ser161-
O(ω-site)
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The EGF-like domain (Leu78-Glu107), a region of approximately 40 amino acids, 
contains six Cysteine residues that form  three intramolecular disulfide bonds. 
While in the canonical EGF motif there are three loops (A, B and C), the EGF-
CFC proteins are characterized by a EGF-like motif variant, that lacks the A loop, 
possesses a truncated B loop and has a C loop completely different compared to 
the other members in the EGF superfamily [17]. 
Like the EGF-like domain, also the CFC domain (Lys112-Asp150) is composed 
of 40 amino acid residues and contains six Cysteine residues. The disulfide bonds 
pattern has been experimentally determined, showing that the six Cysteines are 
linked following the C1-C4, C3-C5, C2-C6 scheme [18]. Moreover, the 3D model 
of CFC domain, proposed by Foley et al. [18], showed a hydrophobic patch 
consisting of Trp134, Leu138, Phe141 and Pro142. Leu138 and homologues of 
Trp134 and Phe141 have been reported to be highly conserved throughout the 
Cripto family and are clustered on the side of the CFC domain opposite to 
residues His120 and Trp123 that are involved in binding of Cripto-1 to ALK4.The 
hydrophobic residues presumably exert a structural role, affecting the folding of 
CR-1 by interacting with the EGF-like domain, or they may represent the 
interaction site with other signaling partners.  
Furthermore, the interaction between the CFC domain and the ALK4 receptor has 
been elucidated by docking studies performed using the NMR structure of the 
synthetic human CFC and ALK4-ECD structure obtained by homology 
modelling. In particular, a close fitting was found between the His120 and Trp123 
of CFC domain and the Phe55 and Tyr56 of ALK4-ECD, that form a pocket in 
which the two residues of hCFC perfectly match. In addition, a contribution is 
even given by favorable electrostatic and hydrophobic interactions. This docking 
study was supported by SPR binding assays on synthetic hCFC on rhALK4 by 
which a KD value of ~13 µM was extrapolated for the ligand-receptor complex 
[19].  
Furthermore, docking studies, carried out by Calvanese et al. [20] to investigate 
the ternary complex ALK4/CR-1/Nodal, showed that the EGF-like domain of CR-
1 forms a polar groove, which perfectly allows the interaction with Tyr58 of  
Nodal helix. Also Glu49 and Glu50, embedded on the pre-helix loop of  Nodal, 
were found as crucial residues for the interaction between Nodal and the EGF-like 
domain of CR-1, establishing favorable electrostatic interactions.        
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Figure 1.2: Ribbon representation of the proposed model for the ternary complex composed of 
Nodal (blue), CR-1 (green) and ALK4-ECD (red) (A). The relevant residues at the binding 
interface between hCFC and ALK-ECD are highlighted. Zoom representation of the contact region 
between hCFC (stick model) and the hydrophobic pocket of ALK4-ECD (Connolly surface  area 
in red) (B). 
                                            
Many studies have shown that the EGF-like domain is involved in binding to 
several partners: in addition to the morphogen Nodal [21], even with  Glypican-1 
[22], Activins [23] and in cross-talk with ErbB4 [1]. By contrast, the CFC domain is 
principally involved in binding to ALK4 receptor [18, 24-26] and GRP78 co-
receptor [27]. 
Cripto-1, as a GPI membrane-anchored protein, undergoes enzymatic cleavage 
from the cell membrane by GPI-phospholipease D (GPI-PLD) so as to be released 
into the cell media.  
Since the presence of the GPI anchoring, Cripto-1 can act as a membrane-
anchored protein within lipid rafts microdomains and  in addition, it can function 
as Nodal co-receptor [24,28,29]. Thus, Cripto-1 can act both as a co-receptor in cis 
ALK4-ECD
ALK4-ECD
CRIPTO-1 
CFC
NODAL
CRIPTO-1
CFC
NODAL
A
B
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(autocrine/cell-autonomous) and as ligand in trans (paracrine/cell-
nonautonomous) conformation [30]. 
Cripto-1 glycosylation sites include O-linked glycosylation at Ser40 and Ser61 
(ω-site for GPI-anchoring), N-linked glycosylation at Asn79 and O-linked 
fucosylation at Thr88 (See Fig. 1.1). Moreover, experiments using O-fucosylation  
mutants have demonstrated that the Thr88 residue but not the fucosylation is 
crucial for activation of Nodal/Cripto-1 dependent signaling pathways [28, 31]. 
 
 
Figure 1.3: Representation of the Cripto-1 domains and domain-dependent signalling. 
 
 
2.2 Functions 
CR-1 is a multifunctional protein involved in various physiological and 
pathological processes, resulting from the interaction between  its extracellular 
form and the intracellular signal transduction pathways activated by several 
partners, ultimately leading to cell proliferation, transformation, survival and 
cancer cells metastatis [32].  
CR-1, as well as other EGF-CFC family members, performs regulatory cell 
functions and  tissue patterning during embryogenesis whereby it plays a crucial 
role in the specification of the posterior-anterior and left-right axis and  in the 
formation of several organs (organogenesis) such as heart and brain development. 
It acts as a co-receptor for the TGF-β ligands ( Nodal, GDF1 and GDF3) during 
gastrulation while together with Apelin and APJ regulates cardiac specification of 
ES cells [4,33,34]. 
CELL PROLIFERATION
Signal sequence CFC-domainEGF-like domain
ErbB4
GRP78
GPC-1
ActRII
Nodal ALK4
P
ALK4
GPI
Cell 
membrane
Activin
ActRII Smad2/3
Smad2/3
Smad2/3
c-Src
•Shc/Ras/Raf/MAPK
•PI3K/Akt/GSK-3β
CELL PROLIFERATION, EMT, 
MIGRATION, SURVIVAL, 
ANGIOGENESIS
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The emerging role of CR-1 to maintain the pluripotential capacity and self-
renewal of human and mouse embryonic stem cells, makes it an innovative and 
attractive stem cell marker [35].  
Furthermore, since CR-1 belongs to “developmental oncoprotein family”, it 
represents a typical example of a gene associated with early embryogenesis and 
re-expressed in human tumors in a dis-regulated manner. It is well-established that 
CR-1 expression is very low in normal differentiated adult tissues, while it is 
highly expressed in 50% to 80% of different types of primary human carcinomas, 
including breast, colon,  lung, ovary, cervix, testis [32].  
Several in vitro experiments have demonstrated its oncogenic activity by 
enhancing proliferation, migration, invasion, epithelial-mesenchymal transition, 
branching morphogenesis of several mouse and human epithelial cell lines and, 
finally it can also promote tumor angiogenesis [35]. 
Interestingly, CR-1 was found to be heterogeneously expressed in human 
embryonal carcinoma (EC) cells, grouped into two different subpopulations 
(reported as CR-1
High
 and CR-1
Low
), on the basis of the protein expression levels 
[36]. Comparing the two subpopulations, the first one exhibits hallmarks of stem 
cells with a higher degree of tumorigenicity than the latter. Thus, the EC cells, 
like the ES cells, can spontaneously differentiate into various types of cells and 
maintain the pluripotency through a transcriptional self-regulatory circuit 
regulated by transcriptional factors such as Oct4 and Nanog [36].  
In addition, expression of  CR-1 is also reported in other human  tumor species, 
including cutaneous melanoma, in particular in a subpopulation of aggressive 
melanoma cells exhibiting stem cell-like characteristics (C8161 and ROS184) 
[37,38] and in EGFR-mutant non-small cell lung cancer (NSLC) [39].  
Recently, Pilgaard et al. [40] have investigated and demonstrated, for the first 
time, the presence of Cripto-1 in glioblastoma multiforme (GBM) tissues and its 
correlation with the disease outcome. In GBM tissues, CR-1 positive cells were 
found bordering glomeruloid blood vessels (localized in the microvasculature) in 
the regions of vascular genesis caused by hypoxia and in areas of rapid tumor 
growth, characterized by higher proliferation. These evidences suggest that CR-1 
may be involved in GBM progression.  
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2.3 Signaling pathways activated by Cripto-1 
 
a) TGF-β dependent signaling pathways 
During embryogenesis, cell-membrane anchored CR-1 functions as a co-receptor 
with the type I Activin serine-threonine kinase receptors (ALK4 or ALK7) for the 
transforming growth factor β (TGF-β)-related proteins , Nodal and Growth and 
Differentiation factor 1 and 3 (GDF1 and GDF3). 
CR-1 is able to bind directly to both Nodal (via EGF-like domain) and ALK4 (via 
CFC domain) to help Nodal signaling through the phosphorylation of Smad-
2/Smad-3, which in turn bind to Smad-4, that then translocate into the nucleus 
enhancing the transcription - with other activators - of specific target genes 
[24,25,30]. So far, it has been reported that the presence of CR-1 represents a pre-
requisite for CR-1/Nodal dependent signaling pathway to support the binding of 
Nodal to ALK4 during the formation of a biologically active ternary complex 
(CR-1/Nodal/ALK4). However, recent biochemical binding assays have revealed 
that Nodal is able to bind physically to ALK4 without the presence of CR-1 [41]; 
these new findings need to be better understood and validated in cellular systems. 
In addition to ALK4, CR-1 hab been shown to significantly potentiate the 
responsiveness of the ALK7/ActRIIB complex to Nodal, indicating that both 
ALK7 and ALK4 cooperate with CR-1 in modulating Nodal signaling [42].  
CR-1 can facilitate Nodal signaling during embryogenesis also interacting with 
antagonists of Nodal, including Tomoregulin-1 and Lefty or acting as inhibitor of 
Activin B (via CFC domain), Activin A, and TGF-β1 (via EGF-like domain) 
signaling [33, 35].  
Moreover, the inhibitory effects of CR-1 on TGF-β1 and Activin signaling can be 
enhanced by the 78-kDa heat shock protein glucose-regulated protein (GRP78), 
which has been found in human carcinoma cells. CR-1, through the CFC domain, 
binds the N-terminus region of GRP78, forming a complex able to inhibits TGF-
β1 signaling and its anti-proliferative effects. Thus, the modulation of these 
factors by Cripto-1 has been  proposed as a possible mechanism by which Cripto-
1 promotes cell proliferation and tumorigenesis [27,43]. 
Finally, CR-1 oncogenic activity is related also to Notch signaling pathway, 
necessary to maintain the normal development and stem cell fate in several tissues 
15 
 
[44]. In particular, Notch4 has been demonstrated to regulate the expression of 
Nodal in malignant melanoma cells, suggesting a potential cross-talk between the 
Nodal/CR-1 and Notch signaling pathways during tumorigenesis [45]. 
 
Figure 1.4:  Cripto-1 modulation of  TGF-β dependent signaling pathways. Cripto-1 functions as 
co-receptor for Nodal, GDF-1, and GDF-3 leading to the activation of a Smad-2/3 intracellular 
signaling pathway (A). Cripro-1 binds to Tomoregulin-1 and Lefty that normally antagonize Nodal 
signaling (B). Cripto-1 and GRP78 antagonize Activin and TGF-β1 signaling (C) [46]. 
 
 
b) TGF-β -independent signaling pathways 
In addition to its function as a co-receptor of TGF-β members 
(Nodal/GDF1/GDF3), CR-1 can induce the signaling of further molecules 
independently of Nodal and ALK4.  
CR-1 can also function as a ligand for Glypican-1, a GPI-anchored heparan 
sulphate proteoglycan (HSPG), linked to the plasma membrane in lipid rafts, 
leading to a phosphorylation of the cytoplasmic tyrosine kinase c-src which, in 
turn, activates mitogen-activated protein kinase (MAPK) phosphatidylinositol 3’-
kinase (PI3K)/Akt signaling pathways, involved in the regulation of cell 
proliferation, motility and survival [22]. The MAPK and AKT pathways are also 
involved in epithelial to mesenchymal transition (EMT) through a canonical 
Wnt/β-catenin signaling pathway, by inhibition of glycogen synthase kinase 
(GSK)-3β activity leading ultimately to the stabilization of β-catenin and Snail 
[47]. Also GRP78 has been demonstrated to be essential for CR-1 activation of the 
MAPK/AKT signaling pathway.  
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Furthermore, several studies have demonstrated a potential interaction between 
CR-1 and the Wnt/β-catenin signaling pathway during embryonic development 
and in colon carcinoma cells [48]. The canonical Wnt/β-catenin/Tcf signaling 
pathway performs several functions including the regulation of proliferation and 
cell lineage specification during embryonic development, the maintenance of the 
undifferentiated state of ES cells and the development of different types of 
carcinomas (skin, intestine, liver and brain) [49].  
An interesting cross-talk between Cripto-1 and ErbB4 receptor has been found. It 
is well known that Cripto-1 cannot bind directly to the ErbB type I tyrosine kinase 
receptors family, including Epidermal Growth Factor Receptor (EGFR), ErbB2, 
ErbB3 and ErbB4, because of its modified EGF-like domain [4]. However, Cripto-
1 has been reported to can indirectly enhance the tyrosine phosphorylation of 
ErbB4 in breast cancer cells, by a Tomoregulin-related mechanism [50].  
 
 
Figure 1.5: Cripto-1 activation TGF-β independent signaling pathways. Cripto-1 binding to 
GRP78 induces the MAPK/AKT activation (A). Cripto-1 interaction with Glypican-1 (B). The 
MAPK/AKT pathway can also inhibit GSK-3b. Cripto-1 and Tomoregulin-1 induce the 
phosphorylation of  ErbB4 (C). Cav-1 binds to Cripto-1 and inhibits the capacity of Cripto-1 to 
activate a c-src/MAPK/AKT signaling pathway (D) [46]. 
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I.3 TARGETING CRIPTO-1 IN CANCER THERAPY 
 
The high expression levels of CR-1 in a variety of human tumors and its low 
expression or the fully absence in healthy tissues, make CR-1 a novel intriguing 
target in cancer therapy.  
Several studies reported the detection of higher levels of CR-1 in plasma of 
patients with breast and colon cancer and, more recently, in the less common 
GBM, compared with levels in the plasma of healthy volunteers, also validating 
the role of CR-1 as a new useful serologic marker correlated to the tumor 
progression in some cancers. Moreover, CR-1 is known to be expressed in cancer 
stem-like cells that exhibit peculiar stem-like hallmarks such as the ability of self-
renewal, as well as resistance to chemotherapy and radiotherapy.  
Considering the relevant role of cancer stem-like cells in the tumor growth and 
progression and drug resistance, the presence of CR-1 both in tumor tissues and in 
cancer stem-like cells strengthens the validation of Cripto-1 as a potential cancer 
target. 
Despite the numerous breakthroughs in anti-cancer therapy, the research of 
specific and efficient anti-tumoral therapeutic agents is still a big challenge. In 
this context, the identification of specific neutralizing molecules (monoclonal 
antibodies, antibody fragments or peptide fragments) against CR-1 could 
represent a promising strategy in cancer therapy to treat human solid tumors in 
which this protein is over-expressed. The use of these biotherapeutic agents 
should preserve the healthy tissues and minimize the common side effects related 
to the use of broad ranging anti-tumoral therapeutics. 
For instance, anti-CR-1 antibodies can be classified in four classes: N-terminal 
tip, N-terminal, EGF-like domain and CFC domain. mAbs targeting either the 
EGF or the CFC domains of CR-1 were able to inhibit tumor growth in vivo; by 
contrast, the anti- N-terminal mAbs showed no significant effects on the tumor 
growth of NCCIT or GEO xenografts, indicating that monoclonal antibodies 
targeting the N-terminal region of CR-1 act as simple binding antibodies without 
any blocking action [21,51,52]. 
Interestingly, Biogen-Idec has developed a N-terminal binding antibody 
conjugated to the DM4 cytotoxin to target CR-1 in human tumors. Upon 
internalization by cells expressing CR-1, the DM4 moiety binds to tubulin, 
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disrupting microtubule structures and leading to inhibition of cell division. This 
DM4-conjugated humanized mAb was tested on NCCIT human embryonal 
carcinoma and CLAU-6 lung cancer xenografts to assess its capability of allowing 
tumor regression and a strong inhibitory effect on tumor growth was detected 
(Biogen-Idec: Cripto binding molecules. US0008906. 2010). 
In addition, the emerging role of GRP78 in the modulation of CR-1 oncogenic 
signaling strengthens the importance to develop anti-CR-1 antibodies. 
However, since the pharmacological therapy based on the simple use of 
monoclonal antibodies is often not sufficient to eradicate a solid tumor, despite a 
robust anti-tumoral effectiveness in vitro and in vivo, a more robust approach 
could be represented by the combination of the specificity of a monoclonal 
antibody and the toxicity of a cytotoxic drug able to potentiate the therapeutic 
efficacy [53].  
 
 
Figure 1.6: Schematic illustration of antibody/molecules useful in targeting CR-1 in tumor tissues 
. 
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I.4 MONOCLONAL ANTIBODIES  IN ONCOLOGY 
 
4.1 Anatomy of antibody molecule 
Antibodies are glycosylated proteins, characterized by a typical “Y” shape. The 
structure of antibodies, with complete amino acid content and disulfide bond 
pairing, was elucidated by G. Edelman and R. Porter in the early 1960s. 
The Ig monomer is composed of two identical heavy chains (HC) and two 
identical light chains (LC) linked by inter-chain disulfide bonds. 
On the basis of the constant region of the heavy chain, immunoglobulines are 
classified into five classes, IgA (α), IgD (δ), IgE (ε), IgG (γ) and IgM (μ); on the 
other hand, the light chain exists only as two different forms, κ and λ. The IgG 
and IgA classes in turn are classified into further sub-classes by virtue of their 
abundancy in serum, the IgG into four (IgG1, IgG2, IgG3 and IgG4) while the 
IgA only into two (IgA1 and IgA2) respectively.  
defining a structure composed of three main portions: two identical Fabs and the 
Fc. The Fabs are linked to the Fc by the hinge region, which varies in length and 
flexibility in the different antibody classes and isotypes. The antigen-binding sites 
(paratopes) are localized at the N-terminal tips of the Fabs. Specific studies on 
antibody structure [54-57] have demonstrated that all antibody domains, variable 
and constant (defined Immunoglobulin domains), are made up of 70–110 amino 
acids and form a compact globular structure with a characteristic β-barrel fold. 
Each domain consists of a stable arrangement of hydrogen-bonded, anti-parallel 
β-strands which form a bilayer structure, stabilized by a disulfide bond between 
the two layers [58] . 
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Figure 1.7: Overall structure and domain architecture of antibodies. Domain arrangement of an 
IgG antibody molecule. The light chains are shown in green, the heavy chains in blue (a). Domain 
architecture of the light chain variable (VL) (b) and constant (CL) domains (c) [58]. 
 
 
The antibody structure is characterized by two variable domains, one belonging to 
the heavy chain and the other one to the light chain (VH and VL domains 
respectively), and four constant domains: the CL of the light chain and the CH1 of 
the heavy chain constituting the C-terminal region of Fab, and the CH2 and the 
CH3 domains constituting the Fc. At the N-terminal tip, the Fv of the Fab fragment 
contains the complementarity determining regions (CDRs) which are strictly 
involved in the interaction with the antigen, displaying a surface equated with the 
counterpart of the antibody, represented by the paratope [59]. 
The CDRs, also known as hypervariable regions, are three on each variable 
domain: L1, L2 and L3 on the VL domain, and H1, H2 and H3 on the VH domain. 
The CDR regions are connected by the non-hypervariable or framework regions 
(FRs), four on each domain, that differ in length and composition among all the 
antibodies and that are crucial to stabilize the whole structure of the Fab fragment. 
The CDR loops differ for extent and conformation depending on the nature and 
number of amino acids in the segment, allowing a high variability in the 
topography of the CDR surface, that is characterized by depressions and 
protrusions and may contain a deep pocket or cleft or a protuberance. The 
plasticity of the combining site allows the IgG molecule to assume different 
conformations, in an “induced fit” manner. Instead, the flexibility of IgG molecule 
is provided by  the hinge region between the Fabs and the Fc and the switch 
regions within each fragment, allowing rotation movements [60-62]. 
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The intra-chain disulfides of the HC and LC domains for the four IgG isotypes are 
similar while the inter-chain disulfide bridges arrangements are different, on the 
basis of the different amino acid composition of the hinge region and the number 
and position of the Cysteine residues. Both IgG1 and IgG4 have two disulfide 
linkages between their HC, whereas, IgG2 and IgG3 have four and eleven, 
respectively. The inter-chain linkage between the HC and the LC of IgG1 is 
established between the C-terminal Cysteine belonging to the LC and the first 
Cysteine of the hinge region, whereas, IgG2, IgG3 and IgG4 possess this linkage 
between the terminal Cysteine of the LC and the Cysteine in the Fab region (N-
terminal of the CH1 domain). The variation in hinge length and amino acid 
sequence in the different heavy chain classes and isotypes affect the different 
rotational adaptability, resulting in different spacing and orientations of antigenic 
determinants by the immune system [63-67].  
The IgGs represent the preferred class to be developed as therapeutics, on the 
basis of their more favourable features compared with the other classes, although 
the IgG3 are not used as therapeutic candidates because of their shorter half-life 
and their long hinge region, that is easily accessible to proteases and allotypic 
polymorphism [68]. 
 
4.2 monoclonal antibodies: development as therapeutic tools 
a) From murine to human monoclonal antibody 
The most common method to generate murine monoclonal antibodies is the 
hybridoma technology, developed by Köhler and Milstein in 1975 [69]. This 
procedure is based on the fusion of myeloma cells with B cells from mice spleen, 
generating cell hybrids, capable to ensure a continuous production of fully-murine 
antibodies. 11 years after, Muromonab-CD3 was approved by FDA as the first 
monoclonal antibody in treatment of transplantation rejection (DB00075). Next, to 
reduce the murine portion,  “chimeric antibodies” were generated in mammalian 
cell lines, exploiting the technique of cloning out murine VH and VL genes, by 
PCR technique, leading to antibodies composed of murine VH and VL chains 
fused with human constant regions [70]. Rituximab is an example of the first 
chimeric anti-CD20 monoclonal antibody approved in 1994 for the treatment of 
lymphoma [71]. However, chimeric antibodies, because of their one-third murine 
portion, did not completely avoid the enhanced immunogenicity. Thus, to 
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overcome this limitation the next step was grafting the CDR regions from a 
murine antibody into the closely related human framework, to obtain the so-called 
“humanized antibody” [72]. Daclizumab (anti-CD25) was the first humanized 
mAb introduced in 1997 as biotherapeutic agent to suppress rejection after 
transplantation. The generation of “fully human antibodies” was the final step to 
completely remove murine sequences, performed predominantly by the phage 
display technique, described for the first time by Smith in 1985 and by transgenic 
human mice [73]. Adalimumab, introduced in clinic in 2002, was the first fully 
human antibody generated by phage display technology, while Panitumumab, 
marked in 2006, represented the first fully human mAb generated in engineered 
mice.  
 
b) Pharmacokinetic and Pharmacodynamic properties of IgGs 
Antibody uptake by the tumor depends on a subtle balance between efficient 
penetration and retention in the targeted tissue, and mAbs properties, including 
molecular size, shape, affinity and valency [74]. 
As well known, mAbs are large molecules characterized by very long serum half-
life, since they exceed the renal clearance cut-off (~70 kDa), preventing their 
elimination through the kidney glomeruli. Another factor that affects the mAbs 
serum half-life is the interaction of Fc portion with the neonatal Fc receptor 
(FcRn) expressed at the surface of several cell types, including vascular 
endothelium cells, monocytes and macrophages as well as at sites with barrier 
such as the blood–brain interface, the glomerular filter in the kidneys and the 
intestinal epithelium [74]. 
Firstly, IgGs bind to FcRn at low pH, secondly the complex is carried back to the 
cell surface, where upon it dissociates at neutral pH. FcRn therefore functions as a 
protective carrier that shuttles IgG molecules away from the lysosome and back 
into the serum, ensuring a longer serum half-life. Although these pharmacokinetic 
advantages, even some restrictions may be related to the large size and Fc portion 
of mAbs [75] .   
Furthermore, generally mAbs used in cancer therapy are required to exhibit high 
tissue and extracellular matrix penetration -excluding the case of hematological 
malignancies and diseases- to ensure high efficiency of the treatment. However, 
other important issues to be considered are represented by tumor heterogeneous 
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and tortuous vasculature, high interstitial fluid pressure and high viscosity of the 
tumor blood. Thus, to penetrate tumors, mAb molecules need to fight against the 
high pressure gradient generated by the tumor environment [76].  
The diffusion speed through the tumors is mainly affected by the mAbs size, thus, 
since the rate of diffusion is inversely proportional to their molecular weight, they 
generally exhibit poor tumor penetration. In addition to the size, another relevant 
factor is the ‘binding site barrier effect’ which can further decrease their tumor 
penetration [77]. This effect is due to the fact that antibodies endowed with high 
affinity toward the proper antigen, strongly bind it at the first encounter, thus they 
cannot penetrate deeper inside the tumor until all antigen molecules are saturated 
in the periphery. Thus, antibodies possessing a moderate binding affinity to the 
antigen are more suitable because they can be released from the first encounter 
and penetrate deeper into the tumor, allowing uniform distribution through the 
tumor mass and higher tumor uptake. In addition to these parameters, uptake and 
retention of the mAbs by the tumor depend even on further factor, such as antigen 
density, internalization, association and dissociation rates [78]. 
Furthermore, employing of antibodies as therapeutic tools even requires a suitable 
half-life in the human body, regulated by the combination of several processes, 
including absorption, distribution, metabolism and excretion. However, the hal-
life property is not universally shared by all the IgGs, since it is a function of their 
different affinity to the neonatal Fc-receptor (because of their different 
glycosylation status), which in turn depends on their  isotype: IgG1, IgG2 and 
IgG4 exhibit a half-life of approximately 21 days, while for IgG3 is only 7 days.  
Moreover, the half-lives of therapeutic mAbs generally increase with the degree 
of humanization: murine mAbs exhibit a hal-life of 1.5 days, while for the 
chimeric mAbs is 10 days, finally humanized and fully human share a comparable 
half-life of about 15-20 days [79]. The shorter half-life of murine mAbs derived by 
the combination of two factors: the leak of the binding to human neonatal Fc-
receptor and the generation of human anti-mouse antibodies (HAMA).  
Thus, the elimination of mAbs is a complex multi-factorial process regulated by 
protein catabolism, interaction with neonatal Fc-receptor, target-mediated 
elimination, immunogenicity, proteolytic degradation and glycosylation [79, 80]. 
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With regard to the pharmacodynamic properties, although mAbs can exhibit a 
certain mode of action when tested in vitro, the exact mode of action in patients is 
not always clear.  
The simplest mechanism is the binding of the antibody to its antigen, interfering 
with its activity and/or interaction with binding partners. For instance, the most 
commonly targeted antigens can be represented by soluble ligands (TNF-α, 
VEGF) or a receptor exposed at the cell surface (EGFR, HER1, HER2).  
Moreover, the tumour cell killing effect of monoclonal antibodies can be exerted 
through a variety of mechanisms, some of them are reported below [81]: 
1. Direct effect: the antibody activity is elicited through receptor agonist or 
antagonist activity, resulting in perturbation of signal transduction. 
The direct effect is the mode of action of Cetuximab [82] and Trastuzumab [83], 
which are directed against receptor targets, EGFR and HER2 respectively.  
2. Immune-mediated tumour activity: this effect is mediated by CDC and ADCC 
mechanisms, even correlated to the induction of phagocytosis and the immune 
modulation of T cell function. 
The CDC effect (complement-dependent cytotoxicity) is achieved by the 
interaction of the IgG Fc portion to C1q, recruiting the complement cascade, 
ultimately leading to the formation of pores in the targeted cell membrane, or 
recruiting effector cells through interaction with the C4b/C2b/C3b complex bound 
to the target cell surface and the receptor CR1 (complement receptor) [80]. 
On the other hand, the ADCC effect (antibody dependent cell-mediated 
cytotoxicity) is exerted through the binding of Fc portion to the Fc receptors. The 
glycosylation status of IgG1 molecules is a key modulator of the Fc-affinity for 
FcRIIIa, related to the in vivo efficacy of antibodies [79]. Moreover, a relevant 
restriction is represented by the fact that therapeutic antibodies have to compete 
with a high concentration of patient’s IgGs for binding to FcRIIIa, requiring high 
doses to reach a sufficiently high serum concentration. Finally, the therapeutic 
antibodies may also bind inhibitor Fc receptors such as FcRIIb, expressed by B-
cells, macrophages, dendritic cells and neutrophils that negatively regulate their 
effector functions [78]. 
Examples of mAbs currently used in clinical, that exhibit this type of mode of 
action are represented by Rituximab (anti-CD20) [84], that exerts its effector 
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function mainly through ADCC and Ipilimumab (anti- CTLA-4) [85] that induces 
immune modulation of T cell function.  
3. Specific effects on tumor vasculature and stroma: vascular and stromal cell 
ablation can be induced by vasculature receptor antagonism or ligand trapping; 
stromal cell inhibition; delivery of a toxin to stromal cells and to the vasculature 
[81]. 
Finally, beyond the nature of the target antigen also the safety and efficacy of 
therapeutic mAbs are important to successfully develop a useful product in oncol-
ogy. Ideally, the target antigen should be abundant and accessible and should be 
expressed homogeneously, consistently and exclusively on the surface of cancer 
cells. Antigen secretion should be minimal, since secreted antigens can bind the 
antibody in the circulation, preventing antibody from sufficiently binding to the 
tumor. If the desired mechanism of action is ADCC or CDC, the antigen–mAb 
complex should not be rapidly internalized so as to provide the maximal 
availability of the Fc portion to immune effector cells and complement proteins. 
By contrast, good internalization is required for antibodies or proteins that deliver 
toxins into the cancer cell (in the case of ADCs) and for antibodies whose 
mechanism of action is primarily based on the down-regulation of cell surface 
receptors. Although most of the antibodies that have been successfully used in the 
clinic are intact IgG molecules, new approaches for antibody engineering and for 
the delivery of conjugated cytotoxic drugs are widely being proposed [86]. The 
main mAbs approved by FDA in clinical use are listed in Table 1 [81].   
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Table 1. FDA-approved therapeutic antibodies and Fab fragments
Brand Name Antibody Target Source Year Indication
Orthoclone® Muromonab-CD3 CD3 All rodent 1986 Transplantation rejection
ReoProTM Abiciximab GPIIb, IIIa Chimeric 1994 High-risk angioplasty
RituxanTM Rituximab CD20 Chimeric 1994 Non-Hodgkin’s lymphoma
Rheumatoid arthritis
Zenapax® Daclizumab CD25 Humanized 1997 Transplantation rejection
REMICADE® Inflixinmab TNF-a Chimeric 1998 Crohn’s disease
Simulect® Basiliximab CD25 Chimeric 1998 Transplantation rejection
SynagisTM Palivizumab RSV F protein Humanized 1998 RSV infection
Herceptin® Trastuzumab HER2 Humanized 1998 Breast cancer
MylotargTM Gemtuzumab CD33 Humanized 2000 Acute myeloid leukemia
Campath® Alemtuzumab CD52 Humanized 2001 Chronic lymphoticleucemia
T-cell lynphoma
Zevalin® Ibritumomab tiuxetan CD20 Murine with 
yttrium-90 or 
indium-111
2002 Non-Hodgkin’s lymphoma
HUMIRATM Adalimumab TNF-a Human 2002 Inflammatory diseases
Autoimmune disorders 
Bexxar® Tositumomab CD20 Murine with iodine-
131
2003 Non-Hodgkin’s lymphoma
Xolair® Omalizumab IgE Humanized 2003 Severe allergic asthma
AvastinTM Bevacizumab VEGF Humanized 2004 Metastatic colorectal cancer
NSCLC 
Metastatic breast cancer
Glioblastoma
TYSABRI® Natalizumab α4 subunit of 
α4β1
Humanized 2004 Multiple sclerosis
Chron’s disease
ErbituxTM Cetuximab EGFR Chimeric 2004 Colorectal cancer
Head and neck cancer
VectibixTM Panitumumab EGFR Human 2006 Metastatic colorectal carcinoma
LUCENTISTM Ranibizumab VEGF-A Humanized Fab 2006 Wet macular degeneration
Soliris® Eculizumab CD59 Humanized 2007 Paroxysmal nocturnal hemoglobinuria
CIMZIA® Certolizumab pegol TNF-a Humanized Fab 2008 Chron’s disease
Rheumatoid arthritis
SimponiTM Golimumab TNF-a Human 2009 Rheumatoid and psoriatic arhtritis
Active ankylosing spondylitis
Yervoy® Ipilimumab CTLA-4 Human 2011 Metastatic melanoma
Perjeta® Pertuzumab HER2 Humanized 2012 Breast cancer
Kadcyla® Trastuzumab emtansine HER2 Humanized ADC 2013 Breast cancer
27 
 
d) Antibody humanization iter 
Humanization plays a fundamental role in the development of antibodies as 
therapeutic agents. Monoclonal antibodies humanization is an essential 
engineering step required to reduce the immunogenicity derived from non-human 
sources. The original technique initially developed  to humanize antibodies was 
the ‘‘ CDRs grafting’’ of murine CDRs onto human antibody frameworks [87]. 
However, two main issues were generally related to this methodology: defects at 
the CDR/framework interface  and consequently decread affinity of the antibody 
toward the antigen, thus suggesting that residues non belonging to the CDRs are 
crucial  in maintaining optimal antibody/antigen interface. These residues 
important for maintaining CDR structures was named ‘‘canonical residues’’[88]. 
The next generation approach explored to achieve antibody humanization was the 
‘‘back mutation method”, based on retaining both mouse CDRs and canonical 
residues in antibody framework [89]. For this purpose  a three-dimensional 
structure of the mature donor (non-human) antibody, alone or in complex with the 
target antigen is required to successfully  perform the humanization process. In 
order to produce a humanized antibody with good stability and/or with target 
affinity comparable to the mature donor antibody, it may be necessary the design 
and synthesis of some versions of the humanized antibody, each with a few 
mutations chosen to resolve any clashes or mismatch between the CDRs and the 
framework regions [90]. The traditional way to resolve such mismatches is the so-
called “framework redesign” method, in which the mature donor CDRs alone is 
left intact, performing mutations only at some human acceptor framework 
residues in proximity of the CDRs to the amino acids, located at the 
corresponding positions in the mature donor framework. Thus, the regions 
surrounding the CDRs are made more like the mature donor antibody as a scaffold 
to preserve its CDR structure. A recent alternative method to resolve such 
mismatches, is the ‘‘CDR redesign’’ [91] consisting in leaving the human 
framework intact, while redesigning positions on the backside of the mature donor 
CDRs to the amino acids found at the corresponding positions in the CDR 
backsides of the human sequences from which the human acceptor frameworks 
were taken, or to other amino acids determined by de novo design. Thus, the result 
could be a completely human antibody excepted its mature CDRs.  
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However, humanized antibodies in some patients can evoke anti-idiotypic (anti-
Id) responses, due to their xenogenic CDRs. Thus, a new technique, “SDR 
grafting”, was developed starting from the evidence that only 20–33% of CDR 
residues are critical in the antigen–antibody interaction [92]. These residues, 
located in the regions of high variability and most likely to be unique to each 
antibody, are called SDRs (specificity determining residues) [93]. Thus, this 
strategy consists in grafting only the SDRs of a xenogenic antibody onto the 
human antibody frameworks [94,95], instead of the entire CDRs. 
Once the non-human antibody regions targeted for grafting onto the human FRs 
(framework regions) have been defined, the second step in a humanization process 
is to identify the more suitable source of human FR donors. The most common 
strategies are two: the first, named  “the fixed FR method”, is based on the use of 
FRs belonging to human antibodies with known structure, regardless their 
homology to the non-human antibody [91]; the second one, termed “the best fit 
method “, is based on the use of human sequences with the highest homology to 
the non-human antibody [96]. 
In general, to achieve an antibody humanization, the interaction of the CDRs to 
each other and with the rest of the variable region must be preserved, maintaining 
both framework residues involved in VL–VH contact and those affecting the 
overall domain structure. Both the SDR and CDR grafting procedures require 
selection of the most appropriate human frameworks to be used as templates, and 
identification of the framework residues that are critical to the preservation of the 
structure of the antigen-binding site. When comparing the sequences of the 
frameworks of the target and the template antibodies, if any of the crucial residues 
of the target antibody is found to be different from their corresponding residues in 
the human template, the crucial residues of the target antibody are incorporated in 
the frameworks of the templates for the final design of the humanized antibody.  
With regard to the method chosen to select the human FRs, two sources of human 
sequences can be used: mature and germline sequences. Mature sequences, which 
are products of immune system, carry somatic mutations generated by random 
processes and are not under species selection, resulting in potential immunogenic 
residues. Thus, to avoid immunogenic residues, human germline genes have 
increasingly been preferred as source of FR donors.  
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An alternative method to the CDR grafting is the “Resurfacing” [96] allows to 
retain the non-exposed residues of non-human antibody. Only surface residues in 
non-human antibody are changed to human residues. Since resurfacing does not 
change the residues in the core of V domains, the expectation is to eliminate 
potential B-cell epitope, while minimizing the perturbation of residues 
determining the specificity of antibody. 
Finally, following an empirical approach, Dall’Acqua et al. have described a new 
humanization method called ‘‘framework shuffling’’[97], based on the in which the  
synthesis of a combinatorial library. This library, constituted by six CDRs (three 
in the light chain, L1, L2, and L3 and three in the heavy chain, H1, H2, and H3), 
fused in frame to a pool of individual human germline frameworks, are screened 
for binding to the antigen of interest. This approach allows the selection of the 
most favorable combinations of fully human frameworks retaining the binding 
activity of the parental antibody. Finally, the overall execution of this 
methodology is highly facilitated since it does not require previous  antibody 
structural studies including  CDR analysis or framework design. 
 
d) Development of monoclonal antibodies as biotherapeutics: an overwiew 
The successful development of candidate antibodies for the clinic involves a 
complex process of scientific and preclinical evaluations, informed by deep 
understanding of cancer biology and the properties of antibodies in vivo. Essential 
preclinical characterization includes: identification of the physical and chemical 
properties of the antibody; detailed specificity analysis of antigen expression 
using panels of normal and malignant tissues; study of the immune effector 
functions and signalling pathway effects of the antibody; analysis of in vivo 
antibody localization and distribution in transplanted or syngeneic tumour 
systems; antibody chimerization and humanization and evaluation of the in vivo 
therapeutic activity of the antibody either alone or conjugated with radioactive 
isotopes or other toxic agents [98, 99]. 
However, one of the most essential steps in the clinical evaluation of a potential 
therapeutic antibody is the in vivo specificity determining the bio-distribution of 
an antibody (often radiolabelled) in patients to assess the ratio of antibody uptake 
in the tumor versus normal tissues. This information is essential for the rational 
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design of antibody therapy, for which knowledge about the targeting of normal 
tissues is crucial for predicting toxicity [100]. 
Normal tissue distribution can be quantitated, thus allowing the relationship of the 
loading dose to tumor concentration to be accurately assessed, rather than relying 
on plasma concentration and clearance rates to establish an optimal dose. In con-
junction with other pharmacodynamic studies, including computerized 
tomography with magnetic resonance imaging, positron emission tomography, 
plasma-based protein, cell and genomic analyses, and tumour biopsies, the effect 
of antibody abrogation of a signaling pathway function can also be determined 
[101].  
 
I.5 ANTIBODY FRAGMENTS PRODUCTION: ADVANTAGES AND 
LIMITATIONS 
 
Considering the limitations and disadvantages due to a full-size antibody 
molecule, such as high molecular weight, poor tissue penetration and 
immunogenicity, many attempts have been performed in the last past decades to 
generate antibody fragments so as to improve the efficiency of these molecules as 
diagnostic and therapeutic tools [101]. Two different approaches can be used to 
obtain fragments from the parental antibody: through proteolytic fragmentation by 
specific enzymes or through DNA recombinant technology. 
The most common types of antibody fragments generated by enzymatic 
procedures are Fab, (Fab’)2 and Fab’[102]. However, the enzymatic approach is 
commonly used when the final aim is a biochemical characterization of the final 
product, including the structural study of the distinct regions of an 
immunoglobulin, crystallization study of the Fab-antigen complex and in some 
cases use of a cognate Fab to help the crystallization of proteins [103]. On the 
other hand, the recombinant approach is universally used to develop functional 
fragments as therapeutic tools instead of whole immunoglobulines.  
Since antibody genes can now be cloned, the recombinant DNA technology is 
became an useful tool to express a wide variety of genetically engineered antibody 
formats, including Fab fragments, Fv fragments and so-called scFv. The most 
common expression systems are host organisms, including prokaryotic and 
eukaryotic organisms as well as trangenic organisms.  
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Among the prokaryotic organisms, Escherichia coli, a Gram negative bacterium, 
is the most common system for expression of recombinant proteins, ensuring very 
high volumetric yields [104,105]. The major challenges in bacterial Fab fragment 
expression are the correct assembly of the functional heterodimer and formation 
of all the disulfide bonds. The key to success was the secretion of both 
polypeptide chains, light chain and Fd fragment (N-terminal half of the heavy 
chain) into the periplasmic space of E. coli where the oxidizing environment 
allows the correct formation of disulfide bonds and the assembly to a functional 
fragment [106]. For this purpose bicistronic vectors with the first cistron encoding 
the light chain and the second cistron encoding the Fd fragment are optimal [107].  
Also Gram-positive bacteria (Bacillus brevis, Bacillus subtilis and Bacillus 
megaterium) have already successfully used for the production of different 
antibody fragments. These bacteria directly secrete proteins into the medium since 
they lack an outer membrane which could facilitate production of antibody 
fragments [108-110]. 
On the other hand, eukaryotic cells have developed an advanced folding, post-
translational and secretion apparatus which enhance the secretory production of 
antibody molecules, including full immunoglobulins compared to bacteria.  
Pichia pistoris represents the major yeast strain used for recombinant antibody 
production [111]. Also, insect cells represent a very versatile eukaryotic expression 
system. Insect cell lines (e.g. Sf-9 and Sf-21 of Spodoptera frugiperda) can be 
efficiently transfected with insect-specific viruses from the family of 
Baculoviridae, that are highly species-specific and are considered as safe for 
humans, mammalian and plants [112]. 
Today, 60-70% of all recombinant protein pharmaceuticals and 95% of the 
currently approved therapeutic antibodies are produced in mammalian system 
despite relatively high production costs and difficulty in handling. However, the 
advanced mammalian folding, secretion and post-translational apparatus garantee 
the production of antibodies and their fragments indistinguishable from those in 
the human body, avoiding immunogenic response. 
However, Chinese hamster ovary (CHO) cells represent the most common cell 
line employed in the commercial production of biopharmaceuticals as well as 
Baby hamster kidney (BHK) cells and Human embryonic kidney cell line HEK293 
[113]. Although glycosylation patterns of mammalian glycoproteins are very 
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similar to those in humans, even small differences can affect pharmacokinetics 
and effector functions of antibodies [114]. Finally, the development of transgenic 
plants for the expression of recombinant antibodies is becoming interesting 
especially when high amounts are required. Although this expression system 
exhibits some advantages (higly easily up-scaling of the antibodies production 
process and lower costs compared to the expression in hybridoma cells), the 
glycosylation pattern still represents the main obstacle in developing therapeutic 
antibodie and derivative fragments, compared with the mammalian cells [115]. 
 
 
I.6 NEXT GENERATION ANTIBODY FORMATS 
 
As already mentioned, because of their limited tumor penetration and long serum 
half-life, antibodies are not suitable for applications such as radioimmunotherapy 
or imaging. Antibody fragments exhibiting monovalency and limited size can 
represent a valid alternative so as they are not retained for long time by the 
antigen and they can be even rapidly cleared by kidneys. 
Thus, antibody engineering approach, widely used to produce chimeric or 
humanized mAbs, has been adapted in order to produce recombinant innovative 
antibody formats, beyond the most traditional Fab fragment, to retain the binding 
activity of the intact molecule, but to be more suitable in certain specific 
applications [116].  
The first innovative format, early designed, was the monovalent scFv (single-
chain variable fragment), consisting of only the variable domains of the heavy and 
light chains (Fv)  linked by a flexible linker [117]. However, because of its very 
short half-life in serum (~2 h) related to the MW of about 28 kDa, this fragment is 
not very powerful to be used alone but it has been normally used as a binding 
element incorporated in more complex molecules.  
Thus, an alternative new format has been create, the Diabodies, with positive 
properties, such as bivalency and compact and medium-size (60 kDa). The right 
compromise between the medium molecular weight and the bivalency provides 
many advantages, including rapid tissue penetration, high target retention and 
rapid blood clearance. Given these parameters, diabodies represent promising 
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tools in radioimmunotherapy when labelled with radioisotopes (
123
I or 
111
In), or 
for imaging purposes when labelled with positron emitters (
64
Cu or 
124
I) [118]. 
Furthermore, a new intriguing antibody format is represented by the single-
domain antibodies (sdAbs) also named “nanobodies“ [119], that possess a single 
variable domain which generates high affinity towards multiple antigens. These 
molecules consist of small domains (13 kDa) naturally endowed with very 
powerful characteristics, such as very high stability and the possibility of binding 
strongly to epitopes not accessible to conventional antibodies such as enzyme 
active sites. Furthermore, bispecific antibodies (bsAb) have been created to 
generate a format possessing strong and specific binding capability 
simultaneously to two different antigens [120].  
Another interesting next generation antibody format is represented by intrabodies, 
that have been designed to be expressed intracellularly by the incorporation of 
intracellular peptidic trafficking signals. This allows the antibody to penetrate a 
cellular compartment (cytosol, nucleus, endoplasmic reticulum (ER), 
mitochondria) [121], which is normally not enter, where it can interact specifically 
with the target antigen. Depending on their mechanism, intrabodies can be 
classified into two categories. The mechanism of the first category is based on the 
binding to the target within the ER lumen, thus avoiding the target molecule to 
leave the ER and ultimately to be expressed on the cell surface [122]. Moreover, 
the redox conditions of the ER environment helps the correct formation of 
disulphide bridges of these intrabodies. By contrast, the second category 
comprises antibodies expressed on cytoplasmic polysomes and released into the 
cytoplasm of the cell, thus they need a self-folding ability to correctly fold in the 
reducing environment of the cytoplasm [123]. 
As explained previously, the limited size of antibody fragments provides a more 
rapid and efficient tumor penetration than whole IgG, but this benefit is 
counterbalanced by a very short serum half-life. A most common strategy 
exploited to improve the half-life of antibody fragments is the chemical addition 
of polyethylene glycol (PEG) molecules which notably increase their size and 
simultaneously provide further advantages, such as longer half-life, stability and 
decreased immunogenicity. An example of PEGylated fragment is Certolizumab 
pegol, a FDA- approved anti-TNF-α PEGylated Fab fragment [124]. However, 
since this chemical modifications may lead to partial inactivation or decreased 
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affinity of the fragment, a recently employed alternative approach is represented 
by the fusion of recombinant antibody fragments to human serum albumin (HSA) 
to increase the serum half-life without affecting the binding and activity of the 
fragments [125].  
 
 
 
 
Figure 1.8: Antibody fragments with therapeutic potential. A conventional antibody is illustrated 
in green. The orange colour symbolizes a different specificity. The red molecule represents a 
cytokine or a toxin. bsAb, bispecific antibodies; bsFab, bispecific Fab fragment; HcAb, heavy 
chain only antibodies [126]. 
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I.7 ANTIBODY-DRUG CONJUGATES (ADCs) 
As said, monoclonal antibodies are an important class of biotherapeutic agents. 
There are at least 25 antibody-based medicines approved for human therapy and 
more than 240 antibodies that are being evaluated clinically. Currently also a 
small number of antibody Fab fragments are used in clinical (Ranibizumab, 
Certolizumab pegol) and some classes of engineered antibody fragments (scFv, 
diabodies) are also in development [127].  
Although monoclonal antibodies are known to be very useful in cancer treatment, 
their therapeutic potential is often limited. Thus, the idea of “arming naked” mAbs 
with bioactive payloads (drugs, cytokines, radionuclides) was realized so as to 
create the so-called antibody–drug conjugates (ADCs) [128]. The ADCs represent 
an innovative therapeutic approach that combines the high specificity of the mAb 
portion towards a specific target antigen, with the cell killing activity of cytotoxic 
drugs, to minimize the systemic toxicity and at the same time to enhance the 
therapeutic efficiency for patients, leading simultaneously to the gain of a drug-
delivery system as well as a tumor-homing effect.  
The architecture of a  typical ADC comprises three elements (Fig. 1.8):  
1. a mAb or mAb fragment specific for a target tumor antigen  
2. a highly potent cytotoxic agent as payload 
3. a linker that enables covalent attachment of the cytotoxin to the mAb.  
 
 
                                         
Figure 1.8: Architecture of an antibody-drug conjugate (ADC). 
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Critical parameters to the clinical efficacy of an ADC are the target site-specificity 
and binding properties of the antibody, the in vitro and in vivo stability of the 
linker and drug species, the potency of the drug, and both the distribution and 
average number of drug species on the antibody [128]. 
The most potent cytotoxic drugs currently used for ADC application, are 
calicheamicins [129], maytansinoids [130] and auristatins [131]. One of the critical 
hallmarks of an ADC is the average number of drugs conjugated because this is 
highly determinant the amount of “payload” that can be delivered to the tumor 
cell and can directly affect both safety and efficacy.  
The assembly of the ADC from the components is a key step in determining the 
therapeutic potential of the final product. The conjugation should not alter the 
integrity of the antibody, the binding of the antibody to the antigen or the 
biological activity of the drug upon reaching the target cells. Usually, three 
common methods are reported for conjugation of mAbs to the drug: alkylation of 
reduced interchain disulfide bridges, acylation of Lysines, and alkylation of 
genetically engineered Cysteines. The first of two mentioned strategies generate 
heterogeneous products, with variations in the number of molecules of drug per 
antibody and in the sites of attachment. The third strategy, instead, allows the 
specific insertion of Cysteines into the mAb backbone by recombinant 
methodology, so as to obtain uniform conjugated mAbs [132]. 
An innovative and very intriguing strategy is the conjugation via enzymatic 
reaction performed by the TGase (protein glutamine γ-glutamyltransferase, EC 
2.3.2.13). This enzyme catalyzes acyltransfer reactions between the γ-
carboxamide group of Glutamine (chemically inert under physiological 
conditions) and the primary ε-amino group of Lysine, to form catabolically stable 
isopeptide bonds, leading to a highly efficient site-specific and stoichiometric 
functionalization of antibody molecules [133]. The usefulness of this enzyme is the 
versatility of the reaction because it may be exploited in ADC generation as well 
as to create new antibody formats, for instance a bivalent fragment when two Fabs 
from the same antibody are linked or a bispecific fragment when two Fabs from 
two different antibodies are connected.  
Furthermore, the choice of suitable linkers is determinant for the performance of 
ADC product, since it affects the release of the drug upon reaching the target 
cells.  
37 
 
Thus, the linker must be extremely stable in systemic circulation, avoiding 
nonspecific cell killing and toxicity effects due to the premature release of the 
cytotoxic payload before reaching the target. However, the linker must be labile 
enough to allow efficient release of the cytotoxic drug in its active form inside the 
targeted tumor cells, achieving the cell killing [134,135].  
The linkers currently used are grouped into two categories: cleavable and 
noncleavable linkers. More exactly, the cleavable ones are in turn classified into 
three sub-groups, depending on their cleavage mechanism: i) acid labile 
hydrazone linkers, ii) disulfide-based linkers, iii) linkers based on p-amino 
benzoic acid (PBA), a molecular moiety that, following cleavage of a peptide 
bond by cathepsins, undergoes a rearrangement that expulses the entire linker. 
This technology is patented by Seattle Genetics and licensed to companies that 
want to make use it (http://www.seattlegenetics.com/adc_technology).  
Two different approaches can be used to target tumor tissues via ADC products. 
When the tumor-associated antigens are expressed on the surface of cancer cells –
in the case of receptors- the ADCs typically require internalizing mAbs, uptaken 
by cells via receptor-mediated endocytosis and subsequently by different chemical 
mechanisms, the drug is released [136]. However, targeting antigens on tumor cells 
exhibit physical and kinetic barriers correlated to large solid tumors, and to the 
potential down-regulation of tumor-associated antigens targeted by the 
immunoconjugate. Thus, to overcome this limitation, an alternative approach has 
been developed, targeting markers expressed on tumor neo-vasculature, more 
easily accessible, requiring non-internalizing antibodies. Remarkably, since 
angiogenesis is a common feature of all malignancies and tumors express 
common markers of angiogenesis, a single agent should be exploited in a wide 
range of tumors [137, 138]. 
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Figure 1.9: Illustration of the two possible strategies used for the delivery of the ADCs and their 
effect on the tumor cells. (Left) ADCs specific to markers of angiogenesis expressed on the 
endothelial extracellular matrix (green).(Right) ADCs containing internalizing mAbs (blue) [135].  
 
 
A further important aspect to be considered is the pharmacology of the ADCs. 
Ideally, an ADC acts as an inactive pro-drug when in the bloodstream and only 
upon internalization into target cells or localization to the tumor becomes an 
active released drug. However, only a small amount of the ADC effectively reach 
the target cells, thus a highly potent drug is desired. The remaining drug 
undergoes catabolic processing in normal tissues, causing exposure to the released 
drug. Thus, an optimal drug for ADCs should not exhibit a long residence time 
after releasing in normal tissues, while maintain a high concentration in the tumor 
for an extended time.  
Finally, the size of the ADC delivery vehicle also plays an important role in how 
effectively drug is delivered to tumors [139, 140].  A successfully developed ADC 
is Trastuzumab emtansine [141], the first ADC approved by FDA in treatment of 
HER2 positive metastatic breast cancer, which consists of the full antibody 
conjugated to DM-1 toxin. 
More recently, the development of a Fab ADC, composed of an anti-c-Met Fab 
conjugated to Doxorubicin, has been reported, as a promising therapeutic tool in 
hepatocellular carcinoma (HCC) [142]. 
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I.8 AIM OF THE RESEARCH PROJECT 
The main aim of this research project is the development of functional 
monoclonal antibodies and their fragments, to be employed as powerful 
diagnostic and therapeutic tools to target human CR-1 protein, which is over-
expressed in a broad range of human solid tumors. The specific target pathway 
involves the interaction of CR-1 with its trans-membrane receptor ALK4, which 
triggers a series of downstream events that ultimately lead to tumor growth and 
progression.  
Thus, blocking molecules are required to possess high selectivity and affinity 
toward the CFC domain of CR-1, which is directly involved in the binding to the 
receptor. Moreover, these molecules need to specifically recognize H120 and 
W123, known to be “hot spots” for the CR-1/ALK4  interaction. The molecules 
will be initially tested on cancer cell lines to evaluate their potential as effective 
anti-tumour agents. We will reach this goal by generating monoclonal antibodies 
against the CFC domain of human CR-1 and characterizing them for their affinity 
and selectivity toward the protein. We will also undertake structural and 
functional studies using the antibodies and their fragments to gain insights into the 
interacting surfaces and to improve selectivity and affinity.  
We will also proceed with a step of partial humanization of the antibody to obtain 
a molecule with the potential of being used in humans. We will also investigate 
the feasibility of generating Antibody Drug Conjugates (ADCs), a new powerful 
approach in oncology, to overcome the limitations of monotherapies which are 
generally not sufficient for a cell killing effect on tumor cells. This will be 
achieved by arming the “naked” mAb with a potent cytotoxic agent, linked 
selectively to the antibody on specific sites. 
This goal will be achieved by an innovative conjugation strategy via the M-TGase 
enzyme. These functionalized antibody or fragments will be used to increase 
specificity by exploiting the “tumor homing” effect driven by the antibody, 
providing the drug selectively into tumor cells over-expressing human CR-1, so as 
to minimize the cross-reactivity with healthy tissues. 
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                                               CHAPTER II 
 
MATERIALS AND METHODS 
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II.1 MATERIALS AND CHEMICALS 
 
Protected amino acids for peptide synthesis and coupling agents were purchased 
from GL-Biochem (Shanghai, PRC), and IRIS Biotech GmbH (Marktrewitz, DE). 
The RINK amide resin was from Novabiochem (Darmstadt, DE). Solvents, 
including CH3CN, DMF and CH3OH were from ROMIL (Dublin, IRL). The 
instruments used throughout the peptide generation and characterization were 
Syro system (MultiSynTech, DE), LC8 Shimadzu HPLC system (Shimadzu 
Corporation, Milan, IT) and Waters e2695 (Alliance HPLC). For analytical 
HPLCs an Agilent 1100 system was used. DTT, DMSO, BSA and KLH were 
provided by Sigma-Aldrich (Milan, IT). Nunc MaxiSorp 96 multi-well plates 
were purchased from Thermo Scientific (DK). All chemicals used for ELISA 
assays were provided by Sigma-Aldrich. Microplate plate washer and reader were 
supplied by BioTek (Winooski, VT, USA). 
All the chromatographic columns and AKTA FPLC system were provided by GE 
Healthcare Life Sciences (Milan, IT). All certified reagents used to perform SPR 
analyses and Biacore3000 instrument were supplied by GE Heatlhcare Life 
Sciences. All the chemicals used for electrophoresis and western blot analyses 
were supplied by Bio-rad (Milan, IT), thereby APS and TEMED were provided 
by Sigma-Aldrich. Recombinant proteins were purchased from R&D Systems 
(Minneapolis, MN, USA).Transcriptor High Fidelity cDNA Synthesis Kit (Roche, 
CH) was used to perform RT-PCR reaction. 
All the enzymes used to treat the 1B4 antibody and all the reagents used 
throughout the digestion reaction were supplied by Sigma-Aldrich.The synthetic 
gene was purchased from MWG Eurofins, the pET-26b(+) vector was supplied by 
Novagen and the restriction enzymes, BlpI and KpnI were provided by New 
England biolabs.  
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II.2 METHODS 
 
2.1 CHEMICAL SYNTHESIS, PURIFICATION, CHARACTERIZATION 
AND REFOLDING OF HUMAN CFC DOMAIN AND ITS MUTANTS 
 
a) Solid-phase peptide synthesis and purification 
All peptides were synthesized by using an automatic Syro system. The wild-type 
human CFC domain, denoted as hCFC[112-150], and its three variants were 
prepared by step-wise solid phase synthesis as C-terminally amidated derivatives 
following standard Fmoc chemistry protocol. A Rink-amide MBHA resin 
(substitution 0.53 mmol/g) and amino acid derivatives with standard protections 
were used in the synthesis. Each synthesis was performed starting under canonical 
conditions of peptide synthesis (HATU/DIEA pre-activation, 5-fold excess of 
Fmoc-protected amino acids). Coupling and deprotection cycles were kept at 25 
and 15 min, respectively. Standard side-chain protection groups for Fmoc 
chemistry were used for all residues; the Cysteines were introduced as trityl (Trt) 
derivatives, thus generating after cleavage free thiol groups. 
Finally, acetylation was performed using acetic anhydride at 0.5 M in DMF with 
5% DIEA, 20 min at rt. The cleavage of peptides from the solid support was 
performed by treatment with a TFA/TIS/water (90:5:5, v/v/v) mixture for 2h at rt, 
affording the crude peptides after precipitation in cold diethyl-ether. The 
precipitates were dissolved in water and were finally lyophilized. Products were 
opportunely reduced with DTT and then purified to homogeneity by RP-HPLC 
using an ONYX monolithic C18 column (100 x 10 mm ID) applying a linear 
gradient of 0.05% TFA in CH3CN from 10% to 60% over 20 min (flow rate at 20 
mL/min) using a LC8 Shimadzu HPLC system.   
 
b) Refolding procedure 
Refolding reactions were carried out using each polypeptide opportunely reduced 
and purified, to avoid peptide aggregation and to increase the yield of the final 
product. Peptide refolding was achieved at the concentration of 0.05 mg/mL under 
slightly basic conditions, using 10 mM bicarbonate buffer, pH 9.0. For each 
peptide, refolding was complete at least in 3h as monitored by RP-HPLC using an 
ONYX monolithic C18 column (50 x 2 mm ID) applying a linear gradient of 
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0.05% TFA in CH3CN from 5% to 70% over 10 min (flow rate 0.6 mL/min) using 
a Waters e2695 instrument provided of a 2998 PDA detector.   
The reaction was stopped by acidification. After lyophilization, each refolded 
polypeptide was purified again as described in the previous section. For each 
polypeptide, purity and identity were confirmed by LC-ESI-TOF-MS analysis. 
  
c) Peptides identification by LC- ESI-TOF-MS analysis 
Mass spectrometry analyses were performed with an Agilent 1290 Infinity LC 
System coupled to an Agilent 6230 TOF. The liquid chromatographic Agilent 
1290 LC module was coupled with a PDA detector and a 6230 time-of-flight MS 
detector, along with a binary solvent pump degasser, column heater and 
autosampler. Based on manufacturer’s recommendations, the pump was 
connected to a gradient binary solvent system: A, 0.01% TFA/H2O (v/v) and B, 
0.01% TFA/CH3CN (v/v). The mobile phase was programmed consecutively in 
linear gradients over the different samples. Chromatographic analyses of hCFC 
domains were performed using an Agilent Extend Zorbax reverse phase C18 
column applying a linear gradient of CH3CN, 0.01% TFA from 5% to 70% in 10 
min or 20 min. The column flow rate was kept at 0.2 mL/min with the heater at a 
constant 20 °C. UV spectra were monitored in the range of 200 nm and 400 nm. 
Injection volume was 1 μL for each sample, followed by needle wash. The mass 
analyzer Agilent 6230 TOF-MS was set to operate in positive ion scan mode with 
mass scanning from 100 to 3200 m/z. The ion source was upgraded from the 
original Agilent Jet Stream (AJS) source to the dual-sprayer version for improved 
reference mass delivery. Nitrogen was used as the drying and nebulizer gas. The 
instrument acquired data using the following parameters: drying gas temperature, 
325 °C; drying gas flow, 10 L/min; nebulizer, 20 psi; sheath gas temperature, 400 
°C; sheath gas flow, 11 L/min; VCap. 3.500 V; nozzle, 0 V; fragmentor, 200 V; 
skimmer, 65 V; and octapole RF Vpp was 750. The instrument state was set up to 
extended dynamic range mode (2 GHz). Tuning and calibration were performed 
before sample running. Data collection and integration were performed using the 
MassHunter workstation software (version B.05.00). Data were stored in both 
centroid and profile formats during acquisition. A constant flow of Agilent TOF 
reference solution through the reference nebulizer allowed the system to 
continuously correct for any mass drift by using two independent reference lock-
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mass ions, purine (m/z 119.03632) and HP-922 (m/z 922.000725), to ensure mass 
accuracy and reproducibility. Target compounds were detected and reported from 
accurate-mass scan data using Agilent MassHunter Qualitative software. 
 
 
2.2 GENERATION AND PRODUCTION OF ANTI-CFC MONOCLONAL 
ANTIBODIES 
 
a) Antigen preparation: conjugation of hCFC peptide to KLH and BSA 
The conjugation reaction was carried out mixing 1.0 mg of synthetic wild-type 
hCFC[112-150] N-terminal free polypeptide in 1 mL of 20 mM phosphate buffer, 
pH 7.0, with 3.0 mg of KLH  carrier protein in 1.0 mL of 20 mM phosphate 
buffer, pH 7.0, and 0.2% v/v glutaraldehyde solution. The mixture was left under 
stirring for 3h, and then 1.0 mL of 1.0 M Glycine in water was added to block the 
reaction. The solutions were extensively dialyzed against PBS buffer, pH 7.4 and 
lyophilized. The amount of peptide-protein conjugate was determined by the 
Bradford assay, using Bio-rad kit (Bio-rad). The same procedure was used to 
conjugate the hCFC[112-150] to BSA and to prepare self-conjugated BSA 
(BSA2), without adding peptide solution.  
b) Mice immunization and hybridoma cell generation  
Murine monoclonal antibodies were generated in the laboratory of Prof. Antonio 
Leonardi at University of Naples “Federico II”, Department of Molecular and 
Cellular Biology and Pathology. The procedure was in accordance to that one 
described by Köhler and Milstein [69]. 
BALB/c mice were housed and handled according to the institutional guidelines. 
Four-five weeks old Balb/c mice (Jackson Lab) were immunized with 50 μL of 
suspension containing about 100 μg of incomplete Freund's adjuvant (TiterMax 
Gold Adjuvant, Sigma-Aldrich)-emulsified KLH-conjugated synthetic wild-type 
hCFC[112-150] peptide mixture. Two independent injections were carried out 
sub-cutaneously with 25 μL of immunogen. Before immunization, 250 µL blood 
samples were taken from each mouse from the caudal vein and used as the pre-
immune control (T0 samples). Mice were again immunized with the same amount 
of immunogen at day 30 after the first immunization (T = 30d), at day 40 (T = 
40d) and at day 60 (T = 60d). A final antigen boost was administered 
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intravenously 20 days before animals were sacrificed and splenectomised. Blood 
samples were taken from the caudal vein (250 µL) before every subsequent 
immunization and tested by ELISA to monitor the increase of antibody titer 
compared to the pre-immune serum. Mice showing the highest antibody titer were 
sacrificed and splenectomised. 
Three days after the boost, spleen cells were collected by surgery from an 
immunized mouse sacrificed by CO2 inhalation and for which all efforts were 
taken to reduce animal suffering; the spleen cells were then fused with myeloma 
SP2/0 cells in 50% PEG pH 7.4, the fusion solution to generate hybridomas. The 
splenocytes were fused at a ratio of 5:1 with the mouse plasmacytoma cell line 
SP2/0 (ATCC) using RPMI-GM containing PEG 1300-1600 (Hybri-Max, Sigma-
Aldrich) and 7.5% DMSO, following the standard procedure described by Köhler 
(1975). The fused hybridoma cells were re-suspended in 30 mL of selection 
medium consisting of RPMI–GM medium containing PEG 1300-1600, 10% FCS, 
100 U/ml penicillin, 100 μg/mL streptomycin, 100 μM hypoxanthine, 16 μM 
thymidine and 400 nM aminopterin (RPMI-HAT Sigma-Aldrich). The cell 
suspension (100 μL) was dispensed into 96-well plates and incubated at 37 °C in a 
5% CO2 atmosphere. After 12h, an additional volume of 100 μL of selection 
medium was added to each well. After 24h, half the medium from each well was 
removed, and fresh selection medium was added. Every 2 or 3 days, medium was 
replaced with fresh selection medium. After 10 days, aminopterin was omitted 
from the medium. Between the 12
th
 and 14
th
 day, supernatants from the 96-well 
plates were collected and screened by ELISA assay. Hybridoma clones with 
strong reactivity versus the hCFC peptide were re-cloned twice by limiting 
dilution, and their reactivity was re-confirmed by ELISA assays.  
 
c) Antibody production  
Sub-cloned hybridoma cells were cultured in OPTI-MEM medium containing 
10% FCS, adapted gradually to serum-free cell medium, and then transferred to 
the Bioreactor (INTEGRA Biosciences AG, CH-7000 Chur) for large scale 
production. 
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d) Isotypization 
Isotype of selected monoclonal antibodies was determined by using the 
commercial kit specific for murine antibodies, in accordance to the manufacturer’s 
instructions (Pierce Rapid Mouse antibody Isotyping kit, Thermo scientific). 
 
2.3 ELISA assays 
a) Titration of antibodies  
To determine the antibody titer in mouse sera, 96-well plates were coated with 
100 µL of hCFC[112-150] 0.5 μg/mL (110 nM) in PBS, pH 7.4, and incubated 
o.n. at 4 °C. The excess of ligand was removed from the wells by applying a three 
washes cycle with PBS-T (containing 0.05% Tween 20). Non-specific sites of the 
plate were blocked with 2% BSA and incubated at 37 ºC for 60 min. Wells were 
then washed 3 times again and ascitic fluid was added to the wells in three fold 
serial dilutions starting from 1:100 up to 1:100000. The plate was incubated at 37 
°C for 1h and washed again with PBS-T. Then, 100 μL of a 1:1000 dilution of 
HRP-conjugated rabbit anti-mouse Ig (1.0 mg/mL, 170-6516 Bio-rad ) were 
added to the wells and incubation was carried out for 1h at 37 °C. After washing, 
100 μL of ABTS substrate solution was added to each well. After 15 min, the 
reaction was stopped by adding 100 μL of 1% SDS solution in water to each well. 
OD was measured at 415 nm. Antibody titers were evaluated sufficiently high 
when the average absorbance values from triplicate wells incubated with immune 
sera dilutions at 1:10000 were at least thrice than those determined on wells 
incubated with the pre-immune serum. 
 
b) Hybridoma supernatants screening 
After hybridomas generation, supernatants were screened simultaneously using 
the wild-type antigen peptide, hCFC[112-150] and the hCFC[112-150]W123A 
variant, in which the Triptophan123 was mutated to Alanine residue (Trp123Ala 
or W123A). 96 multi-well plates were coated with 100 μL of the antigen peptide 
solutions at a concentration of 1 μg/mL (220 nM) in PBS, pH 7.4, and incubated 
o.n. at 4 °C. Hybridoma supernatants, diluted in PBS pH 7.4, were tested at a 
single concentration of 5 µg/mL  (33 nM considering the IgGs fraction). To detect 
the antigen-antibody interaction, 100 μL/well of GAM-HRP (170-6516 Bio-rad) 
47 
 
secondary antibody were added, using a 1:1000 dilution (1 μg/mL). The assay was 
carried out as described above, except for the detection performed by OPD 
substrate kit. A peroxidase substrate solution (prepared by dissolving OPD at 0.4 
mg/mL in 0.1 M citric acid and 0.2 M Na2HPO4 buffer, pH 4.8, and adding 0.2 
mL of 30% H2O2) was added to each well (100 μL) and when the orange color 
was sufficiently visible, 2.5 M H2SO4 (50 μL) was added to stop the enzymatic 
reaction, as indicated by the solution turning yellow. The plates were read at 490 
nm. 
c) Epitope mapping assay 
Likewise, epitope mapping was also carried out by ELISA, coating on plates 100 
μL/well of the synthetic wild-type hCFC[112-150] and its three variants 
(hCFC[112-150]H120A;hCFC[112-150]W123A;hCFC[112-150]H120AW123A) 
at a concentration of 0.5 μg/mL (110 nM) in PBS, pH 7.4, incubating o.n. at 4 °C. 
Dose-dependent assays were performed using 10D1 and 1B4 mAb solutions (100 
μL/well), diluted in PBS, pH 7.4, ranging from 0.07 µg/mL (0.5 nM) up to 2.5 
μg/mL (17 nM).  
 
d) Binding assays of  1B4mAb and its recombinant fragments on hCFC[112-
150] antigen polypeptide 
Dose-response comparative binding assays on the hCFC antigen were conducted 
with the full-size 1B4 antibody and its recombinant new formats (rFab and rFab2). 
Plates were coated with 100 μL/well of synthetic hCFC[112-150] at 0.5 μg/mL 
(110 nM) leaving in incubation o.n. at 4 °C. The analyte solutions (100 μL/well) 
were used at increasing concentrations. Both ligand and analyte solutions were 
prepared in PBS, pH 7.4. 
 
e) Specificity ELISA assays on rhCR-1/rmCr-1 
This assay was performed to evaluate the cross-reactivity and to assess the 
specificity of the two selected mAbs, named 10D1 and 1B4, and subsequently of 
the 1B4  rFb4 and 1B4 rFab2, towards the human form of Cripto-1. The 
recombinant human Cripto-1 protein (rhCR-1, 145-CR-010/CF R&D Systems) 
was expressed in baculovirus-derived Spodoptera frugiperda Sf21 cells as Leu31-
Thr172 & Ser63-Thr172 variants and recombinant mouse Cripto-1 (rmCr-1, 1538-
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CR-010/CF, R&D Systems) protein was expressed in the mouse myeloma cell 
line, NS0 derived, as Arg26-Gln50 and added of a 6 x His tag. Plates were coated 
with 100 μL of each protein solution in PBS, pH 7.4, at different concentrations 
(0.12 μg/mL, 0.25 μg/mL, 0.5 μg/mL to 1 μg/mL), corresponding to a total 
amount of 12 ng, 25 ng, 50 ng and 100 ng respectively, to explore the minimum 
amount detectable. Full-size antibodies were used at a concentration of 6.7 nM, 
otherwise the 1B4 rFab was tested at 100 nM and the 1B4 rFab2 at 10 nM. 
 
f) ELISA binding assay of rhCR-1 to rhALK4 receptor 
This ELISA assay was achieved to determine the affinity constant of rhCR-1 
towards rhALK4 and to set up optimal binding conditions. 
rhALK4 (808-AR, R&D systems), was expressed in the murine NS0-derived 
myeloma cell line as a Fc chimera (residues Leu32 to Glu126) and with a 6 x His 
fusion tag. For this assay the usual indirect method was used, coating plates with 
100 µL of rhALK4 solution at a concentration of 25 nM (considered as dimeric 
form). RhCR-1 was used at increasing concentrations (0.37 nM; 0.75 nM; 1.5 nM; 
3 nM) to obtain a dose-response signal. To detect the binding of rhCR-1 to the 
receptor, the commercial anti-Cripto polyclonal antibody (T4454, Sigma-Aldrich) 
was used at a concentration of 5 µg/mL (33 nM). This antibody was choosen since 
it specifically binds the 41-55 region of Cripto-1, so as to not interfere with the 
binding of CFC domain to ALK4. As secondary antibody, 1: 1000 dilution (1 
μg/mL) of GAR-HRP (166-2408 Bio-rad), was used. All ligands, analytes and 
antibody solutions were prepared in PBS pH 7.4.  
 
g) Capture ELISA for detection of human CR-1 in biological samples 
This direct ELISA assay was performed to determine the lowest quantity of rhCR-
1 detected by the 1B4 mAb, so as to set up preliminary conditions for future 
assays for the detection of human Cripto-1 in biological samples, including serum 
and plasma. 
The capture system was assembled using in coating 100 µL/well of the 
commercial anti-Cripto [41-55] polyclonal antibody at a concentration of  6.7 nM. 
100 µL of rhCR-1 were added to each well at concentrations ranging between 
0.007 µg/mL and 0.06 µg/mL, corresponding to 0.7 ng up to 6 ng. The incubation 
time period was 1h at rt followed by 1h at 37 °C. Next, to detect rhCR-1, 1B4 
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mab was used at 3 nM and the 1:5000 dilution of GAM-HRP secondary antibody 
was finally added. All the solutions were prepared as usual in PBS buffer, pH 7.4. 
The antigen-antibody complex was detected by using TMB (100 µL/well) as 
chromogen. After yielding a blue color, the reaction was stopped adding 0.18 M 
H2SO4 (50 µL/well), turning the blue color to yellow. Finally, the absorbance was 
read at 450 nm. 
For all ELISA assays washing cycles were performed using a microplate washer 
and the Abs measurements were conducted using a multi-well plate reader. 
Moreover, the evaluation of all data extrapolated from ELISA assays and the 
dose-response curves fitting, carried out following a non-linear regression 
method, were achieved using the GraphPad Prism software, version 5.0. 
 
 
2.4 PURIFICATION OF ANTI-CFC MONOCLONAL ANTIBODIES 
 
Mouse monoclonal antibodies were efficiently purified from the supernatant of 
hybridomas by two-step procedure including an affinity chromatography on 
protein G column and a size-exclusion chromatography by using an AKTA FPLC 
system. 
The supernatant, clarified by centrifugation at 4000 rpm for 20 min at 4 °C and 
filtering through a 0.45 μm filter to remove cells, debris and other impurities, was 
loaded on protein G column previously equilibrated in PBS, pH 7.4 (binding 
buffer); 0.1 M Glycine, pH 2.7 (elution buffer) was used to elute bound proteins. 
The amount of loaded sample was always about 2 mg to not exceed the binding 
capacity of the column. All the purification processes were performed at a 
constant flow rate of 0.6 mL/min.  The flowthrough fraction was washed away by 
the binding buffer until the UV absorbance, monitored at 280 nm, reached the 
baseline, otherwise the bound fractions, containing the IgGs, eluted with strong 
acidic elution buffer, were immediately neutralized by adding 2 M Tris-HCl, pH 
9.0. Pooled purified fractions were concentrated and at the same time buffer-
exchanged into PBS, pH 7.4, using cut-off 50 kDa Vivaspin at 4000 rpm at 4 °C.  
The next purification step was performed by SEC on a Superdex 200 (10/300 GL) 
column, using PBS, pH 7.4, as elution buffer, at a constant flow rate of 0.5 
mL/min, with a length of elution of 25 mL, monitoring the absorbance at 280 nm. 
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After elution, purified IgGs were concentrated, quantified by Bradford assay and 
analyzed by SDS-PAGE on 10% polyacrylamide gel under non-reducing 
conditions. Gel staining was achieved by Coomassie Brilliant Blue. 
 
 
2.5 SPR BINDING ASSAYS 
 
All SPR analyses were performed on a Biacore 3000 instrument from GE 
Healthcare, using CM5 sensor chips and certified HBS-EP buffer (10 mM 
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20), at 25 °C. 
The immobilization procedures were carried out following the canonical amino 
coupling chemistry, operating at a flow rate of 5 µL/min, using the Wizard 
application. The chip surface was activated by a 50:50 (v/v) EDC/NHS mixture 
(containing 0.4 M EDC and 0.1 M NHS) with a contact time of 7 min; next, the 
ligand opportunely diluted in the pre-selected NaAc buffer (through a pH scouting 
procedure) was coupled until the desired level was reached; the remaining active 
esters were blocked with 1 M ethanolamine-HCl, pH 8.5. 
The optimal immobilization level of each ligand protein, expressed as RU, was 
calculated on the basis of the following formula: 
 
Rmax = MW analyte/MW ligand x Immobilized amount x Stoichiometric 
ratio 
 
For each sensor chip, a non-functionalized channel was used as reference line 
(blank). All analyses were carried out setting up the same parameters: 25 °C 
temperature, 20 µL/min constant flow rate, 60 µL volume of analyte solutions 
opportunely diluted in the HBS-EP at different concentrations. HBS-EP was used 
as running buffer. NaOH was used as regeneration solution at different 
concentrations, ranging from 5 mM to 20 mM, depending on the strength of the 
ligand-analyte interaction.  
Ligand-analyte interactions, detectable as association curves followed by 
dissociation curves, were always monitored for a total time period of 500 seconds. 
For every single analysis, experimental sensorgrams were aligned, subtracted of 
blank signal and overlayed. All mathematical manipulations and fitting were 
performed using the BiaEvaluation software, version 4.1 from GE Healthcare. 
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The data provided a good fit when processed assuming a 1:1 Langmuir binding 
model. 
 
a) Screening of mAbs: dose-dependent binding assays 
SPR binding affinity and selectivity measurements of monoclonal antibodies 
toward rhCR-1 were performed immobilizing the protein on CM5 sensor chip.  
The immobilization process was efficiently performed using rhCR-1 at 5.0 µg/mL 
in 10 mM NaAc, pH 4.5, reaching a low immobilization level (around 600 RU).  
Each monoclonal antibody was tested using a series of concentrations, starting 
from the lowest corresponding to 0.125 nM up to the highest corresponding to 300 
nM.  
 
b) Epitope mapping  
SPR technique was even used to define the epitope recognized by the mAbs. For 
this purpose, CM5 sensor chip was functionalized immobilizing 10D1 and 1B4 
mAbs at 5 µg/mL in 10 mM NaAc, pH 5.0, reaching a final immobilization level 
of 5000 RU. rhCR-1 was used as positive control to assess whether the mabs were 
immobilized with the correct orientation, exposing the Fab regions to the analyte. 
Dose-dependent assays were performed by injection of wild-type hCFC[112-150] 
and mutants at increasing concentrations.  
 
c) Binding assay of rhALK4 receptor on rhCR-1 
The conditions used to functionalize CM5 sensor chip with rhCR-1 were the same 
as reported in the section a). The analyte solutions of rhALK4 were prepared in 
HBS-EP buffer at increasing concentrations (10 nM, 25, nM, 50 nM, 100 nM). 
Dose-response assays were carried out by injecting each solution at increasing 
concentrations.  
 
d) Comparative binding study of 1B4 mAb and fragments  
SPR binding assays were performed to compare the affinity of antibodies and 
related fragments: whole 1B4 mAb, the proteolytically derived Fab, the 
recombinant chimeric 1B4 rFab and the artifical dimeric 1B4 rFab2. The 
immobilization procedure was carried out as described previously in section a. 
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Each analyte was passed on the immobilized protein injecting solutions at 
increasing concentrations.   
 
 
2.6  SEQUENCING OF THE Fab FRAGMENT OF SELECTED mAbs 
 
a) RNA isolation from hybridoma cells 
The total RNA extraction from hybridomas was achieved by the Trizol 
methodology. 
The hybridoma pellet was re-suspended in 1 mL of Trizol, transferred into a 
sterile eppendorf tube and left for 5 min at rt. Then, 0.2 mL of 100% chloroform 
were added into the tube, the resulting mix was left for 2-3 min at rt and 
centrifuged for 15 min, 12.000 rpm at 4 °C. Following centrifugation, the mixture 
resulted to be separated into lower red, phenolchloroform phase, an interphase, 
and a colorless upper aqueous phase. RNA was exclusively in the aqueous phase, 
while the interphase contained DNA and the organic phase contained proteins. 
The upper aqueous phase was transferred carefully without disturbing the 
interphase into a fresh tube and the RNA was precipitated from the aqueous phase 
by mixing with 0.5 ml of isopropyl alcohol. Samples were incubated at rt for 10 
min and subsequently centrifuged at 12,000 rpm for 10 min at 4 °C. The 
supernatant was completely removed and the RNA pellet was washed once with 
75% ethanol, adding 1 mlof 75% ethanol. Then, the samples were centrifuged at 
7,500 rpm for 5 min at 4°C. The supernatant was completely removed and the 
RNA pellet was dried, removing the leftover ethanol by evaporation. RNA was 
dissolved in a small volume (30 μl) of RNAse free water and was quantified and 
the purity evaluated on the basis of Abs260/Abs280 value. The isolated RNA was 
subsequently analyzed by electrophoresis analysis on 1.2 % agarose gel, using 
MOPS as running buffer to check the presence of the two typical ribosomal RNA 
subunits, 18S and 28S. Before loading onto the gel, samples were heated for 10 
min at 55 °C to disassemble the secondary structures of RNA eventually formed. 
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b) RT-PCR 
RT-PCR was achieved as two-step reaction. In the first step a cDNA template 
from RNA mixture was amplified. A denaturation cycle for 10 min at 65 °C and 
immediately an annealing cycle at 4 °C was applied to a mixture containing 1 μg 
of RNA, 60 µM pDN6 random hexamer primer and PCR grade water, reaching a 
final volume of 11.4 µL. Then, a mix containing Transcriptor High Fidelity 
Reverse Tran-scriptase Reaction Buffer, 1× conc. (8 mM MgCl2), 20 U Protector 
RNase Inhibitor, Deoxynucleotide Mix, 1 mM each, 5 mM DTT and 22U 
Transcriptor High Fidelity Reverse Transcriptase, up to a final volume of 20 µL, 
was prepared.The enzymatic reaction was performed for 1 h at 42 °C for the 
elongation cycle, followed by the inactivation of the enzyme for 15 min at 70 °C. 
The second step was the reaction with DNA polymerase to amplify the heavy and 
light chains of the Fab fragment of the mAbs using a mix of degenerated primers 
reported in Tables 2 and 3. The PCR reaction was prepared as following: FastStart 
Buffer 1x (2 mM MgCl2), 0.2 mM PCR Nucleotide Mix, 2U FastStart Taq DNA 
Polymerase, 7.5 μM both forward and reverse primers, 1 µL of  template cDNA 
and water, PCR grade, up to a final volume of 50 µL. The PCR cycles and 
parameters were set up as reported in Table 1. The final PCR products were 
evaluated by electrophoresis analysis, loading the samples onto a 1 % agarose gel 
and using TBE 0.5x (45 mM Tris-borate, 1 mM EDTA) as running buffer, to 
assess the correct size of the amplified regions in term of pairs of bases. The 
nucleotide sequences were analysed using Finch TV software, aligned using 
BLAST program and amino acid sequences were derived using the program 
“Translate” from ExPASy proteomic server.                                
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Table 1. PCR cycle parameters
PCR phase Temp Time period N. of cycles
Initial denaturation 94°C 2 minutes 1  cycle
Denaturation 94°C 15 seconds 10 cycles
Annealing 55°C 30 seconds 1  cycle
Elongation 68°C 30 seconds 35 cycles
Final elongation 72°C 7 minutes 1 cycle
Cooling 4°C
Table 2. Degenerated primers library of Heavy chain of Fab
Forward primers %
1
BamH1
5’-cggggatcc CAG GTY CAR CTG CAG CAG YCT  GG- 3’     33
2 5’ -cggggatcc GAG GTY CAG CTG CAR CAR TCT GG- 3’       28
3 5’-cggggatcc CAG GTG CAG CTG AAG GAG TCA GG- 3’      8
4 5’ -cggggatcc GAR GTG AAG CTG GTG GAR TCT GG- 3’       21
5 5’ -cggggatcc GAG ATC CAG CTG CAG CAG TCT GG- 3’       6
6 5’ -cggggatcc CAG ATC CAG TTG GTG CAG TCT GG3’-3’        4
Reverse primers
1 5’ -CGA GGA GAC KGT GAS HGW GGT- 3’
2 5’ -CGA AGA GAC AGT RAC CAG AGT- 3’
Table 3. Degenerated primers library of Light chain of Fab
Forward primers %
1 5’ -SAM ATT GTK CTS ACH CAR TC- 3’                                 30
2 5’ -GAY ATC CAG ATG ACH CAR WC- 3’                                                                  18
3 5’ -GAT GTT GTG ATG ACC CAR AC- 3’                                                                  12
4 5’ -GAY ATT GTG ATG CAN CAG KC- 3’                                                                  25
5 5’ -GAT GTT TTG ATG ACC CAG TC- 3’                                                                    6
6 5’ -GAC ATC AAG ATG ACC CAG TC- 3’                                                                   5
7 5’ -GAC ATT GTG ATG TCA CAG TC- 3’                                   4
Reverse primers
1 HindIII
5’ -cccaagctt CCG TTT KAT YTC CAR YTT KGT SCC- 3’                                    
2 5’ -cccaagctt CCG TTT CAG YTC CAG CTT GGT CCC- 3’                                    
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2.7 COMPUTATIONAL STUDY 
 
Computational studies (Homology modelling and Docking Study) were performed 
in collaboration with the research group of Prof. Lucia Falcigno and Dr. Luisa 
Calvanese, from niversity of Naples “ Federico II”, Department of Pharmacy. 
a) Homology modelling  
Prior performing the docking study on the antigen-Fab complex, the model of Fab 
for each selected mAb (10D1 and 1B4) was built by homology modelling. The 
identification of the template showing the highest sequence identity for the light 
and heavy chains of each mAb and the subsequent sequence alignment were 
performed by using PIGS (Prediction of Immunoglobulin Structure) and PSI-
BLAST (Position Specific Iterative BLAST) servers 
(http://circe.med.uniroma1.it/pigs/; http://blast.ncbi.nlm.nih.gov). 
A multiple sequence alignment of 10D1 and 1B4 Fab fragments, in combination 
with sequences depositated in the database of the software, was achieved; 
subsequently the CDRs on  light and heavy chains variable fragments, were 
predicted by SSM program (Structure Similarity Match) on the basis of secondary 
structure homology to the antibodies reported in the database. Subsequently, a 
pair-wise sequence alignment was performed between 10D1 and 1B4 Fab 
fragments, allowing a specific comparative analysis. Thus, the molecular model of 
Fab fragment for each antibody was built by homology with known crystal 
structures from PBD of the previously identified templates. 
Finally, a comparative study was performed on the overlay of the two Fab models 
to evidence and remark differences on the paratope region. 
 
b) Docking   
Docking studies were performed using the selected NMR structure of the 
synthetic human CFC[112-150] domain and the Fab model built by homology 
modelling. The complexes were generated with a blind method by ClusPro 2.0 
software, a fully automated algorithm and discrimination method for the 
prediction of protein complexes. 
Since the complex of interest contains an antibody fragment, the “Antibody 
mode” was selected, positioning the molecule with the largest size (Fab) as the 
56 
 
fixed part, reported as receptor, and the antigen (hCFC) as the dynamic part, 
considered as ligand. 
The docking algorithms evaluate billions of putative complexes, retaining a preset 
number with favorable surface complementarities. A filtering method is then 
applied to this set of structures, selecting those with good electrostatic and 
desolvation free energies for further clustering.  
This fast algorithm has been developed for filtering docked conformations with 
good surface complementarity, and ranking them based on their clustering 
properties. The free energy filters select complexes with lowest desolvation and 
electrostatic energies. Clustering is then used to smooth the local minima and to 
select the ones with the broadest energy wells-a property associated with the free 
energy at the binding site [143]. The docked structures exhibiting the best scores 
(lowest energy and largest cluster size) were selected, energy- minimized by 
Haddock software (High Ambiguity Driven protein-protein Docking, 
http://haddock.science.uu.nl/) and the binding energy was calculated by 
submission of the model to the Dcomplex web server 
(http://sparks.informatics.iupui.edu/song/complex.html).  
Each selected complex was subsequently analyzed by PyMOL software 
(https://www.pymol.org), a based molecular visualization system and a more 
detailed analysis was perform by COCOMAPS (bioCOmplexes COntact MAPS, 
https://www.molnac.unisa.it/BioTools/cocomaps/) server, to calculate the specific 
contact regions at the antigen-Fab binding interface, by making use of 
intermolecular contact maps. COCOMAPS output includes three different contact 
maps, as well as tables reporting detailed information about the interacting 
residues, the residues at the interfaces (defined on the basis of the buried surface 
upon complex formation), and the inter-molecular H-bonds [144]. 
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2.8  mAb STRUCTURAL CHARACTERIZATION BY PROTEOLYTIC 
CLEAVAGE 
 
Immunoglobulins digestion by papain is an universal methodology to generate 
antibody fragments, more suitable than the intact IgG molecule, by a proteolytic 
approach. In addition to papain, pepsin and ficin are even routinely used to cleave 
IgGs. 
Papain is a cysteine protease, consisting of a single polypeptide chain with three 
disulfide bridges and a sulfhydryl group that requires the presence of L-Cysteine, 
as reducing agent, to exert its catalytic activity. The concentration of L- Cysteine 
is critical to papain activity to produce Fab or F(ab’)2 fragments. Papain cleaves at 
level of bonds involving basic amino acids (Arg and Lys are preferred) and 
involving Phe, in which the residue following the Phe is preferred [145].  
Pepsin, unlike other peptidases, is able to hydrolyze only peptide bonds, not 
amide or ester linkages. The specific cleavage sites include peptide bonds 
involving residues with an aromatic acid on either side of the bond, especially if 
the other residue is also aromatic or a dicarboxylic amino acid.  Pepsin cleavage 
occurs at the hinge region, below the interchain disulfide bridges, splitting the IgG 
molecule into a bivalent F(ab’)2 and a fragmentated Fc [146].  
Ficin is a thiol protease characterized by an active site containing only one 
reactive Cysteine. This enzyme cleaves proteins at the carboxyl side of many 
aminoacids, including basic (Lys and Arg) and aromatic (Tyr) residues and it is 
routinely used to generate F(ab’)2 fragments from mouse IgG1 antibodies  
resistant  to the treatment with pepsin [147]. 
Thus, papain is commonly used to cleave the IgG molecule into two Fab units, 
that still retain the antigen binding ability, and an intact Fc portion. An alternative 
strategy to generate the monovalent fragment is the single step reduction of the 
F(ab’)2 to the so-called F(ab’) with 2-MEA (2-Mercaptoethanolamine) or 
Cysteamine, a reducing agent selective to the disulfide bridges of the hinge 
region. 
For structural characterization of IgG, the choice of the protease is strictly 
dependent on specific isotype. Mouse antibodies are reported to exhibit a 
subclass-dependent susceptibility (IgG2b>IgG3>IgG2a>IgG1) to proteases [102]. 
In detail, IgG1, IgG2a and IgG3 are known to be susceptible to pepsin cleavage, 
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allowing the production of F(ab’)2 fragment, even successfully obtained by ficin 
action on IgG1 [147]. By contrast, F(ab’)2  can not be obtained by treatment of  
IgG2b neither with papain nor with pepsin [148].  
 
a) Digestion of 1B4 mAb by papain  
Since the selected 1B4 mAb belongs to the IgG2b subclass, papain was used to 
split the antibody into two Fabs and one Fc fragments. A preliminary small-scale 
digestion was conducted to set up the optimal conditions, after a time-course 
procedure, monitoring the proteolytic process after 2h, 4h and 6h. The reaction 
was achieved at neutral pH in PBS buffer, pH 7.4. Firstly, papain was pre-
activated by 5 mM L-Cysteine for 10 min at room temperature, subsequently 2 
mM EDTA (heavy-metal chelator required to enhance the enzyme activation, 
performed by the Cysteine) and mAb were added and the final mixture was 
incubated for 4h at 37 °C in a water bath. The optimal enzyme:substrate ratio was 
fixed at 1:100 (w/w). The reaction was stopped by addition of 25 mM 
Iodoacetamide, leaving the mixture for 20 min at rt in the dark to ensure complete 
alkylation of free Cysteines. 
 
b) O-deglycosylation of 1B4 mAb 
To optimize the proteolytic cleavage of 1B4 mAb to generate a functional Fab 
fragment, the removal of the peculiar O-glycosylations localized on the Thr221 of 
the CH2 domain of the IgG2b antibodies, was required. Despite the N-
deglycosylation of IgG1 molecules, achievable in a single step reaction with 
PNGase F, there is not a comparable enzyme able to perform O-deglycosylation 
in a single passage. Indeed, the removal of O-linked oligosaccarides requires two 
different enzymes, the sialidase to cleave the oligosaccaryde chains and the O-
glycodisase to completely remove the hydrolized chains.  
Sialidase is usually required to remove the N-acylneuraminic acids (sialic acids), 
that commonly represent the terminal region of the O-linked glycan chains, linked 
to the hydroxyl side-chain of Ser or Thr residues. This enzyme shows a broad 
spectrum activity, exerting the release of α(2→3), α(2→6), α(2→8) and α(2→9) 
linked syalic acids from complex glycans, allowing its use when a non-specific 
removal of sialic linkages is required. By contrast, O-glycosidase is able to cleave 
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only the most common core structure consisting of the disaccharide Gal-β-(1→3)-
GalNAc α-linked to the hydroxyl group of Ser or Thr residues [149]. 
Indeed, a first preliminary small-scale deglycosylation process was performed to 
set up the optimal conditions. Before initiating the digestion with papain, the 1B4 
mAb was firstly incubated with 0.05 U/mL sialidase in 50 mM Sodium Phosphate 
buffer, pH 6.0, for 24h at 37 °C in a water bath. Secondly, the antibody was 
buffer-exchanged into 50 mM Sodium Phosphate pH 5.0, so as to be incubated 
with 0.12 U/mL O-glycosydase for additional 24h at 37 °C. The deglycosylation 
was monitored by SDS-PAGE analysis on a 12% polyacrylamide gel under non 
reducing and reducing conditions. Once confirmed that the heavy chains of the 
antibody were deglycosylated, the subsequent proteolytic cleavage was performed 
with papain following the procedure reported above. 
 
2.9 CIRCULAR DICHROISM SPECTROSCOPY 
 
Structural analyses were achieved on each generated fragment, to evaluate wether 
the final product still retained its correct secondary structure and folding. CD 
analyses were conducted using a Jasco spectropolarimeter, J-710 model, equipped 
with a Peltier system to control temperature. Samples were prepared in 10 mM 
Sodium Phosphate, pH 7.5 at a concentration of 0.2 mg/mL and filtered through a 
0.22 µm filter; 110-QS quartz cuvettes of 1.0 mm light path length were used. 
Spectra were collected within the wavelength range of 250-190 nm in far-UV 
region at scan rate of 20 nm/min, with a data pitch of 0.2 nm, a band-width of 1 
nm and a response time of 4 seconds.  
On every sample, five independent spectra were recorded, averaged and smoothed 
using the Spectra Manager software, version 1.53 (Easton, MD, USA). Buffer 
scans were recorded under the same conditions and subtracted. 
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2.10  EXPRESSION STRATEGY OF RECOMBINANT CHIMERIC 1B4 
rFab 
 
The periplasmic expression strategy was chosen to produce the recombinant 
chimeric Fab from 1B4 mAb in Esherichia coli host strain. Compared to the 
cytoplasmic expression, this approach is more suitable, especially when the target 
protein contains fundamental disulfide bonds. This strategy takes many 
advantages: the oxidizing enviroment of periplasm favours the correct formation 
of disulfide bonds and their isomerization is catalyzed by periplasmic enzymes 
such as oxido-reductases and disulfide isomerase; the low presence of proteins in 
the diluted periplasmic environment prevents aggregation of the target protein, 
usually observed within the cytoplasm; the final recombinant product contains its 
authentical N-terminal region, since the signal sequence is cleaved by specific 
signal peptidases after periplasmic translocation, avoiding the presence of an  
unwanted initial Met residue, not belonging to the expressed target protein. The 
latter is a very important advantage because the extra-Met has been reported to 
reduce the biological activity and stability of the final protein or even, when it is 
present on therapeutic proteins, may be responsible of immunogenic response 
[150]. Finally, the recovery of the target protein from the periplasm can be 
achieved by a simple osmotic shock or cell wall permeabilization, without 
disrupting the cytoplasmic membrane, so as to avoid release of contaminants from 
the cytoplasm. Although these advantages, the expression strategy involving the 
periplasmic translocation still presents disadvantages, including a very limited 
expression yield due to the loss of the target protein that can be found also in the 
culture medium. An additional inconvenient may be the uncompleted 
translocation of the target protein from the cytoplasm, expecially protein with 
high molecular weight can be physically trapped in the cytoplasmic membrane. 
Thus, with regard to the Fab fragment (50 kDa), this size is not a limiting factor 
for the periplasmic translocation. A further important parameter is the balance 
between the translation and secretion processes, since a high translation rate can 
overload the capacity of the transport machinery, allowing the accumulation of 
extra-expressed protein in inclusion bodies. Indeed, to avoid this side effect, the 
choice of a not very strong promoter and a suitable secretion mechanism is 
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recommended [151]. The secretion mechanisms used by Gram negative bacteria, 
including E. coli, are classified as type I, type II and type III. The type I 
machinery, commonly used for the secretion of high-molecular-weight toxins and 
exoenzymes transports proteins in a single step across the inner and outer cell 
membranes without a periplasmic intermediate passage [152]. The components of 
this secretion system are two inner membrane proteins (HlyB and HlyD) that 
belong to the ATP binding cassette (ABC) family of transporters, and an 
endogenous outer membrane protein, TolC [153]. This translocation can also be 
influenced by components of other secretion pathways, including SecB [154]. 
   
a) Ad hoc design and engineering of pET-26(+) vector for periplasmic 
expression 
The periplasmic expression strategy exploited to express the chimeric 1B4 rFab is 
characterized by two steps: 1) the initial synthesis of the single heavy and light 
chains in cytoplasm, where the reducing environment keeps them separated, and 
2) the subsequent translocation into the periplasm space, promoted by the pelB 
leader sequence, where the oxidizing environment helps the two chains to 
assemble, allowing the correct formation of the five disulfide bridges (one 
interchain and four intrachain), critical for the folding of the Fab, so as to obtain a 
stable soluble protein.  
Thus, the 1B4 rFab was constructed as composed of a murine variable region 
belonging to the 1B4 anti-Cripto mAb and a human constant region belonging to 
the humanized Trastuzumab (Herceptin®), currently used in clinical treatment of 
HER2 positive breast carcinoma and metastatic breast carcinoma [155]. 
The mouse sequences were determined by sequencing of the specific cDNA after 
RT-PCR, as described in Chapter II (Section 2.6 of Methods), while the human 
sequences of Trastuzumab were directly taken from DrugBank (DB00072). In 
addition, the innovative part of the chimeric 1B4 rFab takes advantage from the 
insertion of the short linker sequence at the C-terminal of the CH1 domain, suitable 
as recognition site for the M-TGase enzyme, so as to carry out a site-specific 
conjugation at the Glutamine residue, exemplified as Q in Fig. 2.1 of additional 
elements, including PEG, albumin, rFab itself, cytotoxic agent, generating new 
rFab formats, avoiding a traditional unselective chemical conjugation.  
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*** Sequences cannot be reported. 
The nucleotidic sequence of this designed gene, adapted to the bacterial 
expression, using the codon usage optimized for E. coli, encodes the following 
elements: 
pelB1-VL1B4-CLHer-RBS-pelB2-VH1B4-CHHer-Tgase linker peptide   
1. pelB1 is the leader sequence of the light chain 
2. VL1B4 is the variable region of the light chain from 1B4 mAb 
3. CLHer  is the constant region of the light chain from Trastuzumab 
4. RBS (Ribosomal binding site) is the linker containing the nucleotidic sequence 
recognized and bound by the ribosome to start protein translation; this linker is 
required in this position to rebind and keep the mRNA linked to the ribosome to 
initiate the heavy chain translation when the completed light chain is released 
5.  pelB2 is the leader sequence of the heavy chain 
6. VH1B4 is the variable region of the heavy chain from 1B4 mAb 
7. CHHer is the constant region of the heavy chain from Trastuzumab 
8. M-TGase linker is the additional sequence, in which Glutamine residue is crucial 
for the enzyme recognition and site-specific transglutamination  
The synthetic gene of 1539 bp, purchased from MWG Eurofins, was cloned in the 
pET-26b(+)vector, possessing Kanamycin resistance, to generate a new 
dicistronic plasmid, named PL564.  
Table 4. Nucleotidic sequences of each element componing the gene encoding the recombinant chimeric Fab protein
Component Nucleotidic sequence
pelB1/pelB2 ATGAAATAC CTG CTG CCG ACC GCT GCT GCT GGT CTG CTG CTC CTC GCT GCC CAG CCG GCG ATG GCC
VL 1B4 ***
CL Her ACCGTTGCTGCGCCAAGTGTGTTCATTTTCCCTCCTTCCGATGAACAGCTGAAAAGTGGCACTGCAAGCGTTGTATGCCTGT
TGAACAACTTCTATCCGCGTGAAGCCAAAGTTCAGTGGAAAGTCGATAATGCCTTACAAAGCGGCAATAGCCAGGAATCT
GTGACAGAGCAGGATTCGAAGGATTCGACCTATTCCCTGTCAAGCACGCTGACTCTGTCCAAAGCGGACTATGAGAAACA
CAAAGTGTATGCGTGTGAAGTGACCCATCAAGGACTCAGTAGCCCAGTCACCAAGTCATTCAATCGTGGCGAATGC
RBS linker CCACTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACAA
VH 1B4 ***
CH Her
GCATCTACGAAAGGTCCGAGCGTATTTCCGTTAGCTCCGTCGTCAAAATCCACCTCAGGCGGTACTGCCGCACTTGGCTGTT
TGGTGAAAGACTACTTTCCGGAACCTGTCACAGTTTCCTGGAATAGTGGGGCGCTGACTAGCGGCGTGCATACGTTTCCAG
CGGTTCTGCAGAGCTCTGGACTGTATTCCCTCTCAAGTGTCGTCACCGTTCCCTCCTCCAGCTTAGGGACCCAGACGTATAT
CTGCAACGTTAATCACAAACCGTCGAATACCAAAGTGGACAAGCGCGTAGAACCCAAAAGCTGC
M-TGase
linker
GGGAGTGGTGCCCTGCAACCAACACAGGGTGCGATGCCGGCG
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For cloning, the synthetic cDNA and pET-26b(+) vector were opportunely 
hydrolysed in the presence of BlpI and KpnI restriction enzymes. The digested 
fragment and vector were extracted from 0.8% agarose gel using QIAquick Gel 
Extraction Kit. Ligation reaction was set up 4 °C o.n. and the product was 
electroporated into TOP10F’ E. coli cells. Some positive clones were isolated 
using QIAprepSpin Miniprep kit and the correct cloning was confirmed by 
nucleotide sequencing. The nucleotidic sequences were analyzed using Finch TV 
program. 
 
 
Figure 2.1: Schematic representation of the expression vector construction: the synthetic gene 
encoding the 1B4 rFab fragment was inserted into the commercial pET-26b(+) vector, creating the 
new plasmid PL564, to be employed to transform E.coli BL21(DE3) host strain. 
 
 
b) Expression of 1B4 rFab 
E. coli BL21(DE3) cells were chemically transformed with 200 ng of PL564 
plasmid and cultured in 1 L of LS10 medium (1% soya peptone, 0.5% yeast 
extract, 1% NaCl) supplemented with 0.1 % glucose and using Kanamycin (30 
μg/ml) as antibiotic, with an orbital shaking of 250 rpm at 37 °C until the OD 
reached 0.5-0.6 at 600 nm. Thus, the colonies were transferred into a new 
medium, FM1 0.5x  (2% yeast extract, 1% soya peptone, 0.3% K2HPO4, 0.06% 
KH2PO4, 0.8% glycerol) supplemented with 4 mM MgSO4. Tryptone and yeast 
extract provide the nitrogen and basic nutrients, including growth factors needed 
for cell growth; NaCl is necessary to provide a suitable osmotic equilibrium, 
helping to maintain an isotonic environment and glucose is added as the main 
carbon and energy source, needed for the bacterial growth cycle, as well as the 
glycerol. 
pET-26b(+)
PL564
6697bp
1B4 rFab gene
VL1B4 CLHer VH1B4RBS CHHer
pelB1 pelB2 M-TGase linker
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Moreover, inorganic salts (MgSO4, NaCl, CaCl2, KCL, NaHCO3, potassium 
phosphate) are essential components to allow bacteria to growth and keep their 
cellular functions and simultaneously to avoid drop of pH due to catabolic 
products, preventing bacterial death. Magnesium sulfate supplies the magnesium 
ions required for enzymatic reactions related to the replication of DNA.  
Then, expression of the 1B4 rFab protein was optimized by induction with 1 mM 
IPTG (isopropyl-β-D-thiogalacto-pyranoside), incubating bacterial cells at 30 °C 
o.n. under orbital shaking (250 rpm). Bacterial cultures were harvested by 
centrifugation at 8000 rpm for 20 min at 4 °C and finally stored at -80 °C. 
 
c) Purification of 1B4 rFab 
The periplasmic extraction of 1B4 rFab protein was achieved by re-suspending 
the pellet in lysis buffer containing 100 mM Tris-HCl and 10 mM EDTA, pH 7.,4 
and protease inhibitors cocktail (Complete EDTA free tablet, Roche) The mixture 
was left in incubation o.n. at 30 °C, under shaking (250 rpm). The extract was 
clarified by centrifugation at 20000 rpm for 30 min at 4 °C to separate the 
periplasmic fraction from the other undesirable cell components and debris. The 
extract was initially salified in 4 M NaCl to be purified by HIC onto a column (26 
mm x 30 cm) packed with Phenyl Sepharose 6 Fast Flow resin, using an AKTA 
Purifier system. The stationary phase was previously sanitized with 1 M NaOH 
and equilibrated with Binding buffer (50 mM Tris-HCl, pH 7.0, 3.5 M NaCl) and 
Elution buffer (50 mM Tris-HCl, pH 7, and 0.25 M NaCl). Prior applying onto the 
column, the periplasmic extract was filtered (0.22 μM steril filter) and the 
purification process was achieved at a flow rate of 10 mL/min monitoring the Abs 
at 280 nm. The unbound fraction was washed away until the absorbance reached 
the baseline, then the bound fraction, containing the 1B4 rFab protein, was eluted. 
The proteins pool was subsequently purified by IEC using a strong cation 
exchanger resin SP Sepharose Fast Flow packed in a column (26mm x 28 cm), 
sanitized with 0.1 M NaOH prior to use. The stationary phase was equilibrated 
with 50 mM Tris-HCl, pH 7.0, and operating at a flow rate of 10 mL/min, 
following a linear gradient from 50 mM to 1 M NaCl. The 1B4 rFab fragment was 
eluted in the fraction washed with equilibration buffer. The recovered fraction 
containing the 1B4 rFab protein was subsequently basified with 0.1 M NaOH, pH 
9.0, to perform the final purification step on the strong anion exchanger Q 
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Sepharose Fast Flow resin packed in a column (16 mm x 20 cm), previously 
sanitized with 0.1 M NaOH. Before applying the sample, the resin was 
equilibrated with 20 mM Tris-HCl, pH 9.0. The elution of the 1B4 rFab was 
performed at a flow rate of 15 mL/min , with 50 mM Tris-HCl, pH 8.0, and all the 
fractions were finally collected. 
A further purification step was achieved by SEC on a Superdex 200 column (10 
mm x 30 cm) to assess the presence of aggregates. Gel filtration analysis was 
carried out using as running buffer 25 mM Tris, pH 7.5, and 50 mM NaCl, 
operating at flow rate of 0.5 mL/min and monitoring the Abs at 280 nm.  
 
2.11 SDS-PAGE AND WESTERN BLOT ANALYSES 
 
The purified 1B4 rFab protein was analyzed by SDS-PAGE on a 15% 
polyacrylamide gel under reducing and non-reducing conditions, using Laemmli 
1x (25 mM Tris base, 0.2 M Glycine, 0.1% SDS, pH 8.3) as running buffer. To 
reduce the samples, 10% (v/v) β-Mercaptoethanol was added to the solution and 
the final mix was boiled for a few minutes at 100 °C. Separated proteins were 
stained with Coomassie Brilliant Blue. For immunoblotting, 1 μg of 1B4 rFab 
protein was loaded onto a 15% SDS-PAGE gel and then transferred onto a PVDF 
membrane, using the Transfer Buffer (10 mM TrisBase, 0.1 M Glycine, 0.1 % 
SDS and 10 % Methanol), by a semi-dry procedure, using the Trans-blot system 
SD Semi-dry Transfer cell system (Biorad). A constant voltage of 18 eV was 
applied for 20 min at r.t. 
The membrane was blocked with TBS-T buffer (20 mM Tris-HCl, pH 7.5, 500 
mM NaCl, 0.05% Tween 20) containing 5% NFDM and incubated for 1 h at r.t. 
The membrane was then washed three times with TBS-T and incubated with the 
solution of HRP-conjugated Anti-human IgG (Fab specific) diluted 1:1000 in 
TBS-T containing 2.5% NFDM.  
After extensive washing, blotted 1B4 rFab was detected both by using ECL 
substrate kit (Supersignal Pierce) to acquire the membrane on ChemiDoc 
instrument (Bio-rad) by QuantityOne software and finally a colorimetric detection 
was performed with OPTI-4CN substrate kit (Biorad). 
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2.12 1B4 rFab-hCFC COMPLEX ANALYSIS BY SE-HPLC 
 
A simple methodology was used to preliminarily evaluate the formation of the 
antigen-Fab complex in solution by SE-HPLC, on a Zorbax GF-250 column (4.6 x 
250 mm), comparing the elution time of the 1B4 rFab alone and complexed with 
the synthetic hCFC[112-150] polypeptide, used as antigen. The molar ratio 1B4 
rFab:hCFC was 1:4, dissolved in 25 mM Tris-HCl, pH 7.5, and 50 mM NaCl. The 
analysis was carried out using 0.1 M K2HPO4, pH 7.4, with the addition of 3% 
Isopropanol, setting up a constant flow rate of 0.35 mL/min. 
 
2.13  CHEMICAL SYNTHESIS, PURIFICATION AND IDENTIFICATION 
OF THE BIFUNCTIONAL LINKER PEPTIDE 
 
A short linker peptide was designed to covalently keep together two 1B4 rFab 
arms, allowing the formation of an artificial recombinant 1B4 rFab2. 
Thus, the linker peptide was chemically synthesized by a typical step-wise solid 
phase Fmoc procedure, purified by RP-HPLC and finally the correct molecular 
mass of the product was determined by LC-ESI-TOF-MS analysis. The 
methodology used to perform chemical synthesis, purification and identification 
of the peptide are reported in Chapter II (Sections 2.1.a and 2.1.c respectively.). 
  
2.14 1B4 rFab-rFab CONJUGATION REACTION CATALYZED BY M-
TGase ENZYME 
 
To generate the dimeric Fab, reported as 1B4 rFab2, an enzymatic strategy, 
alternative to the traditional chemical conjugation to the sulfhydryl goup of free 
Cysteine residues, was explored using M-TGase, supplied by Bio-ker. This 
enzyme selectively catalyzes acyltransfer reactions between the γ-carboxamide 
group of Glutamine (chemically inert under physiological conditions) and the 
primary ε-amino group of Lysine, leading to the formation of catabolically stable 
isopeptide bonds, by a transamination reaction. The Glutamine residue is required  
be located in a flexible region of the protein and flanked by specific amino acids 
[156]. This approach is very smart since guarantees site-specific and stoichiometric 
functionalization of labelled molecules, avoiding the limitations related to the 
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chemical approach, including site-aspecificity, variable stoichiometry and a final 
heterogenous population of  conjugated products. 
To reach this aim, the 1B4 rFab was produced with the additional sequence 
containing Gln residue to be exploited as labeling site. The transamination 
catalyzed by M-TGase is reported in Figure 2.2, where also possible side reactions 
are illustrated. 
 
 
Figure 2.2: Schematic illustration of the three possible reactions catalyzed by M-TGase enzyme 
[157]. 
 
With regard to the reaction performed in this study, the Gln substrate protein is 
represented by the additional sequence on the CH1 domain of the 1B4 rFab, 
otherwise the ε-aminogroup is provided by Lys residue of the bifunctional linker. 
A critical parameter to limit the promiscuity of M-TGase is the availability of 
amino groups, thus to avoid the unwanted deamination reaction with the 
consequent generation of Glutamic acid, a rich excess of amino groups is 
required. 
A preliminary series of pilot reactions were conducted exploring different 
conditions of all the parameters involved in the conjugation process (1B4 
rFab:linker molar ratio, enzyme concentration, ion strength of the buffer, 
temperature and incubation time period) to set up the final optimal conditions.  
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2.15 PURIFICATION OF 1B4 rFab NEW FORMATS 
 
a) Purification of 1B4 rFab2 and 1B4 rFab-Doxo by IEC 
After the specific incubation time period, he reaction mixtures were purified by 
ion-exchange chromatography using a cation exchanger resin (MacroCap SP), 
previously equilibrated with 20 mM NaAc, pH 4.5. Throughout the purification 
process a linear gradient of NaCl, starting from 0 mM and reaching 350 mM in 15 
column volumes, was applied, at a constant flow rate of 2 mL/min.  
 
b) 1B4 rFab2 analysis by SE-HPLC 
In detail, a second step of purification was performed only on 1B4 rFab2 by a SE-
HPLC, using a Zorbax GF-250 column (4.6 x 250 mm) and 63 mM K2HPO4, pH 
7.3, plus 3% Isopropanol, was used as elution buffer to separate the dimeric 1B4 
rFab2 from the unfunctionalized monomeric 1B4 rFab as well as to evaluate the 
products in terms of molecular weight and purity grade. 
 
2.16 GENERATION OF ADC 
 
An universal strategy currently used to enhance the therapeutic potential of 
monoclonal antibodies and their fragments is their conjugation with a cytotoxic 
drug generating a so-called ADC (antibody drug conjugates) product. 
In this study we investigated the feasibility of conjugating a cytotoxic agent to the 
1B4 rFab and for this purpose we designed a strategy for the attachment of 
Doxorubicin through a mixed approach of chemical and enzymatic reactions. 
Doxorubicin is an anthracycline antibiotic that binds to nucleic acids by specific 
intercalation of the planar anthracycline nucleus with the DNA double helix. It is 
widely used to produce regression in disseminated neoplastic conditions, 
including acute lymphoblastic leukemia, acute myeloblastic leukemia, 
neuroblastoma, breast carcinoma, ovarian carcinoma, gastric carcinoma, 
Hodgkin’s disease and malignant lymphoma [158]. However, as for many 
cytotoxic compounds it is unable to discriminate between healthy and cancer 
cells, thus resulting a highly toxic compound when is used at concentrations 
above a given threshold and especially in on healthy tissues. ADC have the 
advantage of overcoming these issues by exploiting the antibody selectivity for 
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the homing and eventual release of the cytotoxic payload on diseased tissues 
overexpressing specific antigens. In our case, the final ADC product (1B4 rFab-
Doxo), exhibits the selectivity of 1B4 rFab toward tumor target cells 
overexpressing human CR-1 protein on their surface and the high cell killing 
effect held by Doxorubicin. This should therefore potentially improve the anti-
tumor activity by concentrating the compound on the cancer site and at the same 
time reduce the side effects of the cytotoxic drug.  
 
a) ADC-conjugation strategy design 
The 1B4 rFab-Doxo, like typical ADC products, was designed as composed by 
three main elements: the antibody portion, the linker and the payload. The linker 
was in this case a peptide with the ability to selectively join together the antibody 
fragment and Doxorubicin conjugated with a heterobifunctional linker. We used 
the commercial spacer 4-Maleimidobutyric acid N-hydroxysuccinimide ester 
(Sigma-Aldrich) containing two reactive groups, localized at opposite sides, 
corresponding to the amine-reactive N-hydroxysuccinimide (NHS ester) and the 
sulfhydryl-reactive maleimide group. 
The NHS ester group reacts with primary amines at basic pH conditions (between 
7 and 9) leading to the formation of stable amide bonds; on the other side the 
reactivity of maleimide group to the sulfhydryl groups at pH 6.5-7.5, allows the 
formation of stable thioeter bonds. This cross-linker was also chosen by virtue of 
its favorable properties, including high stability at physiological pH, its function 
as non-cleavable linker and cell membrane permeability. 
As shown, we also designed a short peptide derivative Ac-cys-Lys-ala-NH2 
containing a D-Cysteine, required to form the thioeter bond with the reactive 
maleimide group of the commercial linker, and a Lysine residue required to allow 
the M-TGase-catalyzed enzymatic conjugation of Doxorubicin to the 1B4 rFab. 
D-Alanine was used as a spacer. The amino acids were used in D configuration to 
prevent linker degradation by cellular proteases during the permanence in the 
bloodstream. The ADC-conjugation strategy is outlined in Fig. 2.3. Such approach 
should lead to the specific attachment of one copy of Doxorubicin to a specific 
site of the antibody. 
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Figure 2.3: Schematic representation of the three step strategy designed to create the 1B4 rFab-
Doxo derivative (ADC product).  
 
The first step (1) is represented by the formation of the amide bond between the 
free primary amine of Doxorubicin and the NHS ester of the I linker, via reaction 
with NHS and formation of the Product A. In the second step (2) the short peptide 
is linked to the Doxorubicin-I linker (Product A) exploiting the maleimide group 
that, reacting with the free sulfhydryl group on the Cys residue through an 
electrophilic addition reaction, allows the formation of a stable and non reducible 
tioether bond and the formation of the intermediate compound, named Product B. 
While the first two steps are chemical reactions, the last one is the site-specific 
conjugation catalyzed by the M-TGase enzyme. The transamination reaction 
occurs between the free primary amine of the Lys residue belonging to the II 
linker and the Gln residue localized on the C-terminal sequence of 1B4 rFab. 
As depicted in Fig. 2.4, the 1B4 rFab-Doxo product (A) could potentially bind to 
the cell surface receptor (Cripto-1), forming the ADC-receptor complex, that is 
subsequently internalized into the cytoplasm via a lysosome-mediated endocytosis 
process. In the strongly acid environment of lysosomal vesicles, the linker is 
cleaved and the antibody is degraded by the proteases, so as to allow the release of 
the cytotoxic drug, leading to cell death.   
Doxorubicin
I linker
Product A
+
1 2
Product B
+
1B4 rFab
ADC Product
+
II linker
3
M-TGase
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Figure 2.4: Steps of typical ADC mechanism  (B) [141]. In this study the ADC product is 
represented by the 1B4 rFab fragment conjugated to the cytotoxic agent Doxorubicin (A). 
 
 
b) Preparation of Doxorubicin-I linker-II linker compound  
Doxorubicin hydrochloride (4.5 mg; 7.8 mol) was dissolved in DMF and the 
cross-linking agent (reported as I
  
linker, Ac-CKA-NH2 ad hoc linker peptide) was 
added (3.1 mg, 12 mol) and the pH was adjusted to around 8 by addition of 2M 
DIEA. Subsequently, for three times the same amount of I linker was added to the 
solution, opportunely adjusting the pH with DIEA. The mixture was left under 
shaking o.n. at rt, assessing the reaction progression by HPLC and ESI-MS. The 
mixture was finally diluted in H20 + 0.1%TFA, and purified by RP-HPLC 
applying a gradient of CH3CN starting from 5% up to 70% in 15 min, at a 
constant flow rate of 12 mL/min and monitoring the Abs at 280 nm, as reported in 
section 2.1.c. The correct product (Product B) was checked by mass spectrometry. 
  
1. ADC in bloodstream
2. ADC-receptor binding
3. ADC-receptor complex internalization
4. Antibody portion removal in lysosome
5. Cytotoxic agent release
6. Cell death (Apoptosis) 
1
2
3
4
5
6
B
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A
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c) Conjugation of 1B4 rFab with Doxorubicin 
The second step of the ADC preparation was the conjugation of the 1B4 rFab 
fragment to the Product B (Doxorubicin-I linker-II linker) via M-TGase reaction. 
The enzymatic reaction was performed adding Product B, dissolved in DMSO, to 
the 1B4 rFab at  2:1 w/w ratio (Product B : rFab)  in presence of M-TGAse (0.25 
U/mL) in  1 M KH2PO4, pH 8.2, buffer, o.n. at rt. 
After the incubation time period, the complete reaction mixture was purified by 
cation exchange chromatography as described previously in section 2.15.a and 
subsequently each isolated peak was analyzed by SDS-PAGE on a 12% 
polyacrylamide gel and by LC-ESI-TOF-MS (see section 2.1.c) to assess the 
integrity and purity of the final products. 
 
2.17 PRELIMINARY IN VITRO ASSAYS OF 1B4 mAb ON HUMAN 
CANCER CELLS OVER-EXPRESSING CR-1 PROTEIN 
 
a) Cell culture 
 
All human cell lines were purchased from ATCC (American Type Culture 
Collection) except the C16 cell line, provided by the Aalborg University Hospital 
of Aalborg (Denmark). These cells were derived from patients exhibiting  clinical 
features of glioblastoma.  
All the human cancer cell lines used in this study were cultured in T175 flasks, 
using complete DMEM-F12 medium (Dulbecco’s modified Eagle’s medium-F12) 
supplemented with 10% FCS, and 1% penicillin/streptomycin. Cultures were kept 
in incubator at 37 °C, with a humidified atmosphere containing 5% CO2. Medium 
was changed routinely twice per week and when cells reached 80-90% 
confluence, they were split 1:5 or 1:10 into a new flask containing fresh medium. 
 
b) Quantitative RT-PCR 
 
Quantitative real-time PCR was carried out on GEO human colon cancer cells to 
measure the mRNA levels corresponding to human CR-1. Total RNA extraction 
was performed as previously described (section 2.6.a); the following qRT-PCR 
reactions were conducted using SYBR Green PCR master mix on an iCycler 
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instrument (Bio-Rad).  hGAPDH was used as internal control. The primers 
(Sigma-Aldrich) used are reported in Table 5.  
 
 
 
c) Western blot analyses  
 
After washing twice in PBS pH 7.4, cells were trypsinized in the incubator 5 min 
at 37 °C. Then, a triple volume of fresh medium was added and cells were 
harvested by centrifugation at 300 rpm for 5 min at 20 °C. Pellets were washed, 
and after aspiration of supernatants were lysed using RIPA buffer (0.1% SDS, 50 
mM Tris-HCl pH 7.4, 1% Igepal, 0.25% sodium deoxycholate, 1 mM EDTA, 150 
mM NaCl), adding 1x Mini Protease Inhibitor Cocktail including phosphatase 
inhibitors prior to use; the mixture was left for 30 min at 4 °C. The total cellular 
lysate was quantified by Bradford assay and 30-50 μg were loaded onto a 12% 
polyacrylamide gel, under reducing conditions (with 10% β-Mercaptoethanol), 
after short heating at 100 °C in a boiling water bath.  
To detect the 1B4 effect on Cripto-1 activity in H9 corresponding to hESC 
(human embryonic stem cells), BT549 and Hs578T (human breast cancer cells) 
and NTERA/2D (human teratocarcinoma cells), both the commercial antibody 
(600401997 Rockland) and the 1B4 mAb were used at 1 μg/mL. Membranes were 
probed with an anti-SRC (MBS 85070433 MyBiosurce), anti-Nodal (EP2058Y 
Epitomics), anti P-Smad (MBS835580 MyBiosource), anti-Phospho MAPK 
(MBS837439 MyBiosource) and anti-β Actin antibody (C4:SC-47778 Santa-
Cruz) in accordance to the manifacturer’s protocol. 
The Western blot and the detection were carried out using the method previously 
described in section 2.11. 
 
d) Immunofluorescence 
Immunostaining on GBM cell lines was performed on non-permeabilized cells, 
previously fixed in 4% PFA on 24-well plate, seeded at a density of 50000 
cells/well. Cells were washed twice with PBS pH 7.4 (0.5 mL/well) and incubated 
Table 5. Primers used for qRT-PCR
Forward Reverse
hGAPDH 5’-GAAGGTGAAGGTCGGAGTC -3’ 5’-GAAGATGGTGATGGGATTTC-3’
hCR-1 5’-CACGATGTGCGCAAAGAGA-3’ 5’-TGACCGTGCCAGCATTTACA-3’
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with 0.3 mL/well of 1% BSA in PBS pH 7.4 (blocking buffer) for 30 min at r.t. 
Then, 0.2 mL/well of the primary antibody solution was added at 5 μg/mL in 
blocking buffer o.n at 4 °C. As positive control, the commercial anti-Cripto-1 
antibody (MAB2772 R&D Systems) was used.  After three washes (5 min each 
wash) with 0.5 mL/min of washing buffer (composed by the blocking buffer 
diluted 1:50 in PBS pH 7.4), the AlexaFluor555 conjugated secondary antibody 
(Ab150114 LifeTechnologies) diluted 1:200 in incubation buffer, was added and 
incubated for 30 min at r.t. Then, after washing the nuclear staining was 
performed using Hoechst 33342 (Invitrogen), 0.2 mL/well, diluted 1:1000 in H20, 
leaving the plate in incubation for 15 min at r.t.  
                                  
e) Proliferation assays 
GBM cell lines 
C16 and U87 cell lines were seeded in T75 flasks at a density of 2000 cells/cm
2 
and left in incubation 24h. Then, the medium was changed and the fresh medium 
containing 1B4 mAb at a concentration of 0.2 μM was added; as negative control 
medium without mAb was also added. Cells were fixed in 4% PFA and cell 
growth rate at the starting point and after 96 hours was evaluated using Cell Trace 
CFSE Cell Proliferation Kit (Invitrogen). CFSE is a cell-tracing reagent that 
passively diffuses into cells. It is colorless and non-fluorescent until the acetate 
groups are cleaved by intracellular esterases to yield highly fluorescent 
carboxyfluorescein succinimidyl ester. The succinimidyl ester group reacts with 
intracellular amines, forming fluorescent conjugates that are well retained and can 
be fixed with aldehyde fixatives. Excess unconjugated reagent and by-products 
passively diffuse to the extracellular medium, where they can be washed away.  
 
GEO cells 
Proliferation assay on GEO colorectal cancer cell line, was achieved monitoring 
the growth rate at the starting point, after 48h, 72h and 96h adding 1B4 mAb the 
first day and freshly every 24h at two different concentrations (0.1 μM and 0.2 
μM), using untreated cells as negative reference. Hoechst nuclear staining was 
employed as cell tracing, to monitor the cellular replication rate. The blue 
fluorescent Hoechst dye is a cell permeable nucleic acid stain, that binds to the 
DNA selectively at the AT regions. Moreover, this dye is highly sensitive to DNA 
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conformation and chromatin state in cells, and it is even able to detect nuclear 
damage. The Hoechst dye and the CFSE above mentioned, are useful vital stains 
for the flow cytometric recognition of DNA damage and other viability 
measurements by monitoring the emission spectral shifts of the dyes. 
The proliferation degree both in GBM and GEO cell lines was monitored by 
FACS analysis, on a Beckman Coulter instrument, and the data were analyzed 
using Kaluza Analysis software. 
 
f) Trypan blue exclusion test 
Viability assay was performed on C16 and U87 cell lines, cultured following the 
procedure above described. To count viable and unviable cells 0.4% Trypan Blue 
(Sigma-Aldrich) was used according to the manufacturer’s instructions. The 
counting was performed in a 4x4 square counting chamber, using a 10x 
magnification. Trypan Blue is the one of the most routinely stains used to perform 
dye exclusion procedures for viable cell counting. This method is based on the 
principle that live (viable) cells do not take up certain dyes, whereas dead 
(unviable) cells do. Moreover, staining facilitates the visualization of cell 
morphology. 
 
g) Migration assay (wound healing assay) 
A scratch assay was performed to evaluate wether the 1B4 mAb exerted any effect 
on the migration of GBM cell lines. Cells were seeded on a 24-well plate (700 
μL/well) with a cell density of 8000 cells/cm2. The following day, the medium 
was replaced with fresh medium containing 1B4 mAb at three different 
concentrations (0-1 μM, 0.2 μM and 0.4 μM), otherwise a negative control lane 
was filled with simple medium without adding the antibody and the remaining 
empty wells were filled with PBS to avoid the evaporation process. A scratch was 
performed using a 200 μL tip, kept 90° angled. Thus, the migration rate was 
monitored for 24h, using a Zeiss Axio Observer Z1 microscope equipped with an 
incubator to keep the temperature at 37 °C. The images were taken every 30 
minutes for 24h and finally were processed by Wimasis server   
(https://mywim.wimasis.com). 
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CHAPTER III 
 
RESULTS 
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III.1 GENERATION AND BIOCHEMICAL CHARACTERIZATION OF 
SPECIFIC ANTI-CFC MONOCLONAL ANTIBODIES 
 
1.1 CHEMICAL SYNTHESIS, PURIFICATION, CHARACTERIZATION 
AND REFOLDING OF HUMAN CFC DOMAIN AND MUTANTS 
 
hCFC [112-150] domain, reported in Fig. 3.1, and its three related variants in 
which H120 or W123 or both residues were replaced with A, is reported in Table 
1. Polypeptides were synthesized as acetylated and amidated products by solid 
phase synthesis (Fig. 3.1).  
       
Figure 3.1: Amino acid sequence of hCFC[112-150]. The disulfide bridges scheme is reported 
(C1-C4, C2-C6, C3-C5).   
 
 
 
Crude products were purified under reducing conditions by RP- HPLC, as 
described in section II.2.1.a of Methods. The refolding process was monitored by 
analytical RP-HPLC as described in section II.2.1.b of Methods.    
Fig. 3.2 reports a panel of representative RP-HPLC profiles recorded during the 
refolding process of the wild-type hCFC[112-150]. As shown, at t0 (Fig. 3.2 A) 
the peak corresponding to the reduced purified hCFC[112-150] polypeptide eluted 
at 7.5 min.  After 1h (t1), the oxidized form already started to appear (Fig. 3.2 B) 
with a peak at 6.9 min. After 3h (t3) the RP-HPLC profile shows only one peak at 
6.9 min, corresponding to the fully oxidized synthetic hCFC[112-150] (Fig. 3.2 
D). This shift of 0.6 minutes between t0 and t3 species confirmed that the 
spontaneous refolding process was complete, since the reduced species were not 
present anymore. In addition, this result revealed that the hCFC [112-150] domain 
possessed the proper sequence since only polypeptides with a correct sequence 
can spontaneously refold, otherwise truncated polypeptides show side reactions 
Table 1. hCFC[112-150] domain variants synthesized as reduced products
hCFC
[112-150]
Amino acid Sequence MW
amu
Wild-type Ac-KENCGSVPHDTWLPKKCSLCKCWHGQLRCFPQAFLPGCD-NH2 4475.235
H120A Ac-KENCGSVPADTWLPKKCSLCKCWHGQLRCFPQAFLPGCD-NH2 4360.101
W123A Ac-KENCGSVPHDTALPKKCSLCKCWHGQLRCFPQAFLPGCD-NH2
4409.173
H120W123AA Ac-KENCGSVPADTALPKKCSLCKCWHGQLRCFPQAFLPGCD-NH2
4294.039
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due to polymerization or low solubility issues. The refolded products were re-
purified to obtain the final homogenous material, as described in section II.2.1.c 
of Methods. Finally, for each polypeptide the purity and the formation of the 
disulphide bridges were estimated by LC-ESI-TOF-MS. All the products showed 
high purity grade (by over 90%), and, as expected, a molecular weight decreased 
of 6 amu compared to the unfolded precursor, due to the formation of the three 
disulfide bridges (see Table 2). The ESI-TOF mass spectra of the refolded and 
reduced hCFC[112-150] are reported in Fig. 3.3.  
                
 
Figure 3.2: Overlay of the hCFC[112-150] refolding process monitored by RP-HPLC analysis: at 
time 0 (t0, A); after 1 h, (t1, B); after 2h, (t2, C), and after 3h, (t3, D).  
Table 2. MW and purity grade of final products
hCFC [112-150] Theor MW
amu
Exp MW
amu
Purity
%
Wild-type 4469.235 4469.04 > 95
H120A 4354.101 4352.99 > 90
W123A 4403.173 4403.02 > 90
H120W123AA 4288.039 4286.97 > 90
A
D
C
B
RP-HPLC REFOLDING PROCESS OF hCFC[112-150] 
79 
 
 
 
Figure 3.3: LC-ESI-TOF-MS analyses of reduced (1) and oxidized hCFC[112-150] (2). In each 
panel RP-HPLC base peak chromatogram (A), m/z mass spectrum (B) and deconvoluted spectrum 
(C) are reported. 
1. Reduced hCFC[112-150] 
A
B
C
4475.09
[M+6H]6
[M+5H]5
[M+4H]4
[M+3H]3
2. Oxidized hCFC[112-150] 
A
B
C
*
[M+6H]6
[M+4H]4
[M+3H]3
4469.09
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1.2 ELISA SCREENING OF HYBRIDOMA SUPERNATANTS ON 
hCFC[112-150] AND hCFC[112-150]W123A 
 
A preliminary hybridoma supernatant screening ELISA assay was set up using 
synthetic wild-type hCFC[112-150] domain obtaining only 7 positive clones, 
indicated as 10D1, 7A4, 3F6, 4H2, 6D4, 1B4 and 1D10. Furthermore, with the 
aim to identify antibodies recognizing residues strictly involved in the interaction 
with ALK4, a second round of screening was performed. An ELISA assay was 
thus carried out using both the synthetic wild-type hCFC[112-150] and 
hCFC[112-150]W123A variant, where Triptophan123 (W123), known to be - 
together with Histidine120 (H120) - a hot spot residue for the ALK4 interaction, 
was mutated to Alanine (A). 
                        
 
Figure 3.4: Preliminary ELISA screening of the hybridoma supernatants on the synthetic wild-
type hCFC[112-150] domain and the singly mutated hCFC[112-150]W123A variant. 
 
The absorbance values for 5 clones (10D1, 7A4, 3F6, 1B4 and 1D10) were found 
to have a higher signal compared to others (4H2 and 6D4), indicating a better 
antigen recognition. In addition, only two clones, 10D1 and 1B4, among the 5 
positive ones, did recognize the wild-type hCFC[112-150] better than the singly 
mutated variant, suggesting that they specifically bind the CFC region containing 
W123.  
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1.3 PURIFICATION OF ANTI-CFC MONOCLONAL ANTIBODIES 
 
Five selected clones were purified by affinity chromatography on protein G 
column, as described in Methods (section II.2.4). The typical affinity 
chromatography profile of a purification from hybridoma supernatant is reported 
in Fig. 3.5. IgGs elution (Peak B) was performed after several injections of 
supernatant (in this case 5), washing away the unbound fraction (Peaks A) with 
the binding buffer (PBS, pH 7.4).   
 
 
Figure 3.5:  Representative chromatographic profile of an affinity protein G purification of 
hybridoma supernatant.  
 
Next, the presence of antibody aggregates was evaluated by SEC using a 
Superdex200 column. All mAbs showed a similar elution profile, with a retention 
volume of 11-12.5 mL, corresponding to a 150 kDa molecular weight. 
Immediately after affinity purification all antibodies were essentially monomeric 
with only a very small fraction of aggregates detected. In Fig. 3.6 a representative 
size exclusion chromatogram of one mAb (A) and an SDS-PAGE analysis (B) of 
the final purified mAbs are reported. Also SDS-PAGE analyses under non 
reducing conditions showed that mAbs did not undergo aggregation; the different 
mobility on the gel is correlated to their different glycosylation status. 
 
PeaksA
Peak B
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A  
B                  
Figure 3.6: A. SE-chromatografic profile of a mAb. B. SDS-PAGE analysis on a 10% 
polyacrylamide gel of each purified mAb. 
 
The different features of the mAbs, evidenced by SDS-PAGE analysis, were 
confirmed by the isotypization (reported in Table 3) revealing that while 1B4 is an 
IgG2b, the remaining four mAbs (10D1, 7A4, 3F6 and 1D10) belong to the more 
common IgG1 sub-class. 
 
 
The murine IgG1 are known to contain N-linked oligosaccharides, almost entirely 
fucosylated, at Asn297 of the CH2 domain of both heavy chains [159]. On the other 
hand IgG2b mAbs are known to possess O-linked oligosaccharides at Thr221 in 
mAb
150
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kDa M
Table 3. mAb isotypes
mAb Isotype
10D1 IgG1
7A4 IgG1
3F6 IgG1
1B4 IgG2b
1D10 IgG1
83 
 
the hinge region [160]. In conclusion, the SDS-PAGE analysis of 1B4 mAb was in 
accordance to the data reported by Kim et al. [161], since only mouse IgG2b 
antibodies exist as three phenotypes (detected as three bands on the gel), that 
differ each other in the sialylation status of the heavy chain, so their typical 
mobility is the consequence of the different acidity of the heavy chain.   
                                       
1.4  SPR DOSE-RESPONSE BINDING ASSAYS OF mAbs ON rhCR-1  
The ability of selected monoclonal antibodies to recognize the full-length rhCR-1 
protein was evaluated by SPR assays. For each antibody a dose-dependent assay 
at increasing concentrations (reported in Table 4), was performed using a rhCR-1 
functionalized sensor chip, prepared as described in Methods (section II.2.5). A 
low immobilization density (600 RU) of protein was preferred to limit mass 
transfer, rebinding effects, and cross-linking of the bivalent analyte (mAb) that 
can bind to two molecules of ligand, avoiding an accurate evaluation of the kinetic 
parameters.         
 
 
The separated kinetic rate constants and the final affinity constant were 
extrapolated using the Langmuir 1:1 binding model, and they are reported as ka 
(association rate constant) and kd (dissociation rate constant), while the KD 
(apparent binding affinity constant) is the result of the kd/ka ratio. By comparing 
the kinetic fitting curves and residual plots related to each mAb, by virtue of the 
KD towards the target protein, 10D1 displayed the highest affinity (KD = 0.07 nM) 
as result of fast association rate and very slow dissociation rate. As shown in the 
overlay of the sensorgrams, reported in Fig. 3.7, the dissociation was practically 
undetectable. 1B4 mAb (Fig. 3.8) acted almost like the 10D1 mAb, exhibiting a 
Table 4. Analyte concentrations tested on rhCR-1
10D1 1B4 7A4 1D10
0.12 nM 0.5 nM 0.12 nM 50 nM
0.25 nM 1 nM 0.25 nM 100 nM
0.5 nM 2.5 nM 0.5 nM 200 nM
1 nM 5 nM 1 nM 300 nM
1.5 nM 10 nM 1.5 nM
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good association (ka=1.4x10
5
 M
-1
s
-1
) combined to a very slow dissociation (kd= 
3.7x10
-5
 s
-1
) rate, providing a KD value (0.24 nM) higher than the 10D1.  
Moreover, the interaction of 7A4 mAb to rhCR-1 (Fig. 3.9) revealed a KD value 
of 2.6 nM. This loss of affinity was due to a faster dissociation rate (kd =1.7 x10
-3
 
s
-1
) rather than to the association rate (ka= 4x10
6
 M
-1
s
-1
) compared to the 10D1 
and 1B4 antibodies. 1D10 mAb (Fig. 3.10) was still able to bind rhCR-1 but the 
interaction was very weak, revealing a 57 nM KD, about 1/1000 lower than the KD 
displayed by the 10D1. Finally, the 3F6 mAb did not recognize rhCR-1 (reported 
as NB in Table 9) even at very high concentration (1 µM). These data suggest that 
the epitope of 3F6 antibody probably contains residues at the interface with the 
EGF-like domain thus not accessible in the full-length protein. 
       
 
                   
Figure 3.7: Sensorgrams overlay and kinetic parameters table of 10D1 mAb binding to rhCR-1. 
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10D1 0.125nM 10D1 0.25nM 10D1 0.5nM 10D1 1nM 10D1 1.5nM
Table 5.  Kinetic rate and apparent affinity constants of 10D1 
mAb binding to rhCR-1  
10D1 ka (1/Ms) kd(1/s) KD (M) SE (RI)
0.5 nM 1.31*106 1.74*10-4 1.33*10-10 0.0239
1 nM 1.68*106 7.99*10-5 4.75*10-11 0.0784
1.5 nM 1.75*106 6.65*10-5 3.80*10-11 0.175
average 1.58*106 1.07*10-4 7.28*10-11 0.0924
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Figure 3.8: Sensorgrams overlay and kinetic parameters table of 1B4 mAb binding to rhCR-1. 
 
 
                
Figure 3.9: Sensorgrams overlay and kinetic parameters table of 7A4 mAb binding to rhCR-1. 
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Table 6.  Kinetic rate and apparent affinity constants of 1B4 
mAb  binding to rhCR-1 
1B4 ka (1/Ms) kd(1/s) KD (M) SE (RI)
0.5 nM 1.34*105 2.12*10-5 1.58*10-10 0.0286
1 nM 6.89*104 1.25*10-5 1.81*10-10 0.028
2.5 nM 7.19*104 1.82*10-5 2.53*10-10 0.024
5 nM 2.19*105 4.94*10-5 2.25*10-10 0.0298
10 nM 2.13*105 8.23*10-5 3.86*10-10 0.0575
average 1.41*105 3.67*10-5 2.41*10-10 0.0336
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Table 7.  Kinetic rate and apparent affinity constants of 7A4 
mAb binding to rhCR-1
7A4 ka (1/Ms) kd(1/s) KD (M) SE(RI)
0.125 nM 1.46*105 1.71*10-3 1.17*10-8 0.0437
0.25nM 4.10*106 1.74*10-3 4.24*10-10 0.0641
0.5nM 6.01*106 1.80*10-3 3.00*10-10 0.101
1nM 5.23*106 1.72*10-3 3.29*10-10 0.152
1.5nM 4.46*106 1.77*10-3 3.97*10-10 0.143
average 3.99*106 1.75*10-3 2.63*10-9 0.101
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Figure 3.10: Sensorgrams overlay and kinetic parameters table of 1D10 mAb binding to rhCR-1. 
 
In summary, by comparing all mAbs (see Table 9), we found that the 10D1 and 
1B4 mAbs displayed sub-nanomolar affinity (KDs = 0.07 nM and 0.24 nM ) 
towards rhCR-1, therefore represent promising molecules to be used to target 
human Cripto-1. The antibodies also denoted high specificity, recognizing 
residues on the surface of the CFC domain involved in the binding to ALK4 
receptor.  
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Table 8.  Kinetic rate and apparent affinity constants of 1D10 
mAb binding to rhCR-1
1D10 ka (1/Ms) kd(1/s) KD (M) SE (RI)
50nM 6.52*104 1.05*10-3 1.61*10-8 0.0522
100nM 3.29*104 1.36*10-3 4.14*10-8 0.0341
200nM 1.92*104 1.72*10-3 8,95*10-8 0.0829
300nM 2.16*104 1.76*10-3 8.13*10-8 0.130
average 3.47*104 1.47*10-3 5.71*10-8 0.0748
Table 9. KD values of mAbs vs rhCR-1
mAb KD (nM)
10D1 0.07
1B4 0.24
7A4 2.6
3F6 NB
1D10 57.0
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1.5 10D1 AND 1B4 SPECIFICITY TEST ON rhCR-/rmCr-1 
ELISA assays were carried out to test the specificity of selected antibodies to 
human Cripto-1 versus the murine variant. The two full-length proteins (h-Cripto-
1, Uniprot code:P13385; m-Cripto-1. Uniprot code: P51865) share an overall 
sequence identity of 63.38 %, however the identity within the CFC domains is 
about 85% (Fig. 3.11).  
 
 
Figure 3.11: Amino acid sequence alignment of CFC domains belonging to human and murine 
form of Cripto-1. A remarkable hallmark is the conserved “hot spots” H120 and W123 in human 
CR-1 corresponding to H104 and W107 in mouse Cr-1. 
 
As shown in Fig. 3.12, Elisa assays, performed as described in Methods (II.2.3.d 
section) coating both human and mouse recombinant Cripto-1, revealed that both 
mAbs recognize the human protein in a highly specific and dose-dependent 
fashion, being almost unable to bind the mouse variant. According to the SPR 
results, 10D1 mAb confirmed its higher affinity to human Cripto-1 compared to 
1B4 mAb, exhibiting an increased absorbance even at very low amounts (12 ng).   
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Figure 3.12: Bar graphs of the ELISA assays, carried out using recombinant Cripto proteins 
(human and mouse) at a range of increasing concentrations (12ng-25ng-50ng-100ng) detected by 
10D1 (A) and 1B4 (B) mAbs, used at a concentration of 6.7 nM. 
 
1.6 PRELIMINARY BINDING ASSAYS OF rhCR-1 TO rhALK4 
 
ELISA and SPR binding assays were performed to determine the affinity constant 
underlying the interaction between CR-1 and its fisiological partner, ALK4 
receptor. 
These preliminary data were next used to set up the optimal conditions to carry 
out competition assays with the 1B4 mAb. Using an ELISA assay, a dose-
response binding of rhCR-1 to rhALK4 was confirmed; such binding was 
characterized by an affinity constant of about 0.4 nM.  
The interaction of rhALK4 to rhCR-1, monitored by SPR, instead, revealed a KD 
of about 4.6 nM, supported by association and dissociation rates of 1.56x10
5
 M
-1
s
-
1 
and of 7.21 x10
-4
 s
-1
, respectively. 
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Figure 3.13: Dose-response ELISA assay showing the binding of rhCR-1 to rhALK4 receptor. 
                    
 
 
Figure 3.14: Sensorgrams overlay and kinetic parameters table of  rhALK4 binding to rhCR-1. 
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Table 10.  Kinetic rate and apparent affinity constants of rhALK4 
binding to rhCR-1 
rhALK4 ka(1/Ms) kd(1/s) KD (M) SE(RI) 
25 nM 1.41*105 6.40*10-4 4.53*10-9 0.0658
50 nM 1.58*105 5.66*10-4 3.57*10-9 0.110
100 nM 1.68*105 9.57*10-4 5.70*10-9 0.131
average 1.56*105 7.21*10-4 4.60*10-9 0.153
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1.7 DETECTION OF rhCR-1 BY 1B4 mAb IN ELISA CAPTURE ASSAY 
 
The capture system, optimized using the commercial anti-Cripto polyclonal 
antibody in coating and the selected 1B4 mAb as primary detecting antibody, 
revealed that the lowest amount of rhCR-1 detectable by 1B4 was about 700 pg, 
as shown in the graph in Fig. 3.15. Here, the ng of protein are reported as a 
function of the absorbance measured at 450 nm.   
 
 
 
Figure 3.15: Calibration curve resulting by the detection of serially diluted rhCR-1 solutions. On 
the graph, the ng of rhCR-1 are reported as a function of the Abs450nm, detected by 1B4 mAb, using 
the capture system. 
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1.8 COMPARATIVE EPITOPE STUDY BETWEEN 10D1 AND 1B4 mAbs 
 
a)  Insights into the antigen-Fab xomplex by computational studies 
The search for the best template for the Fab fragment of each selected antibody 
gave different results. For the 10D1, the best template was a Fab fragment 
reported with the 3grw PDB file name in the RCSB database (www.rcsb.org). 
Thus, a 92.73% sequence homology was observed for the variable region of the 
light chain (VL), while a 63.78% homology for the variable region of the heavy 
chain (VH). By contrast, a perfect match (100% of homology) was found between 
the sequences of the whole constant region. 
On the other hand, for the 1B4 mAb, two templates (1cbv and 1d5i), exhibiting 
the highest sequence homology for the variable region were found. More exactly, 
the 1cbv had a 95.65% identity on the VL domain, while the 1d5i showed a higher 
homology (75.83%) compared with the VH domain. Furthermore, 1cbv was shown 
to possess a higher sequence homology (100%) to the CL region than 1d5i 
(72.25%). For the CH region, the opposite situation was observed, since 1d5i was 
demonstrated to have a 100% identity homology, instead of 48.86% shown by 
1cbv.  
Once identified the best template for each mAb, the sequence alignment of 10D1 
and 1B4 Fab fragments was performed, providing a 75.7% identity sequence.  
Simoultaneously CDRs were predicted on the basis of the secondary structure, as 
determined by homology sequence and homology to crystal structures of IgGs 
reported in the pdb database. 
The six CDRs, three belonging to the light chain (L1, L2 and L3) and three to the 
heavy chain (H1, H2 and H3), were predicted as reported in Table 11 and in Fig. 
3.16.   
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figure 3.16: Sequence alignment of separated  heavy and light chains of 10D1 and 1B4 mAbs. The 
specific CDRs are reported in the red boxes. 
 
 
The model of the Fab fragments, obtained with a RMSD (root mean squared 
deviation) of 1.11 Å for the backbone atoms, showed the canonical secondary 
structure proper of Ig-like domain, made up of a β-sheet motif, in which the β-
loops correspond to the CDRs.  
Table 11.  Identified CDRs of 10D1 and 1B4 mAbs
CDR 10D1 1B4
H1 S24-Y31 A25-Y32
H2 Y51-N56 S52-Y56
H3 M99-Q115 F98-Q108
L1 S26-A32 S26-Y37
L2 Y49-T56 K55-S61
L3 Q90-P95 Q95-P100
                    10        20        30        40        50        60        70        80        90                  
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
10D1       EVQLVESGGGLVQPGGSLR-SCAASGYIFTSYYIHWVRQAPGKGLEWVGWIYPGNVNTKYNENFKGRFTISADTSKNTAYLQMNSLRAED  
1B4        QVQLQQSGAELIRPGTSVKMSCKAAGFTFTNYWIGWVKERPGHGLEWIGDISPGGGYIHYNEKFKGKATLTADTSSSTAYMQLSSLTSED  
Consensus   VQL  SG  L  PG S   SC A G  FT Y I WV   PG GLEW G I PG     YNE FKG  T  ADTS  TAY Q  SL  ED  
 
                   100       110       120       130       140       150       160       170       180         
           ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
10D1       TAVYYCARNMVYGSLSYYSMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL  
1B4        SAIYYCAKYFYA-------MDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL  
Consensus   A YYCA            MDYWGQGT VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL  
 
                   190       200       210       220          
           ....|....|....|....|....|....|....|....|....|. 
10D1       QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC  
1B4        QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC  
Consensus  QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK VEPKSC  
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           ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
10D1       DIQMTQSPSSLSASVGDRVTITCKASQDVS-----TAVAWYQQKPGKAPKLLIYSTSYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAT  
1B4        DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSSGNTYLHWYLQKPGQSPKLLIYKISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGV  
Consensus  D  MTQ P SL  S GD   I C  SQ        T   WY QKPG  PKLLIY  S R  GVP RFSGSGSGTDFTL IS    ED     
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           ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
10D1       YYCQQHYNTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL  
1B4        YFCSQNTHVPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL  
Consensus  Y C Q    P TFG GTK E KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL  
 
                   190       200       210         
           ....|....|....|....|....|....|....|.... 
10D1       SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
1B4        SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
Consensus  SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  
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Comparing the models built for each mAb, we found that the 10D1 mAb (reported 
in red in Fig. 3.17) has a longer H3 loop (17 residues) and a shorter L1 loop (7 
residues) compared to those of 1B4 mAb (reported in blue), whose H3 loop has 6 
residues, while the L1 loop contains 12 residues. 
Such differences could explain the different affinity exhibited by the two mAbs 
toward hCFC as well as rhCR-1 protein. 
A              
B  
Figure 3.17: A. Fab models of 10D1 (red) and 1B4 (blue) mAbs built by homology modelling. 
Fabs are made up of four domains: variable (VL) and constant (CL) domains of the light chain, and 
the variable (VH) and the first constant (CH) domain of the heavy chain. B. Zoom of the variable 
fragment (Fv), containing only the variable regions of the light and heavy chains (VL and VH 
respectively), The six loops corresponding to the CDRs (three on the light chain and three on the 
heavy chain) are reported. Loops H3 and L1 differing in length are underlined. 
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Docking studies performed on the complex formed by the Fabs and the hCFC 
antigen gave similar results for both 10D1 and 1B4 mAbs. 
Considering the energy-minimized antigen-Fab complex, both 10D1 and 1B4 
mAbs appeared to interact with the hCFC domain in a similar  manner, denoting a 
comparable binding energy (Ebind = -11.35 kcal/mol and -10.47 kcal/mol for 
10D1 and 1B4 respectively).  
Moreover, following a more detailed visual inspection of the binding interface, on 
the basis of the contact residues map of each complex, we identified a 
hydrophobic-polar groove at the contact interface, in which favourable 
hydrophobic interactions were detected in combination with H-bonds. Such 
surface formed a pocket in which H120 and W123 of hCFC can easily insert. In 
Tables 12 and 13 the COCOMAPS analysis results are reported. For each 
identified favourable residue, the position on the loop is reported, specifying if the 
binding contribution is given to H120 or W123. 
 
 
  
 
 
Table 12. 10D1-hCFC contact residues
Residue position H120 W123
H3 M99     (H-bond) V100
H3 V100 Y101
H3 Y101 G102
H3 G102 S103
L2 Y49
L2 Y55
L2 T56  (H-bond)
Table 13. 1B4-hCFC contact residues
Residue position H120 W123
H3 Y101 (H-bond) F100
H3 A102 Y101
H3 M103
L2 Y54
L2 F60
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As revealed by the contact maps, the major contibution to the binding is provided 
by residues belonging to the H3 loop, which are able to interact with both H and 
W residues of the epitope, extablishing favourable hydrophobic interactions. 
Moreover, a few aromatic residues (Y and F), embedded in the L2 loop, give a 
contribution only to H120. 
Considering the 10D1-hCFC contact region, the residues exposed by the H3 loop 
to both H120 and W123 are represented by V100, Y101 and G102. Instead, L2 
loop exposes two Y (49 and 55) exclusively to H120. On the other hand, at the 
binding interface of the 1B4-hCFC complex, the aromatic rings of F100 and 
Y101, belonging to the H3 loop, can be involved in aromatic and/or π-stacking 
interactions. This kind of interactions can potentially be established also by Y49, 
Y54 and F60 exposed on the L2 loop, which is bent on the opposite side of the H3 
loop. 
Indeed, the comparison between the contact regions of the two mAbs revealed 
that the 10D1 exposes to the antigen more residues than the 1B4, as expected 
since the H3 loop belonging to the 10D1 mAb is longer than that one of 1B4; 
despite this difference, both mAbs show at the binding interface residues with a 
comparable polarity. Moreover, two residues are conserved (M and Y). A 
remarkable hallmark is the amino acid composition of the L2 loop. As can be 
seen, a perfect match is observable between the aromatic residues residing within 
the two peptide segments, since Y49 and Y55 of 10D1 find as corresponding 
residues the Y54 and F60 of 1B4 (See Fig. 3.18 and 3.19). 
Analysing the entire antibody-antigen complex, a further difference is detectable 
between the two mAbs: 10D1 exposes to hCFC a wider contact region than 1B4, 
which indeed forms a more compact complex compared to the one obtained with 
10D1, suggesting a high fit capability towards the antigen. Remarkably, 1B4 
forms a pocket perfectly surrounded by the H3-L2 loop motif, in which the 
epitope can protrude, leading to the formation of a typical key-lock model. 
Interestingly, the favourable hydrophobic interactions shown by both 10D1 and 
1B4 are similar to those found at the binding interface of the complex hCFC-
ALK4 [23], where Y55 and F56 of the receptor were shown to be responsible of 
aromatic interactions with H120 and W123 of hCFC (See Fig. 3.18 and 3.19). 
These models thus provide a picture of how 10D1 and 1B4 bind the CFC domain 
of Cripto-1 and presumably can neutralize the ALK4 binding and activation. 
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Figure 3.18: Representation of the interaction at the binding interface of 10D1 Fab fragment (stick 
model on the left and Connolly surface area on the right) and hCFC (stick model). On the contact 
region the crucial residues for the antibody-antigen recognition are underlined. In addition, the 
contact map is reported on the right side of the figure. 
 
 
Figure 3.19: Representation of the interaction at the binding interface of 1B4 Fab fragment (stick 
model on the left and Connolly surface area on the right) and hCFC (stick model). On the contact 
region the crucial residues for the antibody-antigen recognition are underlined. In addition, the 
contact map is reported on the right side of the figure. 
 
This computational study provided valuable informations about the binding 
surface of the antibody-antigen complex, thus can be the basis to design 
recombinant fragments and improving them by site-directed mutagenesis studies 
and to generate new variants of these fragments to eventually select the best 
molecule in terms of affinity and specifity to the antigen. 
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b) Epitope mapping assays 
An epitope mapping study was performed to delineate those residues on hCFC 
responsible of antibody recognition. The study was performed by the combination 
of ELISA and SPR assays, using the wild-type hCFC[112-150] and three 
chemically generated variants: hCFC[112-150]H120A, hCFC[112-150]W123A 
and hCFC[112-150]H120AW123A.    
ELISA assays 
Dose-dependent ELISA binding assays between 10D1 and 1B4 mAbs and 
synthetic wild-type hCFC[112-150] and mutated domains were carried out as 
described in the Methods (section 2.3.d). 
As shown in Fig. 3.20 A, 10D1 was still able to recognize the hCFC[112-
150]H120A mutant, whereas no binding was detected to hCFC[112-150]W123A 
and hCFC[112-150]H120AW123A.  
1B4, instead, bound only the wild type hCFC[112-150], as shown in Figure 3.20 
B.  
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To better evaluate the loss of binding we used the binding signal obtained with the 
mAbs at 4 nM, assuming as 100% the one obtained with the wild-type hCFC.  
As shown in Fig. 3.21, 10D1 showed around 60% loss of binding toward H120A 
variant and around 75% toward W123A mutant. Under these conditions the 
doubly mutated H120AW123A showed a residual binding of only about 15% . 
Under the same conditions, mutations occurred at the same residues on hCFC led 
to about 80% loss of binding with 1B4. Data are thus suggestive of the relevant 
role played by both H120 and W123 residues in the binding to the antibodies. 
                         
                         A 
       
 
        B 
Figure 3.20: ELISA epitope mapping. Dose-response curves are reported for 10D1 (A) and 1B4 
(B) mAbs. 
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Figure 3.21: ELISA epitope mapping. Normalization bars graph in which the binding of each 
mAb (4 nM) to hCFC variants is expressed as percentage of binding.  
 
SPR assays 
ELISA epitope mapping results were supported by SPR analyses, by which a 
more detailed insight is provided about the antigen-antibody interaction, defined 
in terms of association and dissociation rate constants. The preliminary dose-
response binding of the full-length rhCR-1 to the immobilized mAbs revealed KD 
values corresponding to ~3.5 nM and ~70 nM on 10D1 and 1B4 mAbs 
respectively. The interaction of both 10D1 and 1B4 mAbs with the specific 
antigen, the synthetic wild-type hCFC[112-150], was underlined by KD values of 
2 nM and 30 nM, respectively, denoting their high specificity. By comparing the 
binding curves of 10D1 to wild-type and H120A hCFC domains, this mAb 
displayed toward the mutant less favorable kinetics parameters revealing that this 
interaction was less strong, since the antigen-antibody complex underwent a very 
fast dissociation with a final KD = 14 nM, which is ten-fold lower than that one of 
wild-type hCFC (KD = 1.8 nM).  Moreover, the interaction with the W123A 
mutant (KD = 200 nM) exhibited a dramatic loss of affinity through the 
dissociation rate, that was faster than the wild-type domain, thus suggesting that 
these mutations negatively influence the strength of antigen-antibody complex. 
Finally, the interaction with the doubly mutated H120W123AA domain showed a 
very fast dissociation and we could not determine any dissociation parameter. 
These data confirmed that both residues H120 and W123 are strongly involved in 
the binding with the antibody (see also Fig. 3.22 through 3.26). 
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Figure 3.22: Sensorgrams overlay and kinetic parameters table of rhCR-1 binding to 10D1 mAb. 
 
        
            
 
Figure 3.23: Sensorgrams overlay kinetic parameters table of  wild-type hCFC[112-150] domain 
binding to 10D1 mAb. 
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Table 14.  Kinetic rate and apparent affinity constants of rhCR-1 
binding to 10D1 mAb  
rhCR-1 ka (1/Ms) kd (1/s) KD (M) SE (RI)
2.5 nM 1.10*105 1.46*10-4 1.33*10-9 0.033
5 nM 9.70*103 2.43*10-5 2.50*10-9 0.0226
10 nM 5.98*103 3.72*10-5 6.22*10-9 0.0362
15 nM 2.06*104 8.39*10-5 4.08*10-9 0.0378
average 3.66*104 7.29*10-5 3.53*10-9 0.0324
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Table 15.  Kinetic rate and apparent affinity constants of wild-
type hCFC binding to 10D1 mAb
wt hCFC ka (1/Ms) kd (1/s) KD (M) SE (RI)
2.5 nM 3.51*104 1.44*10-4 4.10*10-9 0.0393
5 nM 2.16*104 4.63*10-6 2.14*10-10 0.0364
10 nM 1.12*104 2.06*10-5 1.85*10-9 0.0428
15 nM 1.34*105 1.54*10-4 1.15*10-9 0.103
average 5.05*104 8.08*10-5 1.83*10-9 0.0553
101 
 
  
         
Figure 3.24: Sensorgrams overlay and kinetic parameters table of the singly mutated hCFC[112-
150] H120A domain binding to 10D1 mAb. 
                                                                    
 
                                      
Figure 3.25: Sensorgrams overlay and kinetic parameters table of  the singly mutated hCFC[112-
150] W123A domain binding to 10D1 mAb. 
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Table 16.  Kinetic rate and apparent affinity constants of H120A 
hCFC binding to 10D1 mAb  
H120A ka (1/Ms) kd (1/s) KD (M) SE (RI)
10 nM 1.57*104 5.14*10-4 3.28*10-8 0.0404
25 nM 6.12*104 9.94*10-4 1.63*10-8 0.120
50 nM 2.60*105 9.15*10-4 3.52*10-9 0.0686
100 nM 3.47*105 1.15*10-3 3.32*10-9 0.109
average 1.71*105 8.93*10-4 1.40*10-8 0.0845
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Table 17.  Kinetic rate and apparent affinity constants of W123A 
hCFC  binding to 10D1 mAb
W123A ka (1/Ms) kd (1/s) KD (M) SE (RI)
10 nM 2.29*106 0.034 1.48*10-8 0.0878
25 nM 3.63*105 0.043 1.18*10-7 0.124
50 nM 1.71*105 0.0583 3.42*10-7 0.145
100 nM 1.66*105 0.0644 3.88*10-7 0.369
average 7.48*105 4.99*10-2 2.16*10-7 0.181
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                                                             NO FITTING 
Figure 3.26: Sensorgrams overlay of  the doubly mutated hCFC[112-150] H120W123AA  domain 
binding to 10D1 mAb. No fitting means that the kinetic parameters did not converge to any value. 
 
The comparison of kinetic parameters between the interaction of 1B4 mAb and 
synthetic wild-type hCFC[112-150] to the H120A mutant, denoted a decreased 
affinity towards the mutated form of the domain, due to a reduced association 
constant, the dissociation constants were comparable, instead. Thus, the KD value 
extrapolated from the wild-type hCFC-1B4 mAb was ~30 nM, while the KD 
corresponding to the binding to the H120A mutant was 355 nM.  The binding to 
the W123A variant exhibited kinetic constants comparable to the wild-type hCFC, 
but the resulting KD value (127 nM) was ten fold lower (30 nM), since less 
polypeptide was captured by the antibody. 
Finally, the H120W123AA mutant showed an affinity constant (KD=157 nM) ten 
fold lower compared to the wild type. Kinetics parameters showed unfavorable 
association and dissociation constants revealing the importance of both mutated 
residues for the recognition and for the stabilization of the complex (see also Fig. 
3.27 through 3.31). All the extrapolated KD values are summarized in Table 23. 
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Figure 3.27: Sensorgrams overlay and kinetic parameters table of rhCR-1 binding to 1B4 mAb.       
       
 
Figure 3.28: Sensorgrams overlay and kinetic parameters table of wild-type hCFC[112-150] 
domain binding to 1B4 mAb. 
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Table 18.  Kinetic rate and apparent affinity constants of rhCR-1 
binding to 1B4 mAb
rhCR-1 ka (1/Ms) kd (1/s) KD (M) SE (RI)
25 nM 1.08*105 4.20*10-3 3.91*10-8 0.0410
50 nM 3.93*104 3.68*10-3 9.36*10-8 0.0327
100nM 6.14*104 3.52*10-3 5.73*10-8 0.0538
150nM 3.66*104 3.46*10-3 9.44*10-8 0.0851
average 5.84*104 3.51*10-3 6.84*10-8 0.0531
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Table 19.  Kinetic rate and apparent affinity constants of wild-
type hCFC binding to 1B4 mAb
wt hCFC ka (1/Ms) kd (1/s) KD (M) SE (RI)
2.5 nM 4.77*104 3.09*10-3 6.47*10-8 0.0374
5 nM 1.29*105 2.58*10-3 2.00*10-8 0.0515
10 nM 1.01*105 2.81*10-3 2.78*10-8 0.0554
15 nM 2.23*105 3.08*10-3 1.38*10-8 0.0622
average 1.25*105 2.89*10-3 3.16*10-8 0.0516
104 
 
 
         
Figure 3.29: Sensorgrams overlay and kinetic parameters table of the singly mutated hCFC[112-
150]H120A domain binding to 1B4 mAb. 
        
          
Figure 3.30: Sensorgrams overlay and kinetic parameters table of the singly mutated hCFC[112-
150]W123A domain binding to 1B4 mAb. 
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Table 20.  Kinetic rate and apparent affinity constants of H120A 
hCFC binding to 1B4 mAb
H120A ka (1/Ms) kd (1/s) KD (M) SE (RI)
2.5 nM 1.26*105 3.34*10-3 2.65*10-8 0.0439
5 nM 1.63*105 4.37*10-3 2.68*10-8 0.036
10 nM 1.32*104 5.33*10-3 4.05*10-7 0.031
15 nM 6.74*103 6.47*10-3 9.61*10-7 0.0413
average 7.72*104 4.88*10-3 3.55*10-7 0.038
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Table 21.  Kinetic rate and apparent affinity constants of W123A 
hCFC binding to 1B4 mAb
W123A ka (1/Ms) kd (1/s) KD (M) SE (RI)
10nM 7.55*103 3.31*10-3 4.38*10-7 0.032
25nM 1.35*105 3.79*10-3 2.82*10-8 0.0499
50nM 1.78*105 3.78*10-3 2.12*10-8 0.0597
100nM 1.60*105 3.53*10-3 2.20*10-8 0.112
average 1.20*105 3.60*10-3 1.27*10-7 0.0634
105 
 
 
 
 
Figure 3.31: Sensorgrams overlay and kinetic parameters table of the doubly mutated hCFC[112-
150]H120W123AA domain binding to 1B4 mAb. 
              
 
  
-20
0
20
40
60
80
100
-50 0 50 100 150 200 250 300 350 400 450 500
H120W123AA hCFC vs 1B4mAb
R
e
s
p
o
n
s
e
 (
R
U
)
Time (sec)
H120W123AA 100nM H120W123AA 250nM H120W123AA 500nM H120W123AA 1000nM
Table 22.  Kinetic rate and apparent affinity constants of
H120W123AA  hCFC binding to 1B4 mAb
H120W123
AA
ka (1/Ms) kd (1/s) KD (M) SE (RI)
100 nM 9.36*104 9.90*10-3 1.06*10-7 0.0531
250 nM 6.70*104 8.43*10-3 1.26*10-7 0.134
500 nM 4.90*104 8.13*10-3 1.66*10-7 0.404
1000 nM 3.91*104 8.95*10-3 2.29*10-7 0.754
average 6.22*104 8.85*10-3 1.57*10-7 0.336
Table 23. KD values summary of the epitope mapping assays
10D1
nM
1B4
nM
rhCR-1 3.53 68.4
wt hCFC 1.83 31.6
hCFC H120A 14 355
hCFCW123A 216 127
hCFCH120W123AA no fitting 157
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In conclusion, the SPR results are in accordance to the ELISA results, suggesting 
that both mAbs are specific towards the region of the hCFC domain containing 
the two residues, H120 and W123, known to be “hot spots” for the interaction 
CR-1/ALK4. Thus, these mAbs are promising candidates as neutralizing 
antibodies, to block the interaction between the protein and its receptor. By the 
thermodynamic and kinetic binding analysis it appears that 1B4 binds more 
efficiently to both W123 and H120, whereas 10D1 interacts only with W123. 
1B4 was selected for further studies and to generate the recombinant Fab fragment 
to be subsequently developed as potential therapeutic tool targeting CR-1 with 
high specificity.                              
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III.2 GENERATION AND BIOCHEMICAL CHARACTERIZATION OF 
1B4 FUNCTIONAL Fab FRAGMENTS AND NEW FORMATS 
 
2.1 PROTEOLYTIC CLEAVAGE OF 1B4 mAb 
 
a) Papain digestion of 1B4 antibody  
Initially, a proteolytic cleavage with papain was carried out to obtain a functional 
Fab fragment of the 1B4 mAb.  After 4h of incubation, the highly heterogenous 
proteolytic pool was purified in a two-step process: a protein G affinity 
chromatography followed by SEC, as reported previously in Chapter II (section 
2.4 of Methods). 
 
           
Figure 3.32: Chromatographic profiles of 1B4 papain digest purification. A) Protein G affinity 
chromatography. B) SE-chromatography. SDS-PAGE analyses on a 12% polyacrylamide gel 
under non reducing and reducing conditions of the whole 1B4 antibody at the starting point t0 (C) 
and of the separated peaks eluted after SEC analysis (D).  
 
The SEC profile of the products obtained by protein G purification, showed three 
different peaks, corresponding to three different species, as detectable on the 
SDS-PAGE 12% gel, under non reducing and reducing conditions (Fig. 3.32 D). 
Peak 1, eluted at a 12.44 mL retention volume, corresponded to a fragment of 
about 100 kDa (lane 2). This fragment is the so-called Fab/c, a typical product 
generated by the cleavage of IgG2b sub-class (the 1B4 isotype), instead of the 
F(ab’)2. The Fab/c is made up of a single Fab unit linked to the Fc portion by one 
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intact heavy chain, thus under reducing conditions the three observed bands (50 
kDa, 30 kDa and 25 kDa) are the intact heavy chain, half an Fc portion and the 
light chain respectively ( lane 5). This asymmetric cleavage is typical of the 
IgG2b isotype [175] because they posses two heavy chains asymmetrically O-
glycosylated in the hinge region. In fact, the whole antibody, analyzed by SDS-
PAGE (Fig. 3.32 C) under reducing conditions (t0 +β), exhibited two bands at 
around 50 kDa with a different mobility, corresponding to the two heavy chains, 
probably because the slower minor band is more acidic than the other one. 
Moreover, peak 2, with a retention volume of 13.65 ml, corresponded to the Fc 
portion (Fig. 3.32 D, lane 3), that normally appears at a molecular weight of 30 
kDa but in this case showed more than one band, due to the different 
glycosylation status of the CH2 domain of the heavy chain. Finally, peak 3, eluted 
at 15.05 ml corresponded to the Fab fragment, with a molecular weight of around 
45-50 kDa. Indeed, under non reducing conditions (lane 4) this fragment showed a 
homogenous band at around 45 kDa, while under reducing conditions (lane 7) the 
two separated bands were distinguished as the heavy chain (the upper one) and the 
light chain (the lower one). Moreover, since 1B4 is an IgG2b, the sub-class most 
sensitive to the proteases attack, the antibody was totally splitted and no 
uncleaved product was observed. 
 
b) Comparative conformational analysis between 1B4 mAb and its 
proteolytic Fab   
 
 
A conformational analysis by circular dichroism in the region of far-UV was 
carried out to compare the parental 1B4 mAb with its Fab fragment to evaluate if 
the final proteolytic product retained its correct secondary structure after the 
catalytic action of papain. As shown in Fig. 3.33 A, the CD spectrum of the 1B4 
mAb had a negative extreme position at 217 nm, with a broad amplitude and a 
positive extreme position at 202 nm, perfectly in accordance to a canonical β-
sheet secondary structure, typical of the IgG molecules. Compared to the intact 
antibody, the spectrum of the Fab fragment (Fig. 3.33 B) showed the same 
position for the negative extreme at 217 nm and a minimal shift in the position of 
the positive extreme to 200 nm. A remarkable difference was the negative portion 
in the spectrum of the Fab, characterized by an additional weak absorbance at 235 
nm, not belonging to a canonical IgG2b. Thus, an overall β-sheet secondary 
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structure could be defined even for the Fab fragment, but presumably the 
proteolytic reaction damaged some residues that normally exert a structural 
function.  
       
 
A                
 
B 
 
 
Figure 3.33: CD spectra of the full-size 1B4 mAb (A) and the Fab fragment generated by papain 
digestion (B). 
 
Given the poorly productive proteolytic reaction (very low yield of 15%) carried 
out on the whole IgG molecule, related to the generation of by-products, 
predominantly the Fab/c fragment and other unimportant fragments, the digestion 
process required an optimization performing a preventive O-deglycosylation of 
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the mAb, to allows the hinge region to become more easily accessible to the 
papain attack. Thus, the 1B4 mAb was submitted to a two-step deglycosylation 
(firstly with Sialidase and secondly with O-glycosidase) and the resulting products 
were analyzed by SDS-PAGE analysis onto a 12% polycrylamide gel (Fig. 3.34 
A), under both non reducing and reducing conditions, comparing the untreated 
antibody molecule with the molecule after a total incubation time period of 48h. 
      
Figure 3.34: SDS-PAGE analyses of 1B4 deglycosylation reaction (A) and of deglycosylated 1B4 
digestion (Dig*) compared to the normal 1B4(Dig) (B). 
 
As can be seen in Fig. 3.34 A, the final product of the deglycosylation process, 
under non reducing conditions (lane 3) showed a phenotype still comparable to 
the wild-type antibody (lane 2), but remarkable differences were observed on the 
heavy chains under reducing conditions, as they indeed migrated as a single 
homogenous band at around 50 kDa (lane 5 in the red circle), instead of the two 
separated haevy chains (lane 4) with different mobility. The different O-
deglycosylation status influenced, as expected, the 1B4 mAb cleavage by papain, 
because comparing the papain digest of the wild-type form (Dig) with the 
deglycosilated form (Dig*), differential fragments were detectable (Fig. 3.34 B, 
gel on the left). The papain digest of the normal antibody under non reducing 
conditions (lane 2) exhibited a consistent band at 45 kDa, corresponding to the 
Fab fragment, while still contained uncleaved antibody (150 kDa) and in addition 
the canonical Fab/c fragment (110 kDa), thus under reducing conditions (lane 3) 
many heterogenous bands were detected between 37 kDa and 20 kDa, 
corresponding to the reduced Fab and Fc with asymmetic oligosaccharide chains. 
By contrast, the deglycosilated 1B4 antibody digest under non reducing 
conditions (lane 5) lacked the bands with high molecular weight (uncleaved IgG 
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and Fab/c fragment), confirming that the hinge region was sensitive to the papain 
catalytic action, allowing the production of Fab (around 45 kDa) and less 
important fragments, typically migrating at 17-24 kDa. Moreover, the 
deglycoslylation effect on the heavy chains was notable even under reducing 
conditions (lane 6), thus, in addition to the two separated chains belonging to the 
Fab (~25 kDa), a single band (30 kDa) corresponding to the homogenous Fc 
portion, lacking the oligosaccharide chains, was detected. However, this approach 
to obtain antibody Fabs has been abandoned since, given the costs (enzymes) and 
the time-consuming procedure, it appears not suitable for a scaling process to 
generate large amounts of material. 
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c) SPR affinity binding assay of Fab to rhCR-1  
The Fab fragment obtained by this proteolytic procedure was tested by SPR to 
assess if it bound to the target protein, rhCR-1. A dose-dependent binding assay 
was performed testing the analyte at concentrations ranging between 50 nM and 
750 nM, and comparing the fragment with the full-size antibody. 
 
 
                     
Figure 3.35: Sensorgrams overlay and kinetic parameters table of the 1B4 mAb binding to rhCR-
1. 
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Table 24.  Kinetic rate and apparent affinity constants of 1B4 
mAb  binding to rhCR-1 
1B4 ka (1/Ms) kd(1/s) KD (M) SE (RI)
0.5 nM 1.34*105 2.12*10-5 1.58*10-10 0.0286
1 nM 6.89*104 1.25*10-5 1.81*10-10 0.028
2.5 nM 7.19*104 1.82*10-5 2.53*10-10 0.024
5 nM 2.19*105 4.94*10-5 2.25*10-10 0.0298
10 nM 2.13*105 8.23*10-5 3.86*10-10 0.0575
average 1.41*105 3.67*10-5 2.41*10-10 0.0336
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Figure 3.36: Sensorgrams overlay and kinetic parameters table of the 1B4 proteolytic Fab binding 
to rhCR-1. 
 
Comparing the binding curves and the kinetic parameters of the whole antibody 
with the Fab fragment, we observed a dramatic loss of affinity, deriving from a 
reduced association rate (ka = 2*10
4
 M
-1
s
-1
) and an increased dissociation rate (kd 
= 2.6*10
-3 
s
-1
). The resulting KD was 200 nM, a thousand fold lower compared to 
that one of the whole mAb (0.24 nM). This affinity decrease is not explainable as 
a simple consequence of the Fab monovalency, but it is probably due to a loss of 
structural stability of the fragment, as suggested by the circular dichroism 
analysis. We hypothesized that an unspecific cleavage was operated within the 
CDRs by papain and such modification induced the drastic affinity drop. 
In conclusion, the first attempt to generate a functional Fab fragment using a 
proteolytic approach unfortunately led to a product characterized by a loss of 
binding affinity to the antigen.  
Given the disadvantages of the antibody proteolytic fragmentation, such as 
heterogeneity of the product fragments, the time-consuming reaction condition 
optimization as well as for the deglycosylation and low yield, a more suitable and 
productive method has been explored. Therefore the production of a Fab fragment 
-20
0
20
40
60
80
100
120
140
-50 0 50 100 150 200 250 300 350 400 450 500
1B4 Fab vs rhCripto
R
e
s
p
o
n
s
e
 (
R
U
)
Fab 50nM Fab 100nM Fab 250nM Fab 500nM Fab 750nM 
Time (sec)
Table 25. Kinetic rate and apparent affinity constants of 1B4 
proteolytic Fab binding to rhCR-1 
1B4 Fab ka (1/Ms) kd (1/s) KD (M) SE(RI)
50nM 6.37*103 2.55*10-3 4.00*10-7 0.0238
100nM 4.97*104 2.12*10-3 4.27*10-8 0.0408
250nM 2.32*104 3.32*10-3 1.43*10-7 0.0409
500nM 1.65*104 2.61*10-3 1.58*10-7 0.0896
1000nM 1.13*104 2.57*10-3 2.28*10-7 0.168
average 2.14*104 2.63*10-3 1.94*10-7 0.0726
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as recombinant protein has been set up using the bacterial expression in 
Escherichia Coli, an affordable system in terms of cost and time required to 
obtain high yield. 
  
2.2 GENERATION OF THE RECOMBINANT CHIMERIC 1B4 Fab 
 (1B4 rFab) 
 
a) Expression and purification of 1B4 rFab as recombinant protein 
The PL564 plasmid, generated by cloning the synthetic gene (1539 bp) encoding 
the target 1B4 rFab protein (Fig. 3.37) into the pET-26b(+) vector, was used to 
perform the periplasmic expression strategy. Thus, the plasmid was successfully 
transformed in E. coli BL21(DE3) host strain and the expression was optimized at 
30 °C, using 1 mM IPTG. 
        
          
Figure 3.37: Scheme of the synthetic gene constructed to encode the corresponding recombinant 
chimeric 1B4 Fab protein. 
 
After periplasmic extraction (described in section 2.10.c of Methods), with the 
aim of removing all the other contaminant proteins occurring in the periplasmic 
space of the bacterial cells, a stepwise purification process including HIC 
cromatography and two ion-exchange chromatography steps (reported in Fig. 3.38 
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A and B) was conducted. A further purification by SEC (Fig. 3.38 C) was 
performed to evaluate the presence of any aggregrates and to ensure homogeneity 
and high purity of the 1B4 rFab. As shown in the SEC profile, the main peak 
eluted with a retention volume of 16.0 mL in accordance to a molecular weight of 
around 50 kDa, preceded by a minor peak at retention volume of 12.0 mL and 
corresponding to the aggregated 1B4 rFab. At the end of the purification process, 
the final product exhibited a high purity, estimated by over 95%, as detected by 
RP- HPLC analysis (Fig. 3.38 D). The homogeneity and purity are two important 
pre-requisites to set up crystallographic study of complex 1B4 rFab- synthetic 
hCFC domain as well as for in vitro and in vivo test.          
                 
Figure 3.38: Multi-step purification of the 1B4 rFab protein, starting from  HIC chromatogram of 
the whole periplasmic lysate (A); Anion and cation exchange chromatography profile respectively 
(B); the SEC profile (C) and the final RP-HPLC profile (D). 
  
1B4 rFab 
fraction
Hydrophobic interaction chromatography
1B4 rFab
Ion-exchange chromatography
1B4 rFab
A
B
1B4 rFab
aggregate
Size-exclusion chromatography
Reverse-phase HPLC
Main peak : 96.2% purity grade
C
D
116 
 
b) Identification of 1B4 rFab  
SDS-PAGE and Immunoblotting analyses 
The protein corresponding to the predominant peak of SEC was analyzed on a 
15% SDS-PAGE gel to perform a first rough estimation of the 1B4 rFab 
molecular weight . As expected, under non reducing conditions, the 1B4 rFab 
protein exhibited a homogenous band at around 45-50 kDa, while under reducing 
conditions (by addition of 10% β-Mercaptoethanol), two separated bands 
characterized by a different mobility were clearly detectable; the slower was the 
heavy chain, containing also the M-TGase linker at the C-terminus; the faster was 
the light chain (See Fig. 3.39 A). The identity of the 1B4 rFab was assessed also 
by western blot analysis, using an anti-human Fab antibody (Fig. 3.39 B). 
 
Figure 3.39: SDS-PAGE 12% gel analysis of the SEC product under non-reducing and reducing 
conditions (A).Western blot analysis using the anti-human Fab antibody (B). 
 
LC-ESI- TOF-MS Analysis 
The identity and integrity of 1B4 rFab was then confirmed by LC-ESI-TOF-MS 
analysis. For this analysis the fragment was mildly reduced with 50 mM DTT at 
37 °C to ensure the reduction of the interchain disulfide bond, a procedure that 
splitted the 1B4 rFab into the light and heavy chains while maintaining intact the 
four internal disulfide bridges. The RP-HPLC profile of the LC-ESI-TOF-MS 
analysis (Fig. 3.40) showed the two distinct chains eluting at different retention 
times on the basis of their different hydrophobicity: The light chain (abbreviated 
as LC) preceded the heavy chain (HC) through the elution.  
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Figure 3.40: RP-HPLC profile of the LC-ESI-TOF analysis on the reduced 1B4 rFab in which the 
first peak is represented by the light chain while the second peak corresponds to the heavy chain 
instead. 
 
 
 
Figure 3.41: Panel of the LC-ESI-TOF-MS analysis of the single light chain belonging to the 1B4 
rFab: m/z multicharged spectrum (A) and spectrum deconvolution (B).   
Figure 3.42: Panel of the LC-ESI-TOF-MS analysis of the single heavy chain belonging to the 
1B4 rFab: m/z multicharged spectrum (A) and spectru deconvolution (B). 
The mass spectra revealed the correct molecular weight of each chain (reported in 
Table 26), corresponding, as expected, to the chain with the intact two 
intradomain disulfide bridges. Moreover, the molecular weight of the heavy chain 
was in agreement with the presence of the sulfhydryl group on the free Cysteine 
of the CH1 domain in addition to the two intact intradomain disulfide bonds. 
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c) Comparative conformational and stability study between 1B4 rFab and 
Her rFab by circular dichroism.  
To evaluate the correct folding of the generated 1B4 rFab and its stability, a 
circular dichroism comparative study was carried out using as reference the 
recombinant Fab from Trastuzumab, whose CL and CH1 domains are contained in 
the 1B4 rFab. The CD spectra in far-UV region of both recombinant Fab proteins 
revealed a quite similar secondary structure profile. In detail, the Trastuzumab 
recombinant Fab, hereafter named Her rFab, exhibited a canonical β-sheet 
secondary structure, proper of the IgG domain with a negative band at 218 nm and 
a positive band at 204 nm. The CD analysis of the 1B4 rFab fragment confirmed 
the occurrence of β-sheet motifs, denoting only a small difference seen as a 
negative band at 216 nm and a positive band at 200 nm, probably due to the 
combination of two different isotypes, IgG1 (Trastuzumab) and IgG2b (1B4 
mAb), instead of the homogenous Her rFab. 
Then, the thermal denaturation of each fragment, conducted starting from 20 °C 
up to the final temperature of 95 °C, revealed a melting temperature (Tm) of 86°C 
and 71°C for Her rFab and 1B4 rFab, respectively. These data suggest that 1B4 
rFab (Fig. 3.43 A) is less stable compared to the Her rFab (see Fig. 3.43 B). 
Although the anti-Cripto Fab is less stable than the Her rFab, this parameter can 
not be considered negative, since the Tm proper of a Fab belonging to an IgG2b 
normally corresponds to 60 °C, thus the chimeric fragment shows a gain of 
stability compared to a canonical Fab of the same IgG isotype [162].           
Table 26. Molecular mass of each single chain of 1B4 rFab
Theor MW
amu 
Exp MW 
amu
Light chain 23924.8 23924.8
Heavy chain 24612.6 24612.6
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A 
 B  
 
Figure 3.43: Far-UV spectra of recombinnant chimeric Fab from 1B4 mAb (1B4 rFab). Red color 
indicates the native conformation, while the blue color indicates the denaturated form after heating 
at 95 °C (A). Far-UV CD spectra overlay of the recombinant Fab from Trastuzumab (Her rFab). 
Green color indicates the native conformation, the red color indicates the denaturated form after 
heating at 95 °C (B). 
 
d) Affinity Binding assays of 1B4 rFab to the synthetic hCFC[112-150] 
domain   
 
ELISA and SPR binding assays were carried out on the newly generated 1B4 rFab 
to evaluate the influence of human constant domain on Fab ability to retain the 
high affinity toward its specific antigen, hCFC domain, and even toward the full-
length rhCR-1 protein, compared to the whole antibody. 
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ELISA assays 
As previously described, dose -response ELISA binding assays were performed 
coating synthetic wild-type hCFC[112-150] domain at a fixed concentration of 
110 nM and testing the 1B4 rFab at increasing concentrations from 0.6 nM up to 
40 nM, compared to the parental 1B4 mAb, as described in section 2.3.d of 
Methods . A KD of about 12 nM was extrapolated by data fitting using a non 
linear regression analysis of data points (Fig. 3.44). This value was lower 
compared to that one of the whole 1B4 antibody determined using the same 
approach (KD = 1.7 nM).  
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Figure 3.44: Dose-response ELISA binding assay of 1B4 rFab to the synthetic wild-type 
hCFC[112-150] polypeptyde. 
 
A further ELISA assay (Fig. 3.45) was performed to verify the specificity of the 
1B4 rFab to the rhCR-1 versus the rmCr-1, following the procedure reported in 
Chapter II section 2.3.e. Compared to the intact 1B4 mAb, the 1B4 rFab 
recognized rhCR-1 with a dose-dependent trend, although it required a higher 
concentrantion (100 nM) than the full-size antibody (6.7 nM). However, even the 
recombinant fragment specifically recognized rhCR-1 instead of the mouse 
variant, starting from the amount corresponding to 25 ng of protein. 
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Figure 3.45: Bars graph of the ELISA specificity binding assay of 1B4 rFab to rhCR-1 versus 
rmCr-1. 
 
SPR assays 
After validation of antigen recognition by the 1B4 rFab by ELISA, to define 
precisely the interaction with the target protein in terms of association and 
dissociation constant rates, a SPR binding assay between 1B4 rFab and rhCR-1 
was carried out. Thus, the analyte was injected onto the immobilized rhCR-1, 
using a range of concentrations between 1 nM and 10 nM. 
The kinetic parameters (ka and kd), extrapolated fitting the binding curves, 
revealed a loss of affinity toward the target protein, displaying an apparent affinity 
(KD = 6 nM) about ten fold lower than the whole antibody 1B4 (KD = 0.24 nM). 
Interestingly, the 1B4 rFab exhibited a ka more favorable than the whole antibody, 
probably due to smaller size and the orientation of CDRs perfectly exposed and 
accessible to the antigen in the absence of the remaining IgG molecule. In spite of 
the quicker association rate, the 1B4 rFab showed a much higher dissociation rate, 
about one hundred fold higher than that one displayed by the parental antibody. 
This suggested a faster interaction with the target protein, but it was not strong 
enough to stabilize the antigen-Fab complex.  
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Figure 3.46: Sensorgrams overlay and kinetic parameters table 1B4 rFab binding to rhCR-1. 
In summary, the SPR analysis confirmed the ELISA results, revealing that the 
monovalency of the 1B4 rFab unit negatively influences the binding affinity 
toward both the hCFC antigen and the full length rhCR-1. On the basis of these 
data, we hypothesised that the antibody bivalency plays a crucial role in the 
antigen-antibody interaction. 
Indeed, a strategy to improve the binding affinity of the monovalent 1B4 rFab was 
the artificial restoring of the bivalency of a full antibody, without the Fc portion, 
possibly generating a recombinant homodimer composed of two 1B4 rFab units, 
joined together by a simple short linker peptide.  
 
e) Preliminary analysis of the antigen-1B4 rFab complex  
To investigate the effective antigen-antibody interaction, a crystallographic study 
could be required on the antigen-Fab complex, to precisely localize the binding 
site. For this purpose, a preliminary experiment was conducted to confirm the 
formation of the antigen-Fab complex prior to carry out possible crystallographic 
study. A simple SE-HPLC comparative analysis was performed between the 
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Table 27.  Kinetic rate and apparent affinity constants of 1B4
rFab binding to rhCR-1  
1B4 rFab ka (1/Ms) kd (1/s) KD (M) SE (RI)
1nM 7.73*105 3.21*10-3 4.16*10-9 0.0628
2.5nM 2.41*106 2.87*10-3 1.19*10-9 0.0665
5nM 1.85*106 5.44*10-3 2.93*10-9 0.0597
7.5nM 1.28*105 4.57*10-4 3.56*10-9 0.042
10nM 2.58*105 5.07*10-3 1.97*10-9 0.038
average 1.08*106 3.41*10-3 6.31*10-9 0.05675
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single 1B4 rFab and after incubation with the synthetic hCFC[112-150]. The 
chromatographic profile of the 1B4 rFab showed a single peak at a retention time 
of 7.488 min (Fig. 3.47 A), corresponding to a protein with a molecular weight of 
about 50 kDa. In contrast, the elution profile of the 1B4 rFab-hCFC mixture (Fig. 
3.47 B) exhibited a predominant peak at a retention time of  7.564 min, 
corresponding to the 1B4 rFab-antigen complex and a second less intense peak at 
around 11 min, corresponding to the hCFC peptide excess, non associated to the 
1B4 rFab.            
                                    
A  
B  
Figure 3.47: SE-HPLC profiles of the sinlge 1B4 rFab (A) and the 1B4 rFab-hCFC mixture (B). 
The difference in retention time and the shape of the resulting new peak clearly 
showed that the complex was formed and eluted at a longer retention time, as 
expected. The occurrence of the two molecules within the same fractions under 
the peak was confirmed by SDS-PAGE analysis (not shown).  
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2.3 GENERATION OF ARTIFICIAL 1B4 rFab2 
a) Chemical synthesis, purification and identification of the bifunctional 
linker peptide 
 
The bifunctional linker peptide, designed to join together two 1B4 rFab units to 
create the dimeric derivative, called 1B4 rFab2, was synthesized as acetylated and 
amidated product, purified by RP-HPLC and the correct molecular mass was 
determined by LC-ESI-TOF-MS analysis. The linker, possessing a very simple 
amino acid sequence, Ac-KAYA-GA-KAYA-CONH2, had a molecular mass 
corresponding to 1053.6 amu (See Fig. 3.48). 
 
Figure 3.48: LC-ESI-TOF-MS analysis of the short linker pepride. In this panel RP-HPLC profile 
(A), m/z spectrum (B) and deconvoluted peak (C) are reported.  
 
The two KAYA motives permit the formation of the isopeptide bonds, catalyzed 
by the M-TGase enzyme simultaneously with two 1B4 rFab monomers. The 
KAYA motif was identified in a previous study as optimally recognized and 
processed by the M-TGase [163]. Gly (G) and Ala (A) residues were inserted 
between the two KAYA sequences as a spacer.  
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b)1B4 rFab-rFab conjugation reaction and purification 
To create the artificial 1B4 rFab2 the transamidation reaction was performed as 
illustrated in Fig. 3.49. The M-TGase enzyme catalyzes the formation of the 
isopeptide bond between the ε-aminogroup belonging to the K residue of the 
linker peptide and the γ-carboxamide group of the Q residue belonging to the 
additional sequence at the C-terminus of the 1B4 rFab CH1 domain. Since the 
linker peptide is bifunctional, it allows the simultaneous conjugation of two 1B4 
rFab units.  
 
 
Figure 3.49: Schematic representation of the conjugation reaction, catalyzed by M-TGase 
enzyme, to create the artificial 1B4 rFab2 product. 
 
After the conjugation reaction, carried out in 6h, the dimeric product was isolated 
from the reaction mixture, removing the unfunctionalized monomeric 1B4 rFab 
by a cation exchange chromatography step as described in section  2.15 of 
Methods. The 1B4 rFab2 eluted in correspondance of a conducibility of 21.8 
mS/cm. Finally, a further SE-HPLC analysis was performed on the reaction 
mixture (Fig. 3.50 A) and on the final product (Fig. 3.50 B) to determine its purity 
grade as well as its molecular weight. 
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B 
Figure 3.50: SE-HPLC profiles of the reaction mixture after 6h incubation time period (A) and of 
the isolated peak corresponding to the final rFab2 product (B). 
 
The first SE-HPLC chromatogram (Fig. 3.50 A) showed the presence of two 
different species eluting with a retention time shift of about 1 min, the first peak 
(7.937 min) corresponded to a protein possessing a molecular weight of about 100 
kDa, in agreement to the dimeric derivative of the 1B4 rFab. The second peak 
(8.761 min) corresponded to the monomeric 1B4 rFab, with a MW of about 50 
kDa.  The comparison of the peak areas suggested a reaction yield of about 50%. 
The presence of the monomeric 1B4 rFab after  6h incubation was due to the 
concomitant deamidation of the Gln side chain and generation of a M-TGase-
inactive glutamic acid. 
The second SE-HPLC profile (Fig. 3.50 B) revealed that the final functionalized 
product exhibited a purity grade by over 95%. 
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c)1B4  rFab2 Identification  
A preliminary analysis by SDS-PAGE was carried out to evaluate the correct 
formation of the desired product. For this purpose the 1B4 rFab at the beginning 
of the reaction (t0) was compared with the final dimeric product, after 6h reaction 
(t6h) by western blot analysis, carried out using the specific anti-human Fab 
antibody. As shown in Fig. 3.51 (A and B), the monomeric 1B4 rFab migrated as 
a single compact band at 50 kDa, by contrast the dimeric product, although had a 
molecular weight of 100 kDa, apparently migrated like a protein of 150 kDa. This 
behavior was expected for the presence of the bifunctional linker that providing a 
high flexibility confers to the molecule a less compact globular structure, thus 
with an apparent higher molecular weight. 
 
Figure 3.51: SDS-PAGE  (A) and western blot (B) analyses on both 1B4 rFab (t0) and bivalent 
rFab2 (t6h) when the reaction is finished. SDS-PAGE analysis of the final dimeric product under 
non-reducing and reducing conditions (C).  
 
The structural differences between the artificial 1B4 rFab2 and a canonical F(ab’)2 
can be appreciate even by SDS-PAGE under reducing conditions, revealing the 
presence of two bands with a different MW (Fig. 3.51 C). This is in agreement 
with the artificial nature of this product, because the band at 50 kDa corresponded 
to the heavy chains covalently linked by the bifunctional linker, resistant to the 
reducing agent, while the band at 25 kDa corresponded to the light chains, 
separated from the heavy chains after the reduction of the interchain disulfide 
bond. Unlikely, a proteolytic F(ab’)2, when reduced, normally exhibits two bands 
at around 25 kDa, corresponding to the completely separated heavy (slower) and 
light (faster) chains. 
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d) Affinity binding assays of 1B4 rFab2 to hCFC domain and rhCR-1 protein 
 
ELISA assays 
The 1B4 rFab2 was subsequently characterized by ELISA and SPR binding assays 
to assess the generation of a functional protein, able to recognize and bind the 
single antigen, the specific CFC domain as well as the whole rhCR-1 protein, 
evaluating if the artificial bivalent fragment possessed a binding affinity 
comparable to the full-size antibody. Thus, a dose-response ELISA binding assay 
(Fig. 3.52) was performed using the synthetic hCFC[112-150] polypeptide in 
coating (110 nM)  and the analyte at increasing concentrations (in the range 
comprised between 0.7 nM and 25 nM).                                                                                                           
 
Figure 3.52: Dose-response ELISA binding assay of 1B4 rFab2 to the synthetic wild-type 
hCFC[112-150] polypeptyde. 
 
Comparing the rFab2 derivative with the parental 1B4 antibody, they remarkably 
exhibited the same trend, suggesting that the respective affinity constants were 
comparable: for the antibody was 1.7 nM, for the dimeric protein was 2.7 nM, 
indicating the importance of the bivalency for the interaction with the antigen (to 
be compared with the KD of the monomeric 1B4 rFab of 12 nM). 
Furthermore, a preliminary ELISA binding assay was carried out to test the ability 
of the 1B4 rFab2 to bind the full-length rhCR-1 protein and simultaneously to 
confirm the high specificity toward the human form versus the murine form. We 
achieved the experiment under the same conditions used in the assay with the 1B4 
whole antibody (the full procedure is reported in Chapter II section 2.3.d). As 
expected, like the parental antibody, even the bivalent fragment was selective to 
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the human form of CR-1 protein, showing a binding characterized by a dose-
dependent trend (Fig. 3.53). 
 
 
Figure 3.53: Bar graphs of ELISA assay, carried out using recombinant Cripto protein (human and 
murine) at a range of increasing concentrations (12 ng-25 ng-50 ng-100 ng) detected by 1B4 
rFab2, used at a concentration of 10 nM. 
 
 
 
SPR assays 
We next analyzed the binding to rhCR-1 by SPR technique using a chip with 
immobilized rhCR-1. Solutions of the 1B4 rFab2 at increasing concentrations 
were passed on the ligand observing dose-response signals (Fig. 3.54). The kinetic 
parameters, exprapolated from the binding/dissociation curves, revealed a 
surprisingly emprovement of the binding affinity of the 1B4 rFab2 compared to 
the single 1B4 rFab unit, confirming that bivalency played a crucial role in the 
recognition of the target protein and of the specific CFC domain, as seen by 
ELISA. The KD estimated for the artificial 1B4 rFab2 was about 0.26 nM, very 
similar to that determined for the full length antibody (0.24 nM), while for the 
monomeric fragment the KD value was 6.5 nM. 
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Figure 3.54: Sensorgrams overlay and kinetic parameters table of 1B4 rFab2 binding to rhCR-1. 
 
In conclusion, the new 1B4 rFab2 format displayed a functional behavior 
comparable to the whole parental antibody, showing a remarkably enhanced 
binding affinity compared to the monomeric 1B4 rFab fragment.  
Thus, artificially restoring the bivalency, the new fragment exhibits a powerful 
gain of affinity, matching the one of the whole antibody. 
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Table 28.  Kinetic rate and apparent affinity constants of 1B4 
rFab2 binding to rhCR-1 
1B4 rFab2 ka (1/Ms) kd (1/s) KD (M) SE (RI)
0.5 nM 1.00*105 2.95*10-5 2.94*10-10 0.0408
1 nM 1.48*105 8.65*10-5 5.86*10-10 0.0322
2.5 nM 1.12*105 2.81*10-5 2.51*10-10 0.037
5 nM 1.78*105 1.83*10-5 1.03*10-10 0.0499
7.5 nM 1.52*105 1.64*10-5 1.08*10-10 0.0479
average 1.38*105 3.58*10-5 2.68*10-10 0.04156
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2.4 GENERATION OF 1B4 rFab-DOXORUBICIN ADC 
 
The identity of the two linkers (I linker and II linker) used for conjugation were 
confirmed by mass spectrometry. All conjugation steps were monitored by RP-
HPLC analyses. In Fig. 3.55, an overlay of chromatographic profiles of the 
reaction between Doxorubicin and I
 
linker after 1 and 3 days, is reported. As 
shown, after 24h (green) two main sharp peaks with different elution times were 
observed, where the first corresponded to the free Doxorubicin (retention time: 
11.4 min) and the second to the Doxorubicin functionalized with the I linker 
(retention time: 12.7 min). 
After 3 days, the RP-HPLC profile (black) changed, showing the disappearance of 
the unreacted Doxorubicin at retention time of 11.4 min, and the increase of the 
peak at 12.7 min due to the Doxorubicin- I
 
linker product.  
 
Figure 3.55: Overlay plot of the RP-HPLC profiles corresponding to the reaction  mixture 
containing Doxorubicin and I linker, after 1 day (green) and after 3 days (black).  
 
The second step was the conjugation between the intermediate product 
Doxorubicin-I linker indicated as Product A  (see scheme reported in the Fig. 2.4 
in Methods) and the II
  
linker to obtain the Product B (Doxorubicin-I linker-II 
linker). The RP-HPLC chromatogram (Fig. 3.56) clearly showed the presence of 
two main peaks: the predominant peak (peak 1), at 11.2 min, corresponding to 
Product B (Doxorubicin-I linker-II linker) and the second peak (peak 2), at a 
retention time of 12.7 min, corresponding to the excess of the starting 
Doxorubicin-I linker product. The final product, obtained with a yield of 64%, 
1
2
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was finally analyzed by ESI-MS to assess the correct molecular mass, found to be 
1070 amu (not shown). 
 
Figure 3.56: RP-HPLC profile of the conjugation reaction of the intermediate product 
(Doxorubicin-I linker) with the Ac-CKA-NH2 linker (II linker). 
 
 
Next, Product B was isolated by preparative RP-HPLC and used to perform the 
enzymatic reaction with the 1B4 rFab via M-TGase under the reported conditions 
(section 2.16.b of Methods). The reaction mixture, composed of the Doxorubicin 
previously functionalized with the two linkers, the 1B4 rFab and the M-TGase, 
was monitored by RP-HPLC analysis. To isolate the desired ADC product, the 
reaction mixture was purified by cation-exchange chromatography (section 2.15 
of Methods). As shown in the chromatographic profile (Fig. 3.57), the excess of 
Doxorubicin did not interact with the matrix and eluted in the equilibration phase; 
two peaks of comparable intensity (reported as A and B), probably corresponding 
to different species of 1B4 rFab-Doxo, eluted during the linear gradient from 0 
mM to 350 mM NaCl.  
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Figure 3.57: IEC profile of the reaction mixture containing the three components:  Doxorubicin-I 
linker-II linker, 1B4 rFab and M-TGase enzyme. 
 
 
The two isolated peaks, A and B, were analyzed by SDS-PAGE onto a 12% 
polyacrylamide gel under non reducing and reducing conditions, to have a 
comparison with the wild-type 1B4 rFab (t0) (see Fig. 3.58). As expected, all three 
species migrated as a single band at 45 kDa under non-reducing and reducing 
conditions and showed an apparent integrity and homogeneity.  
 
Figure 3.58: SDS-PAGE analysis of each eluted peak (A and B) compared to the unconjugated 
1B4 rFab (t0). 
 
 
 
Next, an LC-ESI-TOF-MS analysis was performed on each single peak isolated 
by IEC to identify the corresponding products. The mass spectrometry analysis 
was carried out after mildy reduction with 20 mM DTT to separate the two chains, 
while retaining the intra-disulfide bridges. 
Both samples exhibited the same UV profile where the first peak and the second 
one corresponded to the light chain (LC) and heavy chain (HC), respectively (Fig. 
3.59 A).  
Doxorubicin
B
1B4 rFab-Doxo
A
25
50
37
75
kDa M
1       2        3     4       5         6          7 
134 
 
The light chain mass spectrum deconvolution of each sample confirmed the same 
experimental MW, in perfect agreement with the theoretical one (MWtheor/ 
MWexp 23924.5/ 23924.5 amu). 
These data confirmed the integrity of the light chain as well as the specificity of 
the conjugation reaction on the heavy chain.  
By contrast, the chromatographic peak corresponding to the heavy chain was not 
homogeneous, thus suggesting the presence of different species for both the ion-
exchange separated products (peak A and peak B).  
The deconvolution of the mass spectrum of the heavy chain derived from peak A 
(Fig. 3.59 C) revealed the occurrence of at least four products: the correct ADC 
product 1B4 (rFab-Doxorubicin-I linker-II linker) with a molecular mass of 
25664.1 (peak 4); the unconjugated 1B4 rFab, with a molecular mass of 24611.9 
amu (peak 3) and two remaining peaks (peak1 and peak2) corresponding to two 
degradation products of the C-terminal linker.  
In detail, the peak 1 (23617.4 amu) had the linker cleaved at the A residue next to 
the K, while peak 2 (24056.5 amu) corresponded to the species in which the linker 
was cleaved at the T residue.  
The high amount of unfunctionalized species was presumably due to the 
reversibility of the enzymatic reaction rather than to uncomplete conjugation of 
the fragment. 
Likewise, the mass spectrum of peak B (Fig. 3.59 D) displayed the presence of 
four species. In this case, the products exhibited a molecular weight 
corresponding to dehydrated products (all MW had a Δmass of -18 Da). The exact 
position where this side-reaction occurred needs further investigation.   
In Table 29, all products identified as heavy chain conjugation products are 
reported (* indicates the dehydrated products).  
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Figure 3.59: LC-ESI-TOF-MS analyses of the reduced 1B4 rFab-Doxo. UV profile at 280 nm 
(A). Mass spectrum deconvolution of the light chain (B). Mass spectrum deconvolution of the 
heavy chain from the Peak A (C) and from the Peak B (D), isolated by IEC. 
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In conclusion, the 1B4 rFab-Doxo was generated. The conjugation reaction was 
not very efficient, as the final product was obtained mixed with other side reaction 
impurities. Most side products were correlated to the simultaneous formation of 
undesired degraded fragments as well as to the reversibility of the enzymatic 
reaction. An optimization process is required to improve the production of this 
ADC. 
  
Table 29. MW of Heavy chain conjugation products
Product Theor MW
(amu)
Exp MW
(amu)
Peak
Exp MW
(amu)
Peak*
HeavyChain-GSGA 23617.4 1    23617.1 1*    23600.4
HeavyChain-GSGAKQPT 24057.0 2     24056.5 2*    24039.0
HeavyChain-GSGAKQPTQGAMPA 24612.6 3     24611.9 3*   24594.8
HeavyChain-GSGAKQPTQGAMPA-Doxorubicin 25664.6 4    25664.1 4* 25674.1
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III.3 PRELIMINARY IN VITRO ASSAYS OF 1B4 mAb ON HUMAN 
CANCER CELLS OVER-EXPRESSING CR-1 PROTEIN 
 
3.1 Detection of human CR-1 in GBM cell lines 
Since the expression of human CR-1 has been recently demonstrated by Pilgaard 
et al. [45] also in IV grade glioblastoma multiforme tumor cells (GBM), a study to 
test 1B4 mAb was conducted at the laboratory of the Prof. Meg Duroux, Dept. of 
Biomedicine of Aalborg University. 
We used two GBM cell lines, the commercial U87 and the C16, provided by the 
Aalborg University Hospital, in which expression levels of CR-1 were found.  
A preliminary detection of CR-1 by western blot analysis was performed using 
both the 1B4 antibody and the commercial polyclonal anti-cripto antibody 
directed against the 41-55 region of N-terminal part of CR-1 (not shown). Then 
the detection of human CR-1 was assessed by Immunofluorescence, as described 
in section 2.17.d of Methods.  As shown in Fig. 3.60, the 1B4 mAb staining was 
comparable to the signal obtained with the commercial antibody. The staining of 
CR-1 without permeabilization of cells, confirmed the ability of 1B4 mAb to 
recognize the form of the target protein anchored to the cell membrane. 
 
Figure 3.60: Immunostaining obtained by merge of Hoechst nuclear dye (blue) and 
AlexaFluor555 signal (red). In this image the comparison of commercial antibody (left) and 1B4 
mAb (right) fluorescence signal is reported. 
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3.2 Functional assays on GBM cell lines 
To investigate the intracellular pathways on which the 1B4 mAb exerts a possible 
inhibition effect to block both anchored and soluble CR-1 protein and to further 
evaluate its possible use as a therapeutic tool, some functional assays were carried 
out.  
a) Proliferation assay 
The proliferation assay was conducted measuring the emission of the CFSE by 
FACS analysis. Cells were treated using the 1B4 mAb at 0.2 μM (30 μg/mL). The 
outcome was negative and as shown in the Fig. 3.61, after 4 days the fluorescence 
emitted by the untreated cells (D4 Ctrl) was overlaying to the fluorescence 
emitted by the treated population (D4 mAB), showing the same shift as the 
population at the starting point (D0 Ctrl). This shift indicates the cell proliferation, 
since the signal decreases compared to the starting population, denoting that the 
cellular division has happened. In fact from the comparison of the emitted signal 
value (X-Med) for both cell lines the untreated and treated cells show a 
comparable value. In C16 population it was 0.3 for the treated cells, while it was 
0.4 for the negative control. The same behavior was observed for the U87, in 
which the negative control and the treated population exhibited exactly the same 
X-Med value of 0.5. These data suggest that the 1B4 antibody was not able to 
inhibit the cell proliferation of both cell lines.  
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A            
B              
Figure 3.61: FACS analysis plots of the proliferation assays conducted on C16 (A) and U87 (B) 
cell lines, using CFSE as cell tracing. 
 
 
b) Cell viability assay by trypan blue exclusion test  
Since the FACS analysis of the proliferation assay does not provide any 
information about cell death induction by the 1B4, a viability assay was 
performed to evaluate the capability of the mAb to promote cell death instead of 
blocking cell proliferation. The effect of the antibody was evaluated determining 
the percentage of unviable and viable cells after treatment with 0.2 and 0.4 μM of 
1B4 mAb after 2 days and 4 days; untreated cells were used as negative control 
(CTL).  
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Figure 3.62: Viability assays performed using trypan blue exclusion test on C16 (A) and U87 (B) 
cell lines at the indicated exposure times. 
 
As shown in Fig. 3.62 A, C16 cells underwent only a slightly detectable decrease 
of viability by comparison to negative control. Also treatment of U87 (Fig. 3.62 
B) cells with 0.2 μM 1B4 led to a slight decrease of viability (12%), which was 
essentially unchanged (17.5%) when the concentration of mAb was doubled. 
Probably, a much higher concentration of mAb is required to observe cell death 
effects. 
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c) Migration assay 
A migration assay was carried out by the scratch methodology - that mimics the 
wound healing process - so as to determine the ability of the 1B4 mAb to reduce 
or totally block cell migration. The migration assay on C16 revealed that the 
antibody had not any inhibition activity. Instead, the migration degree of treated 
cells seemed to progressively increase at 0.2 μM and 0.4 μM concentrations of 
antibody (See Fig. 3.63 A). Indeed, the scratch area (expressed as % of all the 
covered area) resulted to be less wide than the area of the negative control 
(CTRL) as calculated by the Wimasis server.    
 
Figure 3.63: Migration assay on C16. The wound healing-mimicking effect was monitored for 
24h (A). Plot of the values of scratch area, reported as % of the total covered area (B). 
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Figure 3.64: Migration assay on U87. The wound healing was monitored for 24h (A) Plot of the 
values of scratch area, reported as % of the total covered area (B). 
 
At variance with the C16, the migration assay performed on U87 provided 
different results. Indeed,  as shown in Fig. 3.64 A, a slight decrease of migration 
degree was observed after 24h after treatment at both the two concentrations (9.3 
% of scratch area versus 4.6% of the control at 0.2 μM and 11.4% versus 4.6% of 
the control for the 0.4 μM treatment). The 1B4 antibody had therefore a slightly 
inhibitory effect on the migration of these cells and the effect appeared to be also 
dependent on the antibody concentration. Likely, a higher concentration of 
antibody was required to induce a more sustained inhibition of cell migration and 
further investigations are underway.  
In conclusion, the 1B4 mAb tested on GBM cell lines (C16 and U87), exhibited 
the ability to detect the target CR-1 protein, but it was not able to exert functional 
effects on proliferation and death. A slight decrease of cell motility was instead 
detecdted on U87 cells, but this requires further investigations at higher antibody 
CTL 1B4mAb 0.2μM 1B4mAb 0.4μM
t24h
t0
U87
0
10
20
30
40
U87
S
c
ra
tc
h
 A
re
a
(%
)
CTL
1B4mAb 0.2M
1B4mAb 0.4M
27.6%
4.6%
32.5%
30.4%
9.3%
11.4%
t0 t24h t0 t0t24h t24h
A
B
143 
 
concentrations. The different behavior on the two cell lines can be attributed to a 
difference in expression of CR-1 at higher levels in C16 than in U87, as already 
determined [45]. 
 
3.3 1B4 mAb activity on colorectal cancer cells 
We evaluate the activity of 1B4 also on GEO colorectal cancer line. Before 
starting the antibody treatment, we verified the expression levels of human CR-1, 
using the P19 mouse teratocarcinoma cell line as negative control. As shown in 
Fig. 3.65, the GEO cell lines expressed high levels of the Cripto-1 mRNA 
compared to the control, so on these cells, we started the treatment with the 1B4 
mAb and monitored the effect after 24h and 96h. 
 
 
 
Figure 3.65: qRT-PCR data related to the expression levels of human CR-1 mRNA in GEO cells. 
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Figure 3.66: Proliferation assay as performed on GEO cells treated with 1B4 and monitored after 
24h, 72h and 96h. Data are shown for the single dose addition (0.1 μM and 0.2 μM) (A) and after 
daily fresh addition of the antibody at the same concentrations (B). 
 
A first assay was carried out by adding 1B4 mAb only at the first day and 
comparing the proliferation rate of untreated cells (CTL) with that one of the 
treated cells. As shown in Fig. 3.66 A, an anti-proliferative effect was already 
detected  after 48h and was also dose-dependent (32% inhibition at 0.1 μM and 
62% inhibition at 0.2 μM). Instead, at the second (48h) and at the fourth day (96h) 
the antibody lost its activity, likely due to degradation in the cell medium, so the 
cells started to re-grow. Interestingly, when the antibody was added freshly every 
24h, the anti-proliferative activity was remarkably enhanced. Indeed, only about 
20% and 11% of the cells were still viable at 24h after treatment with 0.1 μM and 
0.2 μM antibody, respectively. The effect was persistent also after 48h and 96h, 
although some cell re-growth was observed also under these conditions. 
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3.4 Effect of 1B4 mAb on melanoma cancer cells 
Since the expression of CR-1 has been also reported in melanoma cancer cells by 
Strizzi et al. [57], the 1B4 mAb was also tested on human melanoma cell lines. 
This study was performed by the research group at the Ann & Robert H. Lurie 
Children’s hospital of Chicago led by Prof. Mary Hendrix.  
The 1B4 mAb was firstly tested by western blot analysis on a panel of melanoma 
cell lines to determine its ability to recognize human CR-1 in this cancer cells 
(Fig. 3.67). 
 
Figure 3.67: Western blot analyses on melanoma cell lines (C8161, SkMeI, MV3, Ros184) 
comparing the commercial antibody (A) with the 1B4 mAb (B). The remaining cell lines were 
used as positive control.  
 
As shown, by comparing the bands detected by the commercial anti-Cripto 
antibody (Fig. 3.67 A) with those stained by the 1B4 mAb (B), it was evident that 
the commercial antibody readily recognized the core protein (~18 kDa), whereas 
the 1B4 antibody was more efficient in detecting the heavier CR-1 isoforms 
corresponding to the differential glycosylation status of the protein (44 kDa, 
50kDa).  
The C8161 cell line (malignant melanoma) was chosen to perform a functional 
assay to evaluate if the 1B4 mAb was able to block the phosphorylation of 
Smad2/3 Nodal-dependent and eventually of MAPK and c-Src, triggered by a 
Nodal-independent mechanism (Fig. 3.68). 
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Figure 3.68: Western blot analysis on C8161 treated with 1B4, to detect the phosphorylated forms 
of CR-1 cellular partners. 
 
As shown in Fig. 3.68, the 1B4 mAb exerted a weak negative effect on Smad2/3 
phosphorylation, only after 72h. At intermediate time intervals, the antibody 
actually increased the Smad2/3 activation, whereas after 72h a sustained reduction 
was observed. Instead, the antibody strongly and persistently (up to 72h) blocked 
the phosphorylation of ERK1/2 yet after 4h. This suggested a strong inhibitory 
effect on the Nodal-independent signaling pathways mediated by raf/ras and shc 
and this hypothesis was further confirmed by the inhibition of activation of Src at 
6h until 72h. 
These findings indicate that in C8161 cell line, in which CR-1 is co-expressed 
with Nodal, the 1B4 mAb can intensively block the phosphorylation of MAPK 
and Src induced by CR-1 via a Nodal- independent mechanism, which is mediated 
by the interaction of the CR-1 CFC with GRP78 and/or with  Glypican-1. 
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Human Cripto-1 (CR-1) is the founding member of the EGF-CFC superfamily 
that exhibits different functions depending on the organism in which its members 
are expressed. CR-1 is a key regulator of embryogenesis, promoting the 
differentiation of embryonic stem cells, and it is involved in organogenesis, with a 
predominant function in the neuronal and cardiac development. As many other 
developmental growth factors, CR-1 also promotes tumorigenesis, by regulating 
cell proliferation, migration, epithelial-mesenchimal transition, survival and 
angiogenesis. It is therefore described as an oncogenic growth factor. CR-1 is 
composed by two functional Cysteine Rich Domains, EGF-like and CFC, both 
independently involved in various interactions with several partners which 
mediate its pro-oncogenic activity. Each domain consists of about 40 amino acids 
and contains three disulfide bridges that render them highly compact structures. 
While the EGF-like domain is involved in the interaction with members of the 
TGF-β family (Nodal, GDF1, GDF3), ALK7 and Glypican-1 [26,28,29,34,47], the 
CFC domain is reported to interact with the ALK4 receptor and GRP78 hsp70, 
which both, through different signaling pathways, activate major anti-apoptotic 
mechanisms [28,31]. 
CR-1 is highly expressed in a wide range of human solid tumors (breast, colon, 
brain, lung, melanoma) whereas it is poorly expressed or completely absent in 
adult normal tissues [36]. CR-1 is therefore a well-established therapeutic target 
for those type of tumours where the protein is overexpressed. In addition, since 
high levels of soluble CR-1 are detectable in plasma of patients affected by breast, 
colon and glioblastoma tumors, CR-1 may be considered as a novel serologic 
marker for early diagnosis of tumors over-expressing this protein. 
CR-1 can promote tumorigenesis acting as a non competitive antagonist of 
Activin B or as a co-receptor of Nodal. In both cases the binding of CR-1 to 
ALK4 receptor, via the CFC domain, is fundamental to trigger the Smads cascade 
that ultimately lead to the expression of tumor-related factors. On the basis of 
these premises we have designed a strategy based on the use of monoclonal 
antibodies to block the several activities exerted by CR-1 through its CFC 
domain. The CFC domain of CR-1 is readily accessible by chemical synthesis as 
demonstrated by several papers reporting its assembling, refolding and disulfide 
pattern [19,164] and its 3D structure [165]. The 39-residues long polypeptide has a 
natural propensity to refold forming the correct pattern of disulfide bridges, a 
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property that suggests it is an independent structural module of the protein, other 
than a functional motif. However, the domain by itself has poor recognition 
properties toward the ALK4 receptor [26] (the binding to GRP78 has not been 
tested yet) and could be used therefore as a soluble inhibitor only at high 
concentrations. Attempts are underway to use a soluble variant of ALK4 to inhibit 
CR-1, generated as a dimeric FC-fused protein (PCT n° 7820620, filed Sep 14, 
2004). One very versatile option for inhibiting the CFC-mediated CR-1 activity is 
to generate monoclonal antibodies specifically targeting such region and capable 
of masking the ALK4 and the GRP78 binding site. mAbs have the advantage of 
very high specificity, generally high affinity and the perspective of producing 
them in large amounts from engineered cells or hybridomas. Previously, mAbs 
against the CR-1 CFC domain have been reported  [25], however, such antibodies 
have never been developed to the stage of a therapeutic, nor characterized in terms 
of binding affinity, epitope delineation and sequence. This last point is of huge 
importance in the perspective of antibody humanization strategies and for the 
generation of new antibody formats, including recombinant Fab, Fab2, scFv or 
other similar fragments which have simplified structures, higher tissue penetration 
features, versatility in terms of affinity enhancement, reduction of 
immunogenicity, increase of stability, structure modifications to increase half-life 
and other properties.  
Using the synthetic, fully refolded human CFC domain of CR-1 – [112-150] 
residues - we immunized mice and generated mAbs against this key structural 
motif using the hybridoma technique. mAbs binding the original antigen, have 
been further selected to choose those able to: i) bind the full length protein and ii) 
bind it in proximity of the H120 and W123 residues of CFC strongly involved in 
the binding to ALK4. Several mAbs binding the domain have thus been further 
tested to select those enable to recognize the H120/W123 mutated molecule, so 
that they are endowed with the ability to bind the side chains of these selected 
residues and therefore with the potential of inhibiting the interaction with both 
ALK4 and GRP78. The antibodies have been prepared in sufficient amounts to 
perform a number of biochemical studies, including binding to the synthetic 
human CFC, binding to human and mouse recombinant CR-1, inhibition of the 
binding to ALK4. Remarkably, the two mAbs isolated by this approach, 10D1 and 
1B4, exhibit both the ability to selectively recognize the human variant over the 
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mouse (See Fig. 3.11 for a sequence comparison) and to also be selective toward 
the fully refolded human CFC domain. The KDs of the interaction between 10D1 
and 1B4 with CR-1 were 70 pM and 240 pM, respectively. These observations 
suggest two important features of the selected antibodies: i) they bind 
conformational epitopes, though a partial recognition of the unfolded protein still 
occurs with a lower affinity, as suggested by poor recognition of rhCR-1 in 
western blot experiments (data not shown); ii) both antibodies likely also bind the 
residue D121 which is only present in the human variant (in the mouse sequence 
there is a glycine) and localized between H120 and W123.  
Full sequencing of the 1B4 and 10D1 antibodies CDRs allowed the generation of 
molecular models of their 3D structures and, using docking softwares, also 3D 
models of the antibody-CFC complexes have been generated and deeply studied. 
The mutual interacting surfaces from both the CFC and the antibodies CDR have 
been clearly identified and finely mapped, so to gain insights for further affinity 
maturation or humanization studies. We next sought to investigate the biological 
properties of these antibodies. Most studies were performed with the 1B4 on 
different cancer cell lines overexpressing CR-1 to test the cell killing and 
migration blocking activity. While no pro-apoptotic activity was shown in GBM 
cell lines (U87 and C16), only a modest anti-migration activity was observed only 
on the U87 line. At variance, a strong cell killing activity was observed on the 
GEO cancer cell line expressing high levels of the CR-1 mRNA compared to the 
control. Under these conditions, the antibody at 100 nM and 200 nM, killed 
between 80% and 90% of cells after 24h.  
Preliminary attempts to obtain the Fab fragment from 1B4 mAb by proteolytic 
approach failed, since only partially active fragment was generated, displaying a 
100-fold binding affinity reduction compared to the intact IgG. Therefore, this 
approach was soon abandoned in favor of the recombinant preparation of a 
partially humanized (chimeric), C-terminally modified recombinant Fab. The 
recombinant Fab of 1B4 (1B4 rFab) was generated using the humanized scaffold 
of the well-known Trastuzumab antibody in the perspective of using it in in vivo 
experiments. On the C-terminus of the heavy chain, a M-TGase recognition 
sequence was introduced with the aim of conjugating, in a very specific manner, 
molecular synthons on the side chain of a Glutamine residue. The recombinant 
Fab was thus expressed in an E.Coli host strain with a signal peptide that – 
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favouring the polypeptide translocation into the periplasmic space – allowed the 
contextual refolding of the Fab. This approach was successful, as it allowed the 
rapid preparation of several mg of the desired Fab. The antibody fragment was 
fully characterized in terms of structure and binding affinity toward the single 
hCFC antigen and the full-length rhCR-1 protein. Indeed, by SPR we measured a 
KD of only 6 nM, largely reduced compared to the 240 pM KD exhibited by the 
full-size antibody.  
To improve the affinity, an innovative artificial dimeric format of the Fab (1B4 
rFab2) was designed and obtained.  The dimer was achieved by using a pseudo-
symmetrical homobifunctional linker able to join together two Fab molecules 
under the conditions of enzymatic conjugation with M-TGase. The approach was 
successful, since we could achieve a dimeric artificial Fab with a MW of about 
100 kDa held together by isoamide bonds between the Lysine side chains of the 
linker and the Glutamine side chain of the M-TGase consensus sequence. 
Remarkably, this bivalent fragment exhibited a KD of 270 pM, which is similar to 
that one displayed by the full-size antibody.  
Using the 1B4 rFab as scaffold we next explored the possibility to also generate 
ADCs (Antibody Drug conjugates) exploiting the occurrence of the M-TGase 
conjugation site. ADCs are new, smart molecules where the high specificity of 
antibody portion is complemented by the high cytotoxic activity of the linked 
payload. Antibody specificity for antigens selectively expressed on the surface of 
cancer cells is exploited to deliver high activity, otherwise toxic compounds to 
such cells, thus allowing reduction of their cytotoxic potential in normal tissues 
and increasing it at the site of the tumour. Also this approach was successful, 
since the designed strategy was applied to prepare an ADC with the 1B4 rFab and 
Doxorubicin. The strategy was based on both chemical and enzymatic steps, 
whereby Doxorubicin was first chemically conjugated to a linker bearing an 
amino-group (the ε-amino group of a Lysine). In a second step, such amino group 
was site-specifically conjugated to the C-terminal of the rFab heavy chain in order 
to have one single Doxorubicin molecule linked to the antibody fragment. The 
analytical characterization of the 1B4 rFab-Doxo conjugate demonstrated that the 
expected reactions had occurred and that the expected compound was isolated. 
Biological assays are underway to assess the activity of this new molecule. 
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In conclusion, we have generated mAbs having very high affinity to the CFC 
domain of human CR-1 and we have deeply characterized them at biochemical 
level to determine their affinity toward the target. In addition to a biochemical 
approach, by computational studies on Fab-antigen complex, we have investigated 
how they interact with the antigen at molecular level. Finally, starting with the 
1B4 mAb, we have explored which are the perspective for the utilization of this 
antibody as a biotherapeutic (in vivo blocking of CR-1 activity) or as a diagnostic 
agent for the detection of the protein in biological fluids of patients 
overexpressing the protein. Preliminary data on selected Cripto-expressing cancer 
cells suggest that the 1B4 mab has a potential as single-treatment biotherapeutic. 
Also a major application for the generation of ADCs is expected, given the high 
selectivity of the antibody and possibility to produce recombinant Fab format 
bearing a site-specific conjugation site.  
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Abs: Absorbance 
ABTS: 2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
amu: Atomic mass unit 
APS: Ammonium persulfate 
bp: base pair 
BSA: Bovine serum albumin 
CD: Circular dichroism 
cDNcA: complementary DNA 
CDR: Complemetarity determining region 
CM5: Carboxy-methylated dextran sensor chip 
DIEA: N,N-Diisopropylethylamine 
DMEM-F12: Dulbecco’s modified eagle medium-F12 
DMF: Dimethylformamide  
DMSO:Dimetilsulphoxide 
DTT: Dithiothreitol  
ECL: Enhanced Chemiluminescence 
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA: Ethylenediaminetetraacetic acid 
ELISA: Enzyme linked immunosorbent assay 
Fab: Fragment antigen-binding  
FACS: Fluorescence-activated cell sorting 
Fc: Fragment Cystallizable  
Fmoc: Fluorenylmethyloxycarbonyl chloride 
FPLC: Fast Protein Liquid Chromatography 
GAM-HRP: Goat anti mouse-Horseradish peroxidase 
GAR-HRP: Goat anti rabbit-Horseradish peroxidise 
h: hours 
HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 
hCFC: Human  Cripto_Frl-1_Cryptic domain 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIC: Hydrophobic Interaction Chromatography 
HPLC: High performance liquid chromatography 
IgG: Immunoglobulin G 
kDa: kiloDalton 
kbp: kilobase pair 
KLH: Keyhole Hemocyanin Limpet 
LC-ESI-TOF-MS: Liquid Chromatography-Electron Spray Ionization-Time of flight-Mass 
Spectrometry 
mAb: Monoclonal antibody 
MBHA: resin 4-Methylbenzhydrylamine Hydrochloride Salt Resin 
min: minutes 
MOPS: 3-Morpholinopropanesulfonic acid 
M-TGase: Microbial Transglutaminase 
MW: Molecular Weight 
NaAc: Sodium Acetate  
NFDM: Not Fat Dry Milk 
NHS: N-hydroxysuccinimide ester  
OD: Optical Density 
o.n.: overnight 
OPD: o-Phenylenediamine dihydrochloride 
OPTI-4-CN: 4-Chloro-1-naphthol 
PBS: Phosphate-Buffered Saline 
PBS-T: Phosphate-Buffered Saline-Tween20 
PDA: Photodiode Array 
PEG: Polyetilen gycole 
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PVDF: Polyvinylidene fluoride 
psi: pound per square inch 
rhALK4: recombinant human ALK4 
rhCR-1: Recombinant human Cripto-1 
rmCr-1: Recombinant mouse Cripto-1 
RP-HPLC: Reverse phase-high performance liquid chromatography 
rpm: Revolutions per minute 
r.t.: room temperature 
RT-PCR: Reverse transcriptase-Polymerase chain reaction              
RU: Resonance Unit 
SDS: Sodium Dodecyl Sulphate 
SDS-PAGE: Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
SEC: Size-exclusion chromatography 
SE-HPLC: Size exclusion- high performance liquid chromatography 
SPR: Surface Plasmon Resonance 
TBE: Tris-Borate-EDTA buffer 
TBS-T: Tris-Buffered Saline-Tween20 
TEMED: Tetramethylethylenediamine  
TFA: Trifluoroacetic Acid 
TIS: Triisopropylsilane 
U/ml: Unit/ml 
UV:  ultraviolet 
- β:  without  β-Mercaptoethanol 
+β:  with β-Mercaptoetanol 
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and Menotti Ruvoa,b*Nodal, a member of the TGF-β superfamily, is a potent embryonic morphogen also implicated in tumor progression. As for other
TGF-βs, it triggers the signaling functions through the interaction with the extracellular domains of type I and type II
serine/threonine kinase receptors and with the co-receptor Cripto. Recently, we reported the molecular models of Nodal in com-
plex with its type I receptors (ALK4 and ALK7) as well as with Cripto, as obtained by homologymodeling and docking simulations.
From such models, potential binding epitopes have been identified. To validate such hypotheses, a series of mutated Nodal frag-
ments have been synthesized. These peptide analogs encompass residues 44–67 of the Nodal protein, corresponding to the pre-
helix loop and the H3 helix, and reproduce the wild-type sequence or bear some modifications to evaluate the hot-spot role of
modified residues in the receptor binding.
Here, we show the structural characterization in solution by CD andNMRof theNodal peptides and themeasurement of binding
affinity toward Cripto by surface plasmon resonance. Data collected by both conformational analyses and binding measurements
suggest a role for Y58 of Nodal in the recognition with Cripto and confirm that previously reported for E49 and E50.
Surface plasmon resonance binding assays with recombinant proteins show that Nodal interacts in vitro also with ALK7 and
ALK4 and preliminary data, generated using the Nodal synthetic fragments, suggest that Y58 of Nodal may also be involved in
the recognition with these protein partners. Copyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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Nodal belongs to the transforming growth factor-β (TGF-β) super-
family and plays essential roles in regulating embryonic develop-
ment [1] and cell fate determination [2,3]. As with other growth
factors, its late re-expression in adult tissues contributes to tumor
development and progression. Nodal overexpression is indeed im-
plicated in tumorigenesis, metastasis and cancer vascularization
and has been associated to various cancers [4], including ovarian
[5], pancreatic [6,7], endometrial [8], breast [9–11], prostate
[12,13], testicular [14], brain [15,16], colon [17], melanoma [18,19]
and hepatocellular carcinoma [20]. Because the TGF-β roles in tu-
morigenesis frequently reflect their function in embryonic develop-
ment, in the current literature, their signaling pathways are
observed with a special regard as possible therapeutic targets
[10,16,21–24]. The overexpression of Nodal in numerous cancers,
as well as its low abundance in normal tissues, makes Nodal a
potential biomarker or antitumor target. In order to achieve this
goal, many efforts have been made to fully understand how Nodal
works in both normal and neoplastic conditions [4].
As for other TGF-βs, Nodal triggers the signaling functions
through the interaction with the extracellular domains (ECD) of
type I and type II serine/threonine kinase receptors. In particular,
Nodal can signal via ActRIIB type II receptor and ALK7 or ALK4 type
I receptors [25,26]. Effective signaling through ALK4 requires theCopyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.
CALVANESE ET AL.additional interaction of Nodal with the co-receptor Cripto [27].
Cripto is a membrane protein bound to the extracellular surface
via glycosylphosphatidylinositol linkages [28]. It belongs to the
Epidermal Growth Factor - Cripto_FRL-1_Cryptic (EGF-CFC) family
and contains two cysteine-rich domains: the EGF-like domain,
highly homologous to epidermal growth factor domains, and the
prototypical CFC domain. Both domains are compact structural
modules held together by three disulfide bridges and likely fur-
ther stabilized by reciprocal interactions. Cripto is required for
the formation of the multimeric complex involving Nodal and
the ALK4/ActRIIB receptors. Indeed, Cripto binds ALK4 by means
of its CFC domain while it interacts with Nodal via the EGF-like
domain [27] (Figure 1). It is worth remembering that Nodal is
absent in most normal adult tissues, but, like its cognate co-
receptor Cripto, is expressed in many different tumors where
they potently promote cell proliferation and growth through
the phosphorylation of Smads [4]. These findings make the
Nodal–Cripto signaling pathway a very attractive target for tumor
therapy [24]. Indeed, many efforts are currently made to develop
specific Nodal inhibitors, mostly antibodies, which can interfere
with one of the several interactions established by Nodal with
Cripto or with ALK7 and efficiently interrupt the downstream
Smad signaling [4]. Several groups have proposed anti-Nodal
antibodies that potentially target its interaction with Cripto and
block tumor growth in models of metastatic melanoma cells [29].
However, developing effective and selective inhibitors remains a
very challenging task in absence of a more comprehensive view
of the network of interactions established by these proteins and,
more importantly, in absence of a detailed understanding of theFigure 1. Schematic representation of ALK4/Cripto/Nodal/ActRIIB complex.
wileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europstructural features underlying mutual recognition. For these pur-
poses, we have investigated the structural aspects underpinning
the Nodal–Cripto binding and have reported the first molecular
models of Nodal in complex with its receptors [30,31].
Nodal is a homodimer consisting of two subunits, eachwith three
disulfidebonds, linkedbyanadditional inter-chaincovalentdisulfide
bond,highly conserved in theTGF-β superfamily [32] . Thehomology
model of Nodal, we previously reported [30], shows the canonical,
symmetric and elongated TGF-β topology (Figure 2). Each Nodal
monomer is characterized by two pairs of antiparallel β-strands
stretching out from the cysteine core-like fingers and by an α-helix
(H3 helix). The typical curvature of these fingers creates concave
andconvexsurfaces,namelywristandknuckleregions,whichenable
the interaction of Nodal with type I and type II receptor binding epi-
topes, respectively. Inparticular, tothewrist regionparticipate, the in-
ner concave surface of the fingers of one monomer and the α-helix
(H3 helix) and the pre-helix loop of the other monomer [33–35].
The molecular models of Nodal in complex with the ECDs of its
type I receptors (ALK4 and ALK7), as well as with Cripto, were ob-
tained by homology modeling and docking simulations. Also, po-
tential binding epitopes were identified [30,31]. These comprise
residues belonging to the Nodal wrist region. To validate such hy-
pothesis, a series of new Nodal fragments has been now designed
and synthesized. This series includes peptides from the pre-helix
loop and the H3 helix of Nodal (residues 44–67) (Figure 2), and
bears somemutations that will help to evaluate the role of selected
hot spots in receptors binding, as discussed in the Results section.
Peptides have been synthesized, and their conformational fea-
tures have been analyzed in solution by CD and NMR. To evaluate
their binding affinity toward ALK4 and ALK7 receptors, as well as to-
ward Cripto co-receptor, surface plasmon resonance (SPR) assays
have been carried out. Also, a comparative binding analysis of
Nodal to the ECD of recombinant human rhCripto, rhALK4 and
rhALK7 has been performed to assess that the reagents used are
fully active in terms of recognition and that interacting surfaces
are properly exposed.
The set of data, resulting from conformational analyses and bind-
ingmeasurements, provide useful information that confirms the re-
liability of the theoretical models. On these grounds, the design of
new molecules, acting as antagonists in the Nodal-receptors com-
plex formation, can be improved with the outlook to their thera-
peutic and diagnostic applications.Materials and Methods
Reagents
Reagents for peptide synthesiswere fromNovabiochem (Laufelfingen,
Switzerland), Inbios (Napoli, Italy) and GL Biochem (Shanghai, China).
Solvents for peptide synthesis and purification, including ACN, DMF,
DCM and MeOH were from Romil (Dublin, Ireland). Recombinant
proteins were purchased from R&D system (MN, USA).
Peptides Synthesis and Purification
Peptides were prepared by stepwise solid-phase synthesis as
C-terminally amidated molecules following standard Fmoc chem-
istry protocols. To increase the polypeptide’s stability, the
N-terminal and C-terminal ends were acetylated and amidated,
respectively. A Rink-amide resin (substitution 0.53mmol/g) and
amino acid derivatives with standard protections were used in
the synthesis [36]. The syntheses were performed underean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 2. Ribbon representation of Nodal dimer model, with the twomonomers colored in green and gray, respectively. The disulfide bridges are shown as
yellow sticks. The Nodal wrist and knuckle regions, responsible for the binding to the type I and II receptors, are schematically indicated. At the bottom, both
the primary and secondary structures of the Nodal monomer are reported. The Nodal fragment selected in this study is circled in orange.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTScanonical conditions of peptide synthesis (HATU/DIEA pre-
activation, fivefold excess of Fmoc-protected amino acids).
Coupling and deprotection times were kept at 30 and 20min, re-
spectively. Finally, N-terminal acetylation was performed on the
resin using acetic anhydride at 0.5M in DMF with 5% DIEA,
20min at room temperature. The cleavage of peptides from
the solid support was performed by treatment with a TFA/TIS/
water (90 : 5 : 5, v/v/v) mixture for 3 h at room temperature,
affording the crude peptides after precipitation in cold diethyl-
ether. The precipitates were dissolved in water and were lyoph-
ilized. Products were purified to homogeneity by RP-HPLC using
an ONYX monolithic C18 column (100×10mm ID) applying a
linear gradient of 0.05% TFA in ACN from 5% to 70% over
10min (flow rate 20mL/min). The purity and integrity of all pep-
tides were estimated by LC-MS analyses using an LCQ mass
spectrometer (ThermoFisher, Milano, Italy) coupled to a Surveyor
system HPLC or an HCT Ultra ESI Ion Trap mass spectrometer
(Bruker), coupled to a Waters Alliance HPLC system (Milford,
MA, USA). LC-MS analyses were performed under conditions
standardized for the detection of peptides in the positive mode.
Typical gradients applied to elute the peptides were as follows:
flow 0.2mL/min; gradients from 5% solvent B (ACN, 0.05% TFA)
to 70% solvent B in 10min. Solvent A was H2O, 0.08% TFA.
Biobasic C18 50×2mm ID columns (ThermoFisher, Milano, Italy)
were used to separate peptides during LC-MS analyses.
Peptides were all prepared in amounts sufficient for the CD and
NMR analyses and for the binding assays. Purities were >95% as
determined by LC-MS analysis (Table 1).Table 1. Sequences of Nodal fragments investigated in this study
Peptide name Sequence
Nodal[44-67] Ac-PNPVGEEFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]EE-AA Ac-PNPVGAAFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]PV-AA Ac-PNAAGEEFHPTNHAYIQSLLKRYQ–NH2
Nodal[44-67]Y-A Ac-PNPVGEEFHPTNHAAIQSLLKRYQ–NH2
J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and JohCircular Dichroism Analysis
All CD analyses were performed using a JASCO J-710 spectropolar-
imeter (Halifax, Canada), equipped with a Peltier system for
changing the temperature in a controlled way and quartz cuvettes
110-QS with 1.0mm path length. Experiments were performed in
10mM phosphate, pH 8.0 at a concentration of 0.5×105M. In ad-
dition, spectra in the same buffer with added 20% of TFE were col-
lected to increase the α-helix structure.
Spectra were collectedwithin thewavelength range 250–190nm
at a scan rate of 50 nm/min, with a data pitch of 0.2nm, a band-
width of 1 nm and a response time of 4 s.
On every sample, five independent spectra were recorded, aver-
aged and smoothed using the Spectra Manager software, version
1.53 (Easton, MD, USA). Buffer scans were recorded under the same
conditions and subtracted.NMR Analysis
NMR characterization of Nodal fragments was performed in a
water/deuterated trifluoethanol TFE-d3/H2O 20 : 80 (v/v) mixture at
298K. Samples were prepared by dissolving weighted amounts of
each peptide in water (spectroscopic purity) and adding TFE-d3
(Sigma-Aldrich Chemicals, St. Louis, MO, USA, 99.9% D) up to a final
ratio of 80/20 v/v. Final concentrations were about 3mM.
One-dimensional and two-dimensional NMR spectra were ac-
quired on a Varian Inova spectrometer (Agilent Technologies, Palo
Alto, California, USA), operating at a proton frequency of 500MHz,Molecular Weight theor. Molecular Weight exp.
2880.2 2880.0
2764.1 2764.2
2826.1 2826.6
2788.1 2788.2
n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
CALVANESE ET AL.located at the ‘Centro Interdipartimentale di Metodologie Chimico-
Fisiche (CIMCF)’ of the University Federico II of Naples. Two-
dimensional (2D) experiments, such as total correlation spectroscopy
(TOCSY) [37], nuclear Overhauser effect spectroscopy (NOESY) [37],
and double quantum-filtered correlated spectroscopy (DQFCOSY)
were recorded by the phase-sensitive States-Haberkorn method
[38]. The data file generally consisted of 512 and 2048 (4096 for
DQFCOSY) data points in the ω1 and ω2 dimensions, respectively.
TOCSY experiments were acquired with a 70ms mixing time, while
NOESY experiments were acquired with 300ms mixing time. The
water resonance was suppressed by using gradients [37]. Chemical
shifts were referred to internal sodium 3-(trimethylsilyl) propionate
2,2,3,3-d4.
Spectra were analyzed by using the CARA program [39,40]. Pro-
ton sequential assignments of the amino acid spin systems are re-
ported as Supporting Information (Tables S1–S3). NOE intensities,
evaluated by integration of cross-peaks in the 300ms NOESY spec-
tra, were converted into inter-proton distances by use of the
CALIBA program [41]. Geminal protons were chosen as reference
with a distance of 2.2 Å.
Computational Methods
Structure calculations for Nodal[44-67], Nodal[44-67]EE-AA and
Nodal[44-67]Y-A started from 100 randomized conformers and
used the standard CYANA-simulated annealing schedule [42] with
20 000 torsion angle dynamics steps per conformer. Three-
dimensional structures were obtained by using inter-proton dis-
tances evaluated from NOEs as upper limits without the use of ste-
reospecific assignments. All the conformers showed a fair
agreement with experimental constraints showing no violations.
The 40 conformers with the lowest final CYANA target function
(TF) [43] values (TF average value= 0.42± 0.12Å2, 4.02E-02
± 3.03E-02Å2, and 4.41E-02±4.40E-02Å2 for Nodal[44-67], Nodal
[44-67]EE-AA and Nodal[44-67]Y-A, respectively; mean global back-
bone RMSD=3.51±0.97Å, 3.15± 0.65Å, and 3.44± 0.69Å for
Nodal[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A) were sub-
jected to restrained energy minimization by use of the SANDER
module of the AMBER 6.0 package [44].
The 40 minimized structures were subjected to the program CHI-
MERA [45] that divided them, based on structural similarity
(RMSD< 0.5), into 7 clusters for Nodal[44-67], 7 clusters for Nodal
[44-67]EE-AA and 6 clusters for Nodal[44-67]Y-A. The structures
present in the first cluster (13 for Nodal[44-67], 17 for Nodal
[44-67]EE-AA and 12 for Nodal[44-67]Y-A) were chosen as represen-
tative of the conformational space accessible to the peptide. The
molecular graphics program MOLMOL [46] was employed to per-
form the structural statistics analysis. Statistical data are reported
as Supporting Information (Tables S4 and S5).
SPR Analyses
All analyses were performed on a Biacore 3000 instrument from
GE Healthcare (Little Chalfont, UK) using certified HEPES
Buffered Saline (HBS) buffer (20mM Hepes, 0.15M NaCl, pH 7.2,
P20 at 0.005%), at 25 °C.
Human ALK4 (rhALK4-ECD) and ALK7 (rhALK7-ECD) and Cripto
(rhCripto) recombinant proteins were purchased from R&D system.
Proteins immobilization was carried out on the flow cells of CM5 sen-
sor chips at 5.0μg/mL following the canonical EDC/HOSu (amine cou-
pling) method, operating at 5μL/min. In detail, human ALK7-ECD
bearing as fusion protein Fc fragment human and Criptowileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europrecombinant proteins were efficiently immobilized in NaAc pH=4.5.
For human ALK4-ECD bearing as fusion Fc fragment and the Fc frag-
ment alone derived from an unrelated IgG1 of the same isotype, the
immobilization procedure was performed in sodium acetate (NaAc)
pH=4.0. An underivatized and Fc-derivatized (IgG1) surfacewere pre-
pared and used as control blank. Analyses were carried out at a flow
rate of 20μL/min, injecting a constant volume of 60μL of peptides so-
lutions at concentrations ranging between 0.1 and 1.0mM. Regener-
ations were performed by injecting 20μL of a solution of 10mM
glycine, pH2.7. The proteins were immobilized at a similar level
(around 3000 RU), using the wizard procedure. All binding experi-
ments were performed at 20μL/min with a total contact time of
180 s (60μL injected for every run) and the samples opportunely di-
luted in the HBS running buffer. For every single analysis, experimen-
tal sensorgrams were aligned, subtracted of blank signals and
overlapped. The binding of synthetic peptides to ALK4, ALK7 and to
Cripto was performed by injecting peptide solutions (60μL injected
for every run) at increasing concentrations, between 25μΜ and
1mM. All mathematical manipulations and fitting were performed
using the BIA evaluation software, version 4.1 from GE Healthcare.Results
Peptide Preparation
All peptides were obtained in yields ranging from about 20–30%.
After purification, homogeneous products were isolated. Molecular
weights were consistent with the expected values as assessed by
LC-MS analyses (Table 1).
Binding of Nodal to the Immobilized Receptors
Before testing the binding of synthetic peptides to the different re-
ceptors, we first probedwhether the interaction of full-length Nodal
was productive under the chosen experimental conditions. To this
end, we injected the recombinant protein at increasing concentra-
tions over the three channels where the proteins were immobilized.
As shown in Figure 3, Nodal binds in a dose-dependent manner to
both Cripto and ALK7 and exhibiting KDs of 5.8nM and 1.6 nM,
respectively (Table 2). These values were indicative of very strong
interactions and suggested that protein surfaces required for
interaction were properly and well exposed. Surprisingly, Nodal
was found to bind with high affinity (1.8nM, Table 2) also the
immobilized ALK4 (Figure 3B). That result was unexpected because,
according to the accepted literature, Nodal/ALK4 binding occurs
in vivo only in the presence of the co-receptor Cripto.
Computational Analysis
Through a computational analysis of the complex containing
ALK4/Cripto/Nodal (Figure 4), and ALK7/Nodal (Figure 5), obtained
by homology modeling and docking simulations [30], we identified
Nodal residues potentially involved in the interaction with Cripto
and ALK7.
In the ternary complex containing ALK4/Cripto/Nodal (Figure 4),
the EGF-like domain of Cripto was predicted to form, with G87, T88,
N79, T82 and G92 residues, a polar groove in which Nodal Y58 can
pocket. Furthermore, favorable electrostatic interactions are ob-
served between E49 and E50 lying on the pre-helix loop of Nodal
and the Cripto R80 residue [30].
In the ALK7/Nodal complex (Figure 5), the binding is driven by
hydrophobic interactions and hydrogen bonds. Of note, majorean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Table 2. KDs, Kas and Kds for the interaction of soluble Nodal with the
ECD of Cripto, ALK7 and ALK4
KD (M) Ka (1/Ms) Kd (1/s)
Cripto 5.79 * 109 3.20 * 105 6.11 * 104
ALK7 1.58 * 109 1.48 * 106 7.68 * 104
ALK4 1.82 * 109 1.49 * 106 5.80 * 104
Figure 3. SPR dose–response binding sensorgrams between rhNodal and (A) rhCripto; (B) rhALK4-ECD; and (C) rhALK7-ECD, immobilized on CM5
sensor chips.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSbinding interactions are driven by a single Nodal monomer and the
residues involved belong to the α-helix H3 (Y58 and L62) and pre-
helix loop of Nodal (P46 and V47) and to loop 23 of ALK7 (V51
and F52) [30].
In a previous study, we demonstrated that the entire 43–69
sequence of Nodal, encompassing the α-helix H3 and pre-helix
loop region, is able to bind to Cripto, while peptides reproducing
the helix H3 alone do not. Moreover, the substitution of the E49J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and Johand E50 pre-helix loop residues with alanine negatively affects
the binding to Cripto, confirming their involvement in the inter-
action [30].
On this basis, we have now designed a set of Nodal-derived
peptides comprising residues 44–67, still reproducing the helix
H3 and pre-helix loop region of the protein but shorter than
the first published ones [30] (Table 2). Indeed, the N-terminal cys-
teine (C43) and the C-terminal proline (P68) and histidine (H69)
have been removed as not influencing the peptide structural
and binding properties.
Single or double point Ala-mutated peptides have been synthe-
sized, purified and characterized by mass spectrometry together
with the unmodified molecule. A structural characterization by
NMR and circular dichroism has been then carried out in the at-
tempt of correlating binding and structural data. Binding to Cripto,
ALK4 and ALK7 receptors has been analyzed for all the peptides by
SPR assays.n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Figure 4. (A) Cartoon representation of the Nodal (green)/Cripto (orange)/ALK4-ECD (pink) complexmodel. (B) Cripto co-receptor is represented as Connolly
surface (orange). Residues at the binding interface are colored by type.
CALVANESE ET AL.Nodal[44-67] reproduces the 44–67 region of native human
Nodal, while the first mutant, Nodal[44-67]EE-AA, bears Ala residues
in place of E49 and E50; it was designed and prepared to confirm
the role of the two acidic residues in the binding with Cripto [30]
and a potential involvement in the interaction with ALK receptors.
In the second mutant, Nodal[44-67]PV-AA, the P46 and V47 resi-
dues were replaced with alanines to verify the influence of the
two hydrophobic residues of the pre-helix loop in the binding to
Cripto and to ALKs. In the last mutant, Nodal[44-67]Y-A, the Y58 res-
idue was substituted by alanine. Indeed, by analyzing the
ALK7/Nodal [31] and ALK4/Cripto/Nodal molecular complexes,
Y58 should be one of the residues mostly involved in the binding
with the Nodal helix H3.CD and NMR of Nodal Fragments
As shown, CD spectra (Figure 6) of peptides analyzed at 20° C in H20
or buffer exhibited a negative band at 201nm, typical of random
coil structures. However, in presence of TFE, 20% all peptides
adopted α-helical structures as suggested by the two negative
bands at 207nm and 223nm and a positive band at 192 nm.
NMR characterization of Nodal fragments (Nodal[44-67],
Nodal[44-67]EE-AA and Nodal[44-67]Y-A) was performed in a
trifluoethanol/water TFE-d3/H2O 20 : 80 (v/v) mixture at 298 K.wileyonlinelibrary.com/journal/jpepsci Copyright © 2014 EuropProton assignment was carried out with the procedure sug-
gested by Wuthrich [47], and the chemical shifts are reported in
Tables S1–S3 of the Supporting Information.
Negative deviations of the αCH proton chemical shift of each res-
idue from random coil values [48] are observed for all the peptides
from Y58 to R65 residues, indicating the presence of helical struc-
tures in this region (see Figure S1 of the Supporting Information).
Positive deviations observed in the remaining parts suggest ex-
tended conformations.
These structural diagnoses were consistent with the NOE pat-
terns. NOE long-range effects, such as (αi, NHi+3), (αi, βi+3) and (αi,
NHi+4) contacts (Figure 7), confirmed the occurrence of helical con-
formations in the 59–65 segment of all the three examined
peptides.
A set of 153 (87 intra-residual, 48 sequential and 18 long-range),
204 (115 intra-residual, 65 sequential and 24 long-range) and 181
(129 intra-residual, 32 sequential and 20 long-range) experimental
NOE constraints for Nodal[44-67], Nodal[44-67]EE-AA and Nodal
[44-67]Y-A, respectively, was used as upper limits of inter-proton
distances for structure calculations by CYANA program [43].
For all the peptides, the 40 CYANA structures with the lowest
values of target function were subjected to restrained energy min-
imization by use of the AMBER 6.0 package [44] and then clustered
by CHIMERA program [45]. The structures contained in the first and
most-populated cluster (13 structures for Nodal[44-67], 17 forean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 5. (A) Cartoon representation of the Nodal (green)/ALK7-ECD (pink) complex model. (B) ALK7 receptor is represented as Connolly surface (orange).
Residues at the binding interface are colored by type.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSNodal[44-67]EE-AA and 12 for Nodal[44-67]Y-A) were chosen as
representative of the conformational space accessible to the pep-
tide. The statistics of the structural analysis are reported in Tables
S4 and S5 of the Supporting Information.
For all the peptides, the representative clusters show struc-
tures characterized by an α-helix conformation in the 58–65 seg-
ment, where the backbone RMSD are 0.24± 0.12Å, 0.26± 0.17Å
and 1.15± 0.41Å for Nodal[44-67], Nodal[44-67]EE-AA, and
Nodal[44-67]Y-A and a C-terminal flexible segment. It is worth
noticing that the helical structure characterizing all three pep-
tides reproduces the same secondary structure in the
corresponding region of wild-type Nodal. In Figure 8, a superpo-
sition of the Nodal homology model (HM) [30] with the repre-
sentative NMR structures of Nodal[44-67], Nodal[44-67]EE-AA
and Nodal[44-67]Y-A, well represents this structural similarity.
The backbone RMSD values, obtained by superimposing Nodal
[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A NMR structures
in the 58–65 segment of Nodal HM, are 0.41Å, 0.60Å and
0.30Å, respectively.J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and JohThe molecular model of Nodal[44-67]PV-AA was not computed,
as it contains modifications that, occurring in the loop region,
would not expectedly alter the helical conformation in the 58–65
tract, common to the other analogs. This hypothesis is corroborated
by its CD spectrum that shows a profile similar to the others
(Figure 6).
Surface Plasmon Resonance Analysis
Wehave studied the interaction between peptides reproducing the
Nodal region 44–67 and the ECDs of ALK4, ALK7 and Cripto, evalu-
ating the effect of specific substitutions of hot-spot residues within
the pre-helix loop and helix H3 in protein recognition. SPR dose-
dependent binding assays between each Nodal peptide and every
single protein were carried out.
All sensorgrams obtained for the binding of Nodal peptides to
immobilized Cripto, ALK4 and ALK7 recombinant proteins showed
a similar kinetics profile with both fast association and dissociation
rates resulting in typical ‘square-pulse’ sensorgrams (Figure 9 andn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Figure 7. (A) NOE contacts graph for Nodal[44-67], Nodal[44-67]EE-AA and Nodal[44-67]Y-A. (B) Backbone superposition in the I59–Y66 segment of the
structures constituting the first cluster. The representative structure of the cluster is shown with blue cartoon for Nodal[44-67], green cartoon for Nodal
[44-67]EE-AA and red cartoon for Nodal[44-67]Y-A.
Figure 6. CD spectra of the Nodal fragments within the range 190–250 nm. (A) Nodal[44-67]: in water (blue line) and in water containing 20% TFE (v/v) (red
line). (B) Nodal[44-67]EE-AA: in water (green line) and in water containing 20% TFE (v/v) (light green line). (C) Nodal[44-67]PV-AA: in water (violet line) and in
water containing 20% TFE (v/v) (pink line). (D) Nodal[44-67]Y-A: in water (blue line) and in water containing 20% TFE (v/v) (cyan line).
CALVANESE ET AL.Figures S2 and S3 of the Supporting Information). Comparative
binding data were extrapolated by curve fitting. Remarkably, al-
though we could achieve good-fitting data for the binding of mostwileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europpeptides to Cripto (except for Nodal[44-67]Y-A), all calculations per-
formed on binding and dissociation curves to ALK4 and ALK7 did
not converge to significant values (data are summarized in Table 3).ean Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2014
Figure 8. Structural overlap in the 58–65 segment of Nodal HM (green) [30]
and the representative NMR structures of Nodal[44-67] (blue), Nodal[44-67]
EE-AA (light blue) and Nodal[44-67]Y-A (red).
Table 3. Affinity constant values of Nodal[44-67] and related Ala-mu-
tated peptides to immobilized rhCripto
KD
Peptide Cripto ALK4 ALK7
Nodal[44-67] 1.39 * 106M nf nf
Nodal[44-67]EE-AA 13.3 * 106M nf nf
Nodal[44-67]PV-AA 3.42 * 106M nf nf
Nodal[44-67]Y-A nf nf nf
The KD values were extrapolated by data fitting of dose-dependent
binding curves using the BIA evaluation analysis package (version
4.1, Pharmacia Biosensor).
No fitting (nf) means that fitting of binding and association curves did
not converge to any value.
CONFORMATIONAL AND BINDING PROPERTIES OF NODAL SYNTHETIC FRAGMENTSAccording to this analysis and in agreement with previous findings
[30], we concluded that replacing the two glutamic acids (E49 and
E50) with alanines in Nodal[44-67] reduced the affinity by about ten
times (KD=13.3μM) compared with that obtained with the unmod-
ified Nodal fragment (KD=1.39μM). Conversely, the affinity con-
stant (KD=3.42μM) for Cripto of Nodal[44-67]PV-AA, in which P46
and V47 were substituted with alanines, resulted very close to that
of the wild-type peptide, suggesting a relatively weak contribution
of these residues to the binding with Cripto and to the stability of
the overall complex. Nodal[44-67]Y-A very poorly associated with
immobilized Cripto (Figure 9D), and, furthermore, attempts to fit
the association and dissociation curves to derive the binding pa-
rameters were all unfruitful (Table 3). The results therefore suggest
that the binding of Nodal to Cripto could be mediated by tyrosine
on position 58 (Y58) and is further stabilized by the upstream
glutamic acid pair (E49–E50). Following the same procedure, we
found that none of the peptides tested displayed sufficient binding
capacity for either ALK4 and ALK7. Kinetic data, reported in Table 4,
show that the Nodal peptides exhibit very similar Koffs (NodalFigure 9. SPR sensorgrams obtained for the binding of Nodal peptides to im
ranging between (A) 25–500μM for Nodal[44-67]; (B) 100–500μM for Nodal[4
Nodal[44-67]Y-A.
J. Pept. Sci. 2014 Copyright © 2014 European Peptide Society and Joh[44-67]: Koff = 2.86*10
3 s1; Nodal[44-67]EE-AA: Koff = 2.44*10
3 s1;
Nodal[44-67]PV-AA: Koff = 2.40*10
3 s1) and that the differences
in affinity constants (KD) for Cripto arise mainly from changes in
the association rates (Nodal[44-67]: 2.51*103M1 s1; Nodal[44-67]
PV-AA: 2.15*103M1 s1; Nodal[44-67]EE-AA: 3.23*102M1 s1). Such
observations support the hypothesis that E49 and E50 positively
affect the binding to Cripto by enhancing the association speed.
To try to further rationalize the data obtained and to gain a more
comprehensive overview of the interaction between peptide frag-
ments and target proteins, we also made a comparison of the
RUmax values obtained for all molecules at a given concentration
(0.1mM). Data are reported in the Supporting Information as Figure
S4 and reflect the values from sensorgrams reported in Figure 9
(A–D) and Figures S2 and S3. As shown, the most intense values
are observed for the interaction between Nodal[44-67] with Cripto
whereas the samemolecule only very poorly binds the other recep-
tors. Unexpectedly, peptides Nodal[44-67]EE-AA and Nodal[44-67]
PV-AA were somehow captured by ALK4 and ALK7, although themobilized rhCripto. Dose–response curves were recorded at concentrations
4-67]EE-AA; (C) 100–1000μM for Nodal[44-67]PV-AA; (D) 100–1000μM for
n Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
Table 4. Kinetic constants extrapolated for the binding of Nodal
[44-67] and related Ala-mutated peptides to immobilized rhCripto
Peptide Kon (M
1 s1) Koff (s
1) KD (M)
Nodal[44-67] 2.51 * 103 2.86 * 103 1.39 * 106
Nodal[44-67]EE-AA 3.23 * 102 2.44 * 103 13.3 * 106
Nodal[44-67]PV-AA 2.15 * 103 2.40 * 103 3.42 * 106
Nodal[44-67]Y-A nf nf nf
The KD values were obtained as the ratio between Koffs and Kons.
Data were obtained using the BIA evaluation analysis package
(version 4.1, Pharmacia Biosensor).
No fitting (nf) means that fitting of binding and association curves did
not converge to any value.
CALVANESE ET AL.kinetic parameters could not be determined (Tables 2 and 3). Thus,
it seems that replacement of two glutamic acids (E49 and E50) or of
proline 47 (P47) and valine 48 (V48) with alanine residues may favor
the binding to the ALK receptors. These data could be explained by
looking at the ALK7/Nodal complex binding epitope (Figure 5). In-
deed, the model suggests that the Nodal E49–E50 residues are close
to the ALK7 hydrophobic interface; therefore, when they are changed
to alanine, the hydrophobic interactions could be enhanced. The
same explanation could hold true also for ALK4, assuming that the
theoretical ALK4/Nodal complex adopts the same topological struc-
ture as the ALK7/Nodal complex. Strikingly, the substitution of Y58
with alanine in Nodal[44-67]Y-A completely abolishes the binding
to ALK4 and ALK7, indicating a possible role of such residue in
the Nodal binding with these proteins.Discussion
In this work, we have investigated some structural properties of the
binding of Nodal with its type I receptors, ALK4 and ALK7, and with
the co-receptor Cripto. An approach based on homologymodeling,
CD, NMR and SPR binding assays has been applied to design and
study a set of synthetic peptides reproducing the pre-helix loop
and the H3 α-helix region of Nodal. Nodal is reported to establish
direct interactions with ALK7 and with Cripto, whereas the interac-
tion with ALK4 was so far believed to be only mediated by Cripto.
We find here for the first time that, at least in vitro, Nodal can di-
rectly and strongly interact with ALK4 too. However, whether this
interaction occurs also in vivo or has a functional relevance remains
to be established. We also evaluated for the first time the KD for the
Nodal/ALK7 interaction (1.58 nM). These strong interactions, to-
gether with that underlying the binding of Nodal with Cripto [30],
also in the low nanomolar range, suggest that the members of
the resulting molecular complex are very tightly associated, and
their dissociation is a very difficult task. Using the synthetic pep-
tides, we have further investigated the Nodal main residues in-
volved in the binding with Cripto. Nodal binding residues have
been identified using the previously published ALK4/Cripto/Nodal
[30] and ALK7/Nodal [31] molecular models. On this basis, a series
of Nodal fragments, which include residues 44–67 of the pre-helix
loop and the H3 α-helix, have been synthesized with selected resi-
due replacements to evaluate their putative role in receptor bind-
ing. The conformational NMR and CD analyses of Nodal peptides
show their propensity to adopt α-helix structures, at least in the
N-terminal tract reproducing the H3 α-helix of the parent protein.
Remarkably, substitution of residues on positions 47–50 withwileyonlinelibrary.com/journal/jpepsci Copyright © 2014 Europalanines does not seem to affect the overall propensity of the pep-
tide C-terminal tail to adopt the helical structure. Also, changing
Y58 within the helix with an alanine poorly alters the structural fea-
tures of the molecule.
The ability of Nodal fragments to bind to ALK4, ALK7 receptors
and Cripto, evaluated by SPR assays, has shown a preferential rec-
ognition of the wild-type Nodal 44–67 fragment for Cripto. Indeed,
changing the key residues E49, E50 and Y58 to alanines interferes
with and strongly impairs the recognition with this protein. Our
data are also suggestive of aminor role of P47 and V48. Remarkably,
the mutated synthetic peptides Nodal[44-67]EE-AA and Nodal
[44-67]PV-AA, likely because of an increase of the local hydropho-
bicity, are also attracted to some extent by the ALK4 and the
ALK7 receptors, while the substitution of Y58 abolishes the binding.
All together, these data suggest that the part of the molecular sur-
face corresponding to this region of Nodal could be shared with the
other two protein partners.
In conclusion, the results reported here confirm that the binding
of Nodal to the receptor complex, comprising the type I receptors
ALK7 and ALK4 via the co-receptor Cripto, is influenced by glutamic
acid residues (E49 and E50) and by tyrosine 58 (Y58). Such residues
appear crucial tomodulate Nodal specificity for one or the other re-
ceptor, thus altering also its function.
Considering the outstanding implications of Nodal in cancer, elu-
cidation of the structural features underlying its interaction with re-
ceptors and co-receptors is fundamental in the perspective of
planning strategies aimed at targeting the Nodal/Cripto-ALK
receptors–Smad axis for therapeutic purposes.
Although further structural studies are required to confirm in vivo
our observations, the identification of such hot-spot residues is a
primary step to develop new inhibitors, especially neutralizing
antibodies and small high-affinity peptides reproducing the bind-
ing interfaces on both Nodal and ALK7. The finding that Nodal
can bind directly ALK4, if confirmed by other studies, could suggest
the existence of a new Cripto-independent axis, which could be,
independently or in combination with, targeted for developing
specific antagonists that disrupt the Nodal–receptor complex(es)
and block the growth and proliferation of many cancer cells.
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Introduction  
 
Angiogenesis is a physiological process mostly regulated by activation of VEGF receptors 
VEGF-R1 (Flt-1) and VEGF-R2 (KDR) by a set of structurally conserved ligands of the 
Vascular Endothelial Growth Factor (VEGF) family. Inappropriate receptor activation leads 
to pathological processes strictly correlated to tumour growth and their inhibition is a well-
assessed strategy to stop or slow down cancer growth [1]. Both ligands and receptors have 
been targeted to block pathological angiogenesis, however a broad structural similarity 
amongst the different ligands and the two receptors makes difficult the design of new 
selective inhibitors. Several antiangiogenic compounds have been so far reported and 
developed at various stages [2]. A comparative analysis of known VEGFRs-binding peptides 
suggests that a minimum structural requirement for 
binding to VEGFR2 could be the motif XPR, where 
X is a hydrophobic residue crucial for receptor 
recognition. To identify new selective receptor 
inhibitors, we started from known VEGFR2-binding 
peptides [3-5] and designed and synthesized a small 
set of D-cyclopeptides containing this motif. A 
preliminary screening of their ability to bind to 
VEGFR1 and VEGFR2 by SPR was performed, 
showing that some of them bind both receptors with 
an affinity in the low micromolar range, whereas one 
is able to bind VEGFR1 in a selective manner. 
Results and Discussion 
The library components were designed using as 
template two previously reported VEGFR binding 
peptides: the linear peptide ATWLPPR [3], denoted 
as “CTRL”, and the cysteine-bridged CPQPRPLC 
peptide [4; 5]. Peptide C1 was the retro-inverso of the 
ATWLPPR lacking one Proline, to put the 
hydrophobic Leucine adjacent to the Arginine. 
Peptide C2 was the retro-inverso of ATWLPPR. The 
peptide C3 was designed to exchange the 
hydrophobic patch before the PPR motif with a 
charged residue. Peptides from C5 to C7 were designed as variants of peptide C3, by moving 
the “rp” motif along the sequence. Retro-inversion was introduced to increase proteolytic 
stability, maintaining the overall side chain topology, whereas cyclization was introduced to 
restrict the conformational freedom in solution. 
The synthesis of the library was carried out on the solid phase, following the Sheppard’s 
protocol using Fmoc protected Amino Acids and HATU as coupling reagent. The cyclization 
 
Fig. 1. a) Names, MW and KDs for the 
two VEGFRs determined by dose-
response binding assays. b) SPR 
screening:  plot of RUmax  achieved at 
the concentration of 20 μM  for the 
binding of the different cyclopeptides to 
the two receptors . 
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 was carried out in slightly alkaline buffers (pH 8.0) on crude peptides. Purification was 
accomplished after reaction completion and acidification. 
The interaction between VEGF mimetic cyclopeptides and VEGF-R1 and VEGF-R2 
receptors was assessed by SPR assays using a BIACORE 3000 system. A CM5 sensor chip 
was covalently derivatized with recombinant KDR and Flt-1 proteins following an amino 
coupling strategy. The screening was performed simultaneously on both receptors, starting 
from a concentration of 20 nM until 20 μM. Data (Fig. 1b) showed that C1 and C2 bound to 
both VEGF-R1 and VEGF-R2 receptors while the C3 cyclopeptide seemed specific for Flt-1. 
To further investigate the binding in terms of affinity and specificity on both receptors, we 
carried out a dose-dependent assay for three positive cyclopeptides C1, C2 and C3. By fitting 
data using the BIAevaluation analysis package (version 4.1, Pharmacia Biosensor) we 
extrapolated the KD values (Fig. 1a). The C2 peptide bound with a similar KD to both 
receptors, while C1 recognized Flt-1 with a slightly increased affinity compared to KDR. In 
addition, we found a weak interaction of the linear and C3 peptides with Flt-1 receptor only.  
In conclusion, we confirmed that the motif PR, preceded often by a hydrophobic residue, 
occurring in several VEGF receptor binding peptides , such as the sequence of PlGF-derived 
peptides [4-6], might be an important scaffold for binding to KDR and to Flt-1 [3-5]. We 
found that some of the library components bound both receptors (C1 and C2) with moderate 
affinity, whereas one of them, C3, selectively bound to Flt-1. Preliminary CD analyses (data 
not shown) suggest that the peptides adopt very different conformations in solutions and this, 
together with the different arrays of side chains can affect receptor recognition. NMR 
analyses are currently underway to investigate the contribution to binding deriving from side 
chains and/or backbone conformation. 
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Abstract Intravenous immunoglobulin are important bio-
therapeutics used in the replacement therapy for primary
and secondary immunodeficiencies, chronic inflammatory
disorders and several autoimmune haematologic disorders.
Currently, a number of immunoglobulin intravenous
(IVIG) products have been approved by the Food and Drug
Administration (FDA) and are available commercially. It is
known that small differences in the manufacturing pro-
cesses as well as in the formulations may affect their
clinical efficacy and tolerability. Therefore, given the
complexity of the multi-step process required for the iso-
lation of IVIG from human plasma, it is necessary to ensure
a rigorous quality control of final products. We show here
that a set of different bioanalytical techniques can be
conveniently used to comparatively characterize, at a
quantitative and qualitative level, different lots of IVIG
preparations and to unveil randomly occurring impurities
which can also affect the overall product stability. We have
used circular dichroism, surface plasmon resonance and
two-dimensional electrophoresis (2DE), and have demon-
strated that this combination of bioanalytical approaches is
very useful to improve the quality control of antibodies and
to monitor the reliability of the IVIG manufacturing
process.
Keywords IVIG  Circular dichroism  SPR  Biacore 
Protein A  Thermal denaturation
Introduction
Intravenous immunoglobulin (IVIG) preparations have
become the major plasma-derived product with increas-
ingly important bio-therapeutic applications. Indeed, IVIG
have been successfully employed for the treatment of
several immunological and inflammatory diseases includ-
ing replacement therapies for primary immunodeficiencies,
such as X-linked agammaglobulinemia, hypogammaglob-
ulinemia, some acute graft-versus-host diseases and
chronic B cell lymphocytic leukaemia [1, 2]. In addition,
IVIG preparations are also employed for the therapy of
humoral immunodeficiencies related to several patho-
physiological diseases. In this context, infusion of IVIG has
been widely applied for the treatment and prevention of
infectious and inflammatory diseases such as the coronary
artery aneurysms in Kawasaki disease, the idiopathic
thrombocytopenic purpura and the Guillain–Barre` syn-
drome. Moreover, minor neurologic and dermatologic
pathologies are also treated off-label with IVIG.
Except for the replacement therapy, the IVIG mecha-
nism of action is not yet fully understood. However, clin-
ical evidences suggest their involvement in the modulation
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of multiple networks related to the expression and function
of Fc receptors, the activation of the complement and
cytokine pathways and the regulation of cell growth. Some
effects on the activation, differentiation and effector
functions of dendritic, T and B cells have been also
hypothesized [3, 4].
Intravenous immunoglobulin preparations contain a
pool of polyclonal IgG antibodies extracted from the
plasma derived from a high number of healthy blood
donors. Although manufacturing processes have been sig-
nificantly improved in the last two decades to increase
purity and yield of IVIG molecules, almost all the purifi-
cation strategies include an initial step based on the Cohn–
Oncley ethanol fractionation. Additional procedures (e.g.
ion exchange chromatography, ultrafiltration, enzymatic
digestion, pH and ion strength variations and organic sol-
vent–detergent partitioning) may be applied for removing
proteins and other minor contaminants, for minimizing the
formation of IgG aggregates and for inactivating and
removing viral contaminants such as hepatitis B virus,
hepatitis C virus and human immunodeficiency virus [5].
In this framework, critical issues in the pharmaceutical
production of active products, such as antibodies, are
mainly related to the reproducibility and safety of the
industrial-scale manufacturing processes and to the cost
optimization measures. Increasingly stringent legislation at
national and international level ensures the quality and
safety of drugs and the materials used in their production.
Therefore, given the wide use of IVIG as bio-therapeutics
in a broad range of applications, there is a growing demand
of powerful and reliable methodologies for the control of
the IVIG production process aimed to guarantee the con-
sistency, the quality and safety of the final drug. Although
different commercial IVIG preparations are available and
equivalent by a therapeutic point of view, an intrinsic
variability may be present amongst different commercial
products and different lots of the same products.
In this study, a set of bioanalytical methods have been
used to characterize and comparatively analyse IVIG from
different preparations to evaluate their application for the
routine analysis of IVIG lots.
The experimental protocol for monitoring commercial
IVIG preparations includes structural investigations carried
out by circular dichroism (CD), protein denaturation
studies, surface plasmon resonance (SPR) binding assays
and two-dimensional electrophoresis (2DE).
The approach has proven to be very sensitive and reli-
able for the evaluation of full antibody, as well as of sep-
arate Fc and Fab, stability and integrity and for the
monitoring of lot-to-lot consistency of different IVIG
preparations. To demonstrate its applicability, we have
analyzed in a comparative way, six different 10 % IVIG
lots deriving from two distinct sets: one starting from
cryosupernatant 1 and one from fraction II–III, both puri-
fied by chromatographic methods.
Materials and Methods
Circular Dichroism Analysis
The six lots of 10 % IVIG, comprising 3 lots prepared from
cryosupernatant 1 (lots A1, A2, A3) and 3 lots prepared
from fraction II ? III (lots B1, B2, B3) are produced by
Kedrion S.p.A. 10 % solutions were used as starting
material and properly diluted in the indicated buffers prior
analysis. All CD analyses were performed using a JASCO
J-710 spectropolarimeter, equipped with a Peltier system
for changing the temperature in a controlled way and
quartz cuvettes 110-QS with 1.0 mm path length. Experi-
ments were performed in 10 mM phosphate, pH = 8.0 at a
concentration of 0.20 mg/mL [6]. Spectra were collected
within the wavelength range 250–190 nm at a scan rate of
20 nm/min, with a data pitch of 0.2 nm, a band width of
1 nm and a response of 4 s. In order to compare the dif-
ferent protein lots, far UV CD spectra were recorded at 20,
55, 60, 65, 70, 75, and 85 C and then again at 20 C
(‘after cooling’ condition). The ‘after cooling’ spectrum
was required to assess whether proteins were able to
recover original structures or had undergone irreversible
aggregation. Thermal denaturation experiments were per-
formed by monitoring changes in ellipticity at 209 nm by
exposure to increasing temperatures between 40 and 90 C,
at a speed of 60 C/h (1 C/min). The melting point was
determined by the method of the first derivative.
On every sample, five independent spectra were recor-
ded, averaged and smoothed using the Spectra Manager
software, version 1.53. Buffer scans were recorded under
the same conditions and subtracted. The analysis of sec-
ondary structure content was performed using the online
server named Dichroweb [7, 10].
2D-PAGE Analysis
IVIG preparations at 100 mg/mL (10 %) were used without
any further manipulation except dilution. Immobilized pH
gradient (IPG) buffers, IPG strips and electrophoresis apparatus
were purchased from GE Healthcare (Italy). Electrophoresis
reagents, including acrylamide, N,N,N,N-methylenebisacryla-
mide, N,N,N,N-tetramethylethylenediamine, ammonium per-
sulfate and sodium dodecylsulfate (SDS), were from BioRad
(Milano, Italy). Chemical reagents were from Sigma-Aldrich
(Milano, Italy). Gels were scanned using a Molecular
Dynamics densitometer, model 375–557, from Amersham
Biosciences (USA). Image analysis was performed using the
984 Mol Biotechnol (2013) 54:983–995
123
ImageJ software (Image processing and analysis in Java),
available on-line on the National Institutes of Health website
(Bethesda, Maryland, USA, http://rsbweb.nih.gov/ij). All other
reagents were of analytical grade.
An extensive reduction of IgG disulphide bonds was
performed on aliquots of IgG samples (50 mg/mL) by
adding DTT 2.3 % in aqueous solution containing SDS
10 % (final volume: 15 lL). Following an incubation of
5 min at 95 C, samples were directly diluted in the
rehydration solution to a final concentration of 2 mg/mL.
A total amount of 200 lg of IgG were loaded on
each gel, reduced as reported above, was analyzed by
2D-PAGE. Samples to be processed by isoelectrofocusing
(IEF) were diluted with the rehydration buffer (8 M urea,
0.5 % CHAPS, 0.2 % DTT, 0.5 % IPG ampholytes and
0.002 % bromophenol blue) to a final volume of 125 lL.
The precast IPG strips (3–10 linear pH gradient, 7 cm
long), used for the first dimension, were passively rehy-
drated and loaded with the sample at room temperature for
12 h under low-viscosity paraffin oil. IEF was then per-
formed using an IPGphor isoelectric focusing cell,
according to the following protocol: 50 V for 3 h, 100 V
for 2 h, 500 V for 2 h, 1,000 V for 2 h, 3,000 V for 2 h,
4,000 V for 2 h, 5,000 V for 2 h, 6,000 V for 2 h, 8,000 V
until about 25,000 V h total. Strips were then equilibrated
twice for 15 min with gentle shaking in the equilibration
solution (6 M urea, 50 mM Tris–Cl buffer pH 8.8, 30 %
glycerol, 2 % SDS, 0.002 % bromophenol blue) containing
1 % DTT to reduce disulphide bonds, in the first equili-
bration step, and 2.5 % iodoacetamide to alkylate thiols, in
the second. The second-dimension separation was per-
formed in a 12 % polyacrylamide (7 9 8 cm). The strips
were fixed with 0.5 % agarose and 0.002 % bromophenol
blue dissolved in SDS/Tris running buffer. The run was
carried out at constant power (10 mA/gel for 15 min;
20 mA/gel until the end of the run). At the end of the
electrophoresis, the protein spots were visualized by Coo-
massie Blue R250 staining.
After staining, 2D-gels were scanned using a Molecular
Dynamics densitometer. Gel images were then processed
for background subtraction and analysed for spot identifi-
cation and matching using image analysis Image J software
(http://rsbweb.nih.gov/ij). Quantification of relative band
intensities to determine IgG purity was performed using the
same software.
SPR Analyses
All analyses were performed on a Biacore 3,000 instrument
from GE Healthcare, using certified HBS buffer (20 mM
Hepes, 0.15 M NaCl, pH 7.2, P20, 0.005 %), at 25 C.
Protein A (Sigma-Aldrich, Milano) was dissolved in
deionized water at a concentration of 1.0 mg/mL. Protein
immobilization was efficiently performed on the flow cells
(FC) of CM5 sensor chips at 5.0 lg/mL in sodium acetate
10 mM pH 4.5 following the canonical EDC/NHS (amine
coupling) method, operating at 5 lL/min [8]. An underiv-
atized surface was prepared and used as control blank.
Analyses were carried out at a flow rate of 20 lL/min,
injecting a constant volume of 60 lL of IVIG solutions at
the following concentration: 1.0, 2.5, 5.0, 10.0, 50.0, 100,
250, 500, 1,000, 1,500, 2,500, 3,000 nM. Dissociations
were monitored for at least 600 s, performing at the end a
regeneration step by injecting 20 lL of a solution of
10 mM glycine, pH 2.7.
The immobilization of the anti-k-chain monoclonal
antibody (mAb K4377, Sigma-Aldrich, Milano) was
achieved in 10 mM sodium acetate pH 5, operating at a
flow rate of 5 lL/min. In this case, three flow channels
were derivatized with the mAb at different immobilization
levels: low density on FC2, 613 RU; medium density on
FC3, 1813 RU; high density on FC4, 4718 RU. On FC1,
used as reference, no protein was immobilized. Experi-
ments were performed at 20 lL/min with a total contact
time of 180 s (60 lL injected for every run). Dissociations
were monitored for at least 600 s, regenerating at the end
with a 20 mM solution of HCl with added 0.005 % v/v of
surfactant P20. The concentrations of IgGs used for the
binding experiments were: 10, 25, 50, 100, 500, 1,000,
1,500 and 2,000 nM. For every single analysis, experi-
mental sensorgrams were aligned, subtracted of blank
signals and overlapped. All mathematical manipulations
and fitting were performed using the BiaEvaluation soft-
ware, version 4.1 from GE Healthcare. Analyses were
carried out using the six samples opportunely diluted in the
HBS running buffer.
Fragment Crystallizable (Fc) Function
Because most of the anti-inflammatory properties of IVIG
are mediated by the Fc antibody portion, evaluation of the
Fc functional integrity of IgG is an indirect way to measure
their therapeutic potential. This has been determined by Fc
function in accordance with Eu. Ph., 2.7.9, method A [9],
using haemolytic complement-fixation assay. This test is
based on the haemolysis of antigen-coated fresh human red
blood cells in the presence of guinea pig complement.
Rubella antigen is used in the reference method. Results
are reported as a ratio to an IgG standard (biological ref-
erence preparation—BRP—batch 3). For experimental
details see also: British Pharmacopoeia Volume IV,
Appendix XIV J. Blood and Related Products.
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Results and Discussion
Comparative Evaluation of the Structural Stability
Properties of Different Lots of IgG Preparations
by Circular Dichroism
The thermal stability of the different IVIG lots analysed in
this study, was first evaluated by CD. In Fig. 1a–f, an
overlay of the far UV–CD spectra recorded for the six
different samples at increasing temperatures from 20 to
85 C and then back at 20 C (‘after cooling’ condition), is
reported. As shown, CD spectra of IVIG analyzed at 20 C
exhibited the canonical positive band at 202 nm, the neg-
ative band at 216–218 nm and an intensity equal to zero at
208–210 nm, typical of proteins with a high b-sheet con-
tent. Although the occurrence of several other positive and
negative bands in the near UV, at around 260–300 nm is
reported [6], these bands have not been considered in our
analysis, because they are much less intense and poorly
diagnostic. During thermal denaturation, the canonical
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Fig. 1 a–f CD spectra of samples A1, A2, A3, B1, B2, B3 between 195 and 250 nm at the indicated temperatures
Fig. 2 a–f a-helix, b-sheet and random coil content determined for
samples A1, A2, A3, B1, B2, B3 at the different temperatures using
the Dichroweb server. Normalized root mean square deviation
(NRMSD), expressed as percentage, have also been determined for
all analyses (not shown)
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b-sheet spectrum was maintained up to 60 C for all
samples, confirming the high stability of antibodies. For
temperatures below this threshold, the minimum at
216–218 nm was maintained more or less at the same
intensity, between about -6 and -8 mdegrees.
Afterwards, starting from 65 C, spectra varied consid-
erably, suggesting severe structural changes. As shown in
Fig. 1c, sample A3 exhibited a different behavior at shorter
wavelengths, with the maximum shifting from about 205 to
195 nm. Such changes are suggestive of a general reduced
stability of proteins present in this preparation. By further
temperature increase, a progressive denaturation was
observed for all samples, witnessed by the large changes in
the CD spectra. In particular, the band at 209 nm was
progressively lost, leading to spectra resembling more
those of proteins having a large content of a-helix (see for
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Fig. 3 a Curves of thermal denaturation between 40 and 95 C for all samples analyzed in this study. b The corresponding first derivative for the
curves are reported. Spectra were collected between 195 and 250 nm
Fig. 4 a–f 2D-PAGE analysis
of immunoglobulin preparations
on 7 cm strips (linear gradient
pH 3–10). The basic isoelectric
points are to the right and acidic
to the left. Red squares three-
dimensional magnifications are
reported in 4g–n. g–n Three-
dimensional profiles of
2D-maps of IgG preparations
obtained using the ‘interactive
3D-surface plot’ application of
ImageJ software.
Magnifications of regions
indicated by red squares in
Fig. 1 are shown. Red arrows
indicate streaks not detected in
S220611, 270711 and S280911
2D-maps. (Color figure online)
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example spectra at 85 C). For all samples, except A3, also
a shift of the point at zero millidegrees was observed (from
208 up to about 197 nm). The shift observed by analyzing
sample A3 was instead less intense, and the overall signal
below 200 nm strongly changed with the temperature,
certainly due to premature protein precipitation. After
cooling to record again the spectra at 20 C, original bands
were not restored and white precipitates were observed in
the cuvettes for all samples. In Fig. 2a–f, the global
changes in a-helix, b-sheet and random coil contents, at all
temperatures, obtained using the software Dichroweb, are
reported [8, 9]. According to the changes observed in
spectra, a progressive and remarkable reduction of the
b-sheet content was noticed, paralleled by an increase in
Fig. 4 continued
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the a-helix character and a less intense increase of the
random coil content. As shown, changes in the samples
from cryosupernatant 1 were less intense; furthermore, one
of the these samples, A3, exhibited a decrease of the ran-
dom coil character and a more marked change of the a-
helix and b-sheet contents, in agreement with the spectral
changes below 200 nm described before.
To further unveil possible differences in stability,
melting curves were recorded following signal change at
209 nm as a function of the temperature increase. Since
proteins were essentially very stable up to about 60 C,
melting curves were recorded only between 40 and 95 C.
In Fig. 3a, an overlay of melting curves for all samples is
shown, and as can be seen, except that referred to as sample
A3, which yet declined at 65 C, all exhibited a sudden
drop of signal starting at about 70 C. This difference is
also reflected in the graph of Fig. 3b reporting the first
derivatives of all spectra, where the minimum of sample
A3 is clearly shifted some 5 towards lower temperatures
compared to those of other samples. Altogether, data
indicate that all IVIG samples behave in a similar way in
terms of resistance to thermal denaturation, with a slightly
higher stability exhibited by lots deriving from cryosu-
pernatant 1 fraction. Amongst these, sample A3, more
rapidly aggregated and precipitated upon heating, thus
showing unique properties, presumably deriving by the
occurrence of pre-existing random aggregates.
Analysis of IVIG Preparations by 2D-PAGE
Immunoglobulins (Igs) are a heterogeneous population of
proteins (polyclonal immunoglobulins), whose basic
structure consists of two identical halves connected by
disulphide bonds. Each half is made up of a heavy chain of
*55 kDa and a light chain of *25 kDa, joined together
by a disulphide bond near the carboxyl terminus of the light
chain. The heterogeneity of Igs is not detectable using
monodimensional SDS-PAGE, which only resolves the
most abundant protein bands at 55 and 25 kDa. An
extensive bioanalytical characterization of all samples was
thus performed by 2D-PAGE followed by densitometric
analysis, in order to assess the occurrence of low-abun-
dance impurities and a possible correlation with the dif-
ferent physico-chemical properties evidenced by the CD
analysis. After extensive reduction, aliquots of proteins
(200 lg) were separated by 2D-PAGE using, for the first
dimension, IPG strips with a linear 3–10 pH gradient. The
second dimension was carried out on 12 % polyacrylamide
gel, following further reduction and alkylation steps. At the
end of the run, 2D-gels were stained with Coomassie Blue
R250 and the resulting gels are reported in Fig. 4a–f. As
expected, multiple protein spots were visualized in the
regions with molecular mass of about 25 and 55 kDa,
corresponding to the light and heavy chains of IgG,
respectively. These profiles attested the IgG polyclonal
nature with many isoforms with the same molecular weight
but differing in their isoelectric point. However, though all
samples appeared highly homogeneous, 2D-maps corre-
sponding to the A group, comprising A1, A2 and A3,
showed a set of streaks having MW between about 70 and
150 kDa and pIs comprised between about 4 and 7;
remarkably, the most intense streaks were visible on the gel
corresponding to sample A3.
A more detailed comparison of the 2D-gels of the dif-
ferent IgG preparations was also performed following gel
images acquisition and quantitative analysis. Three-
dimensional profiles of the gel image sections boxed in
Fig. 4a–f are reported in Fig. 4g–n and Fig. S1a–f in the
supporting material, and provide a more quantitative view
of the impurities (indicated by arrows). In Table 1, the
level of purity of samples studied is reported and as shown,
A lots contain detectable levels of impurities (1.12, 1.15
and 1.30 %, respectively), whereas B lots appear 100 %
pure. Remarkably, lot A3 has the highest content of
impurities, which could account for the difference in sta-
bility observed during the CD analysis.
Table 1 Impurities detected on the six samples of IVIGs. Both absolute and percentage values are reported
Intensity IgG samples
A1 A2 A3 B1 B2 B3
IgG light chain 6,174.52 9,175.93 6,372.33 3,483.64 4,229.45 3,700.35
IgG heavy chain 17,293.27 19,822.25 18,559.78 12,689.34 12,496.99 11,052.83
IgG total 23,467.79 28,998.18 24,932.11 16,172.98 16,726.44 14,753.18
Impurities 262.85 334.38 324.01 0.00 0.00
% impurities 1.12 1.15 1.30 0.00 0.00 0.00
% IgG 98.88 98.85 98.70 100.00 100.00 100.00
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Fig. 5 a–c Envelope of
sensorgrams for the IgG lots A1,
A2 and A3. Concentrations are
reported below each group of
curves. d–f Envelope of
sensorgrams for the IgG lots B1,
B2 and B3. Concentrations are
reported below each group of
curves
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Comparative Binding Analysis of the Different Lots
of IVIG to Protein A (pA) by SPR
To have a measure of the integrity of the Fc portion of
IVIG, we performed binding analyses of the different IgG
preparation to pA. pA is a bacterial protein largely used to
purify Igs of different classes from complex matrices. It is
known to bind on a region of the Fc portion that comprises
residues from the Cc2 and Cc3, therefore comparative
binding analyses can provide information on the relative
integrity of this IgG region.
pA is a protein of 42 kDa which binds with high affinity
and selectivity at least two distinct IgG molecules [11],
however the exact stoichiometry is at present not known
and generally is dependent on experimental conditions and
technique used. In solution the stoichiometry can be higher
than 2:1 and also binding sites on the IgGs are two,
therefore the mathematical models for studying this inter-
action can be complex [11].
Analyses were carried out by SPR, using sensor chips
with immobilized pA. Optimal concentrations for these
analyses were between 1 and 2,500 nM.
The envelopes of sensorgrams referred to the six IVIG
lots, reported in Fig. 5a–f, show as all curves have essen-
tially the same shape and trend, reaching the saturation for
concentrations higher than 2,500 nM. Since the binding
stoichiometry between pA and IgGs is not well-defined,
especially for interactions occurring on solid surfaces, to
derive kinetic and thermodynamic binding parameters
Kons, Koffs and KDs, we tried with different mathematical
A B
C D
E F
Fig. 6 a–f Correlation curves
between RUmax values at each
concentrations and
concentrations itself for IgG lots
A1, A2, A3 and B1, B2, B3
expressed as Log M. For each
single plot the EC50 value
calculated by this method is also
reported. Correlation curves
between RUmax values at each
concentrations and
concentrations itself for IgG lots
A1, A2, A3 and B1, B2, B3
expressed as Log M. For each
single plot the EC50 value
calculated by this method is also
reported
Table 2 Values of the EC50 values determined for all IgG lots and the relative standard errors
IgG samples A1 A2 A3 B1 B2 B3
EC50 (M) 3.7 ± 2.0 9 10
-7 1.5 ± 0.8 9 10-7 1.7 ± 0.7 9 10-7 7.7 ± 1.0 9 10-7 11.4 ± 0.7 9 10-7 7.5 ± 0.7 9 10-7
Mol Biotechnol (2013) 54:983–995 991
123
models of interactions (including 1:1, 1:2 stoichiometries
or even higher). However, all attempts to fit the curves
failed or gave inaccurate results (see Fig. S2a, b in the
supporting material as an example of failed fitting).
Therefore, in order to compare the analyses, we built plots
reporting RUmax values versus analyte concentration, as
reported in Fig. 6a–f. Next, using an algorithm of nonlinear
regression and assuming a 1:1 stoichiometry, we derived a
measure of global affinities, expressed as EC50 which could
be seen as the resultant of multiple interactions [12, 13].
EC50s values determined by this method are summarized in
Table 2. As expected, values are all very similar, being
comprised between 1.5 9 10-7 and 3.9 9 10-7 M, how-
ever EC50s for the B lots are slightly higher (about dou-
bled), not only suggesting a higher consistency among lots
within the same group, but also measurable differences
among lots coming from different starting material.
A further comparison was performed by comparing
RUmax values observed at a given concentration. Data are
plotted in Fig. S3 in supporting material, whereby for each
distinct lot, RUmax values at all concentrations are reported.
It can be reasonably assumed that, the more similar are
RUmax values, the more is expected that IgG samples are
similar each other. By analyzing data, it emerged that the
set of B samples comprising lots B1, B2 and B3, appears
more homogeneous with almost identical values at the
same concentrations. This holds not true for samples A1,
A2 and A3 which indeed showed varying RUmax values at
the same concentration. This effect, negligible at low
concentrations, is more evident for concentrations higher
than 10 nM. It should be also noticed that RUmax values are
a little bit higher for IgGs lots from set A, as compared to
those obtained with IgGs from the other one. This differ-
ence could be due to the presence of small amounts of
aggregates in set A, which could form (or be retained after
dilution) at higher concentrations and over time. Aggre-
gates, being bigger than monomeric IgG, provide more
intense SPR signals.
Comparative Analysis of Different Lots of IVIG
to Anti-k-chain mAb by SPR
The study performed with pA was paralleled by another
comparative study carried out using an anti-k-chain
monoclonal antibody, in order to obtain a global evaluation
of the Fab integrity.
Fig. 7 a–c Sensorgrams
obtained for the interaction
between the immobilized Mab
anti-k-chain and IgGs from the
lot A1 on FC4 (high density, a),
on FC3 (medium density, b) and
on FC2 (low density, c)
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Binding experiments were performed in parallel on three
channels with different immobilization levels. In Fig. 7a–c,
the envelopes of sensorgrams obtained for one of the six
samples (sample A1) at three different immobilization
levels, are reported. In the supporting material Fig. S4–S8,
sensorgrams corresponding to the remaining five analyses
are reported. In all plots, time and RU scales were kept at
the same values to visualize at best differences in RUs
achieved on the distinct channels by varying ligand density.
As expected, lower bindings were recorded for lower
ligand density and curves were all very similar. As with the
pA, bindings were analyzed by determining the global KDs
plotting the RUmax values derived from every single
injection on distinct flow channels versus the concentration
of Igs. Data were then best fitted by a nonlinear regression
analysis and are reported in Fig. 8a–f. KDs determined by
this method are instead reported in Table 3. As can be seen,
values are very similar for the same IgG lot on channels at
different immobilization levels, thus suggesting that the
analyses are very reproducible and reliable. It should be
pointed out that KDs are also very similar amongst different
lots with values ranging between about 136 and 288 nM,
suggesting that the population of Igs present in the different
lots are highly comparable in terms of Fab homogeneity.
Fragment Crystallizable (Fc) Function
The functional integrity of the Fc fragment of all analysed
lots was evaluated using a well-established method sug-
gested by the European Pharmacopeia. Data for all six
samples are presented in Table 4 and show that results are
in compliance, therefore proving the full functionality of
the analysed IgGs. Despite large differences in function are
observed between the diverse IVIG lots, they do not cor-
relate with the slight discrepancies emerged at the bioan-
alytical level.
Fig. 8 a–f Plots reporting RUmax values versus IgGs concentration for all lots analyzed
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Conclusions
We have undertaken a comparative evaluation of the
macroscopic physico-chemical properties of six different
lots of IVIG coming from two distinct preparations. Three
lots, A1–A3, came out from a chromatographic purification
from a cryosupernatant fraction, whereas three other lots
were obtained from fraction II–III, using the same chro-
matographic purification procedure. The study has been
carried out using different bioanalytical techniques to gain
a global view of antibody properties, to assess lot-to-lot
consistency and to point out possible differences arising
from the different starting material. For this purpose we
have conducted on all samples: (i) a macroscopic structural
analysis by CD, also evaluating IgG resistance to thermal
denaturation; (ii) an evaluation of purity by 2D-gel analy-
ses and (iii) a macroscopic evaluation of Fc and Fab
integrity by SPR, carrying out comparative binding studies
to pA and to an anti-k chain monoclonal antibody.
As expected, samples displayed quite identical proper-
ties and it was difficult to unveil macroscopic dissimilari-
ties, however subtle but measurable differences emerged
amongst the different lots during the investigation, espe-
cially amongst lots coming from different starting material
(lots A vs. lots B). Since the different lots have the same
age and have been purified all by the same method, the
presence of such impurities or degradation components
demonstrates that side products occurring in these experi-
mental IVIG lots can only arise from the diverse raw
material. The reason for this has not been investigated here;
we can however hypothesize that small impurities are
either co-purified with the main component or generated
during the purification steps or during storage. Irrespective
of the way they are generated, these impurities can be
detected and quantified by 2DE and, looking retrospec-
tively at our CD data, could also be predicted to some
extent by a CD analysis, which seems to be qualitatively
affected by such low levels of contaminants.
Data show that IgGs purified from Fraction II-III are
generally homogeneous compared to those obtained from
cryosupernatant 1, but also that IgGs extracted from the
same starting material have a higher lot-to-lot consistency,
thus suggesting that also the very initial steps of plasma
manipulation can affect final products. Furthermore, we
have observed that one lot (lot A3), showed reduced
resistance to thermal denaturation and, at the same time,
also contained sensibly higher amounts of undetermined
impurities (presumably immunoglobulin fragments), as
detected by 2DE. Remarkably, lots A1 and A2, coming
from the same raw material (cryosupernatant 1) also con-
tained detectable levels of impurities (see Table 1; Fig. 4),
but the resistance to thermal denaturation was comparable
to that of the purer lots B1–B3. In order to further unravel
differences between lots, an extensive characterization by
SPR was also performed. In our experimental setting, the
SPR approach would allow to dissect differences deriving
from the Fab and/or the Fc antibody portions, however it
proved generally less sensitive, being able to measure
subtle differences only for the binding to pA and not to the
anti-k-chain K4377 mAb. While confirming that samples
coming from the same set of lots are more homogeneous,
we also noticed that lots A are less comparable in terms of
relative binding to pA in respect to B lots (see the sup-
plementary Fig. S3).
Altogether, our results show that this set of bioanalytical
techniques is useful and complementary to the analytical
tests provided in the European Pharmacopeia for a better
global view of IVIG purity, stability and integrity of full
antibodies, as well as of separate Fc and Fab fragments.
Table 3 KD values for the binding between IgGs and the immobi-
lized anti-k-chain mAb K4377, as obtained by nonlinear regression
analyses of curves reported in Fig. 8a–f
Low
density
Medium
density
High
density
Average SD
A1
KD (nM) 380.9 251.0 232.4 288.1 80.9
A2
KD (nM) 347.1 254.2 203.8 264.4 73.7
A3
KD (nM) 269.4 171.7 170.6 203.9 56.7
B1
KD (nM) 303.2 176.3 159.5 213.0 78.5
B2
KD (nM) 110.3 141.1 158.4 136.6 24.4
B3
KD (nM) 1,149** 185.5 182.3 183.9 23**
SD standard deviation
** This value has not been considered for calculating the average KD,
therefore the corresponding SD is also meaningless, being derived by
only two values
Table 4 Fragment crystallizable function
Limit From
cryosupernatant 1
From Fr II ? III
Lot
A1
Lot
A2
Lot
A3
Lot
B1
Lot
B2
Lot
B3
Fragment
crystallizable (Fc)
function (%)
[60 82 116 90 79 87 85
Limits are defined in accordance with EU pharmacopoeia: the value is
stated in the leaflet accompanying the reference preparation (BRP—
batch 3)
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